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Abstract 
 
Background 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating condition of the 
central nervous system (CNS). The majority of people with MS have a relapsing onset 
with recurrent episodes of acute or sub-acute onset neurological impairment 
interspersed with periods of functional recovery and relative clinical stability. Many 
people with relapse-onset MS will eventually develop progressive, irreversible 
disability, termed secondary progressive MS. 
 
Pathological studies suggest that there is substantial neuroaxonal loss in MS. Data 
from animal models indicate that this may in part be due to the toxic accumulation of 
sodium in chronically demyelinated axons and that blockade of voltage gated sodium 
channels with drugs such as lamotrigine is potentially neuroprotective. 
 
Quantitative magnetic resonance imaging (MRI) is a powerful tool which allows 
investigators to monitor CNS pathology in vivo and consequently has been integrated 
into clinical treatment trials. Several techniques have been developed which are 
thought to correlate with neuroaxonal loss. These include: volume of T1 hypointense 
lesions (T1LV); whole brain, regional and spinal cord atrophy; and magnetization 
transfer ratio (MTR), a technique that gives a measure of the macromolecular content 
of tissue, such that higher MTR may indicate higher myelin and intact axon content. 
The purpose of this study was to evaluate the potential for T1LV and MTR to quantify 
clinically important brain pathology in secondary progressive MS and evaluate the 
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effect on these measures of treatment with lamotrigine.  
 
Methods 
118 people with secondary progressive MS were recruited into a double-blinded, 
placebo controlled, randomized trial of neuroprotection with lamotrigine. Clinical 
assessment included the multiple sclerosis functional composite (MSFC), expanded 
disability status scale (EDSS) multiple sclerosis impact scale (MSIS-29) and were 
collected at five timepoints: baseline, 6, 12, 18 and 24 months. The incidence of 
relapses was also checked at three monthly intervals during the course of the trial. 
MRI assessment included: central cerebral volume collected every 6 months; MTR of 
normal appearing white matter, normal appearing grey matter (NAWM; NAGM) and 
T2 hyperintense lesions; whole and regional brain volume; spinal cord cross sectional 
area; T1LV and T2 lesion volume (T2LV) collected at three timepoints – baseline, 12 
and 24 months – and whole brain atrophy, detected using a coregistration-subtraction 
protocol (Structural Image Evaluation, using Normalisation, of Atrophy; SIENA) over 
the 24 months of the study.  
 
The correlation of T1LV and brain MTR with brain volume and clinical measures was 
carried out at baseline on the whole cohort while longitudinal correlations were 
assessed in the placebo arm only. Comparison of change in MTR and T1LV measures 
in the verum arm was made with those in the placebo arm by intention to treat and 
two per protocol analyses: ‘serum compliant’ (subjects in whom lamotrigine was 
detected in the serum at 24 months) and ‘tablet compliant’ (subjects who were 
estimated to have taken at least 80% of the prescribed tablets).  
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Results 
There were moderate cross-sectional correlations of MTR measures and T1LV with 
MSFC and component measures and normalized brain volume (NBV), with lower 
MTR values and higher T1LV associated with more severe brain atrophy and 
neurological impairment. In multiple regression models T1LV emerged as the only 
independently significant cross-sectional correlate of both NBV and clinical 
measures. Only NAGM MTR mean correlated with all three components of the 
MSFC. There was no association of any MRI measure with higher or lower EDSS. 
 
The responsiveness of all the MRI measures was limited. In the placebo arm T1LV 
changed significantly over the 24 months of the trial (p<0.0001) and, although the 
responsiveness was comparable to T2LV, it was lower than SIENA. Only three out of 
nine MTR measures – NAGM mean (p<0.0001), lesion peak location (PL) (p=0.018) 
and mean (p<0.0001) – changed significantly over the 24 months.  
 
Comparing the MTR and T1 hypointense lesion volume measures in the verum and 
placebo arms of the study did not show that lamotrigine was neuroprotective. Of nine 
MTR measures evaluated, only two – NAGM and lesion peak height (PH) - differed 
significantly between the two groups. Lesion PH increased over 24 months, by a 
greater magnitude in the placebo arm (p=0.004), while NAGM PH fell more in the 
verum arm (p=0.036). 
 
The longitudinal correlations were limited. There were no significant correlations of 
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change in MRI measures with change in clinical measures. Using a mixed effect 
linear regression model it was possible to show that the correlations were consistent 
across all three timepoints, but there was no correlation of MRI measures with an 
interaction variable of [clinical measure*timepoint]. 
 
A fall in lesion PL MTR and an increase in lesion mean MTR was associated with an 
increased risk of experiencing a sustained increase in EDSS (p=0.049; p=0.002) but 
none of the other MRI measures were associated with a change in EDSS. 
 
T1 to T2 lesion volume ratio was the only independently significant cross-sectional 
MRI correlate of the psychological component of the MSIS-29 (R
2
=0.13, p<0.0001). 
In the longitudinal analysis change in timed walk correlated modestly with the 
physical component of the MSIS-29 (R
2
=0.09, p=0.047) while change in timed walk, 
NAWM MTR mean and NAGM PH correlated modestly with the psychological 
component (R
2
=0.32, p=0.007, p=0.003, p=0.048). The proportion of variability of 
the MSIS explained by these models was small. 
 
Conclusions 
The data suggest that MTR and T1 lesion volume are measures of clinically important 
brain pathology in secondary progressive MS. T1LV may be a more specific measure 
of clinically important brain pathology than T2LV. The results of this study highlight 
the value of NAGM MTR for identifying clinically important pathology, perhaps 
indicating that NAGM pathology is important in determining clinical status in 
secondary progressive MS. The data presented here do not show any neuroprotective 
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effect of lamotrigine treatment in secondary progressive MS. 
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1. Introduction 
1.1. Multiple sclerosis (MS) 
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous 
system (CNS) and one of the commonest causes of neurological disability among 
young people in the western world (Sadovnick and Ebers 1993). There are two major 
clinical phenotypes: relapse-onset, which accounts for approximately 85% of cases 
and primary progressive MS which accounts for the remaining 15% (Weinshenker et 
al 1989).  
 
People diagnosed with relapse-onset MS experience recurrent episodes of acute, focal 
neurological dysfunction (relapse) with a variable level of recovery separated by 
periods of relative functional stability (remission) whereas the clinical course of 
primary progressive MS is the insidious development of progressively severe 
irreversible disability from the start (Thompson et al 2000).  
 
In the majority or people with relapse-onset MS the relapsing-remitting stage is 
followed by the gradual accumulation of irreversible neurological disability 
(Weinshenker et al 1989) which is termed secondary progressive MS (Lublin and 
Reingold 1996). The majority of long term disability arises in this secondary 
progressive phase (Confavreaux et al 2000, Leray et al 2010, Scalfari et al 2010).  
 
The age at the onset of progression in relapse onset MS is approximately the same as 
the age of onset for primary progressive MS and the rate at which progression occurs 
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is very similar in both conditions (Confavreaux et al 2000, Tremlett et al 2005, 
Tremlett et al 2008, Leray et al 2010). Furthermore the rate of progression in 
secondary progressive MS is the same irrespective of the incidence of superimposed 
relapses, perhaps suggesting that the pathophysiological process giving rise to 
progression may be different from that giving rise to relapses (Confavreaux et al 
2000).  
 
1.2. Pathology of MS 
MS is a pathologically heterogeneous condition, with focal lesions in both grey (Kidd 
et al 1999, Peterson et al 2001, Bo et al 2003a, Bo et al 2003b Kutzelnigg et al 2005) 
and white matter (Lucchinetti et al 2000), diffuse white matter inflammation 
(Kutzelnigg et al 2005), diffuse axonal loss (Evangelou et al 2000, Evangelou et al 
2005), global brain atrophy and widespread grey matter demyelination (Kutzelnigg et 
al 2005) and B-cell infiltration of the leptomeninges (Serafini et al 2004). The features 
of relapsing-remitting, primary progressive and secondary progressive MS differ, both 
in terms of the characteristics of focal white matter lesions and in the burden of non-
lesion pathology (Kutzelnigg et al 2005).  
 
White matter lesions 
White matter lesions may demonstrate evidence of: inflammatory activity - activated 
microglia and macrophages, T-cells and plasma cells (although the latter are less 
common) - and demyelination with or without partial remyelination (Luchinetti et al 
2000). Lesions can be described in terms of severity of inflammatory activity as 
acutely active, chronically active and chronic inactive lesions. This has been done 
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using immunohistochemistry major histocompatibility complex (MHC) class II 
markers (van der Valk and der Groot 2000) and qualitatively, defining active lesions 
as those with large numbers of macrophages containing early oligodendrocyte 
breakdown products (Bruck et al 1995); chronic active lesions as those demonstrating 
mild to moderate microglial activation and scattered macrophages especially at the 
outer edge of lesions; and chronic inactive lesions as those which have a well defined 
edge, devoid of macrophage infiltration (Kutzelnigg et al 2005).  
 
Focal white matter lesions also show evidence of axonal damage, dysfunction (Diem 
et al 2007), with build up of amyloid precursor protein (Ferguson et al 1997), 
transection and retraction (Trapp et al 1998, Bitsch et al 2000), with axonal 
transection being most prominent in acute active lesions and around the edge of 
chronic active lesions, where the level of inflammatory activity is highest (Ferguson et 
al 1997, Trapp et al 1998).  
 
Grey matter pathology 
Lesions occur in both cortical grey matter (Kutzelnigg et al 2005, Bo et al 2003a, Bo 
et al 2003b, Peterson et al 2001, Kidd et al 1999) and deep grey structures (Brownell 
and Hughes 1962, Cifelli et al 2002). The number of lesions detected in cortical 
pathological samples can be substantial with one study identifying 478 lesions in 12 
post mortem cases (Kidd et al 1999). Cortical lesions have also been sub-classified 
according to site and structural characteristics. One proposed system identifies 4 
different lesion types: type 1, involving both grey matter and subcortical white matter; 
type 2, small intracortical lesions; type 3, superficial, sub-pial lesions; and type 4, 
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extending from the pial surface up to, but not beyond, the grey matter-white matter 
border (Bo et al 2003a, Bo et al 2003b). Type 3 and 4 lesions may be extensive, 
covering adjacent gyri and effectively causing general cortical demyelination (Bo et al 
2003a, Bo et al 2003b).  
 
In contrast to focal white matter lesions, grey matter lesions show very little 
infiltration with inflammatory cells (Kidd et al 1999, Bo et al 2003a, Bo et al 2003b). 
In fact the majority of inflammatory activity is within the white matter portion of type 
1 lesions (Guerts et al 2005). On the other hand, grey mater lesions are associated 
with dendritic and neuroaxonal transection (Peterson et al 2001). In secondary 
progressive forms of the condition B-cell infiltration of the leptomeninges has also 
been found and may be involved in the development of sub-pial grey matter lesions 
(Serafini et al 2004, Magliozzi et al 2007, Serafini et al 2007, Magliozzi et al 2010, 
Howell et al 2011, Lovato et al 2011, Lucchinetti et al 2011).  
 
Differences between relapsing-remitting and progressive MS 
A recent study compared pathological findings from 52 people with MS (Kutzelnigg 
et al 2005). Although the total volume of white matter lesions was significantly higher 
in samples from people with progressive MS than in relapsing-remitting samples, the 
vast majority of the lesions in progressive MS were inactive, whereas the samples 
from relapsing-remitting patients had a significantly higher proportion of active 
lesions. Grey matter lesions, activated white matter microglia and transected axons in 
non-lesion white matter were significantly more prominent in samples taken from 
people with progressive MS.  
 23 
 
In the samples from people with progressive MS there were significant correlations 
between the extent of diffuse white matter pathology and grey matter demyelination. 
However there were no significant correlations between focal white matter pathology 
and diffuse white matter pathology or grey matter demyelination (Kutzelnigg et al 
2005). A further pathological study demonstrated relatively limited correlation of the 
burden of focal MS plaques with both brain weight and axonal content in the spinal 
cord (De Luca et al 2006). 
 
A third study comparing cord tissue samples from people with primary and secondary 
progressive MS showed that while the level of demyelination was higher in secondary 
progressive MS, the degree of axonal loss was comparable in both groups, perhaps 
suggesting that axonal loss may not be entirely dependent on demyelination 
(Tallantyre et al 2009).  
 
1.3. Pathophysiology of MS 
The mechanisms by which the pathological changes seen in MS give rise to symptoms 
are incompletely understood. Data from animal models of MS, both in vitro and in 
vivo (using experimental allergic encephalomyelitis; EAE), along with pathological 
and MRI data in humans, have allowed investigators to form hypotheses of the 
pathophysiology responsible for relapses, paroxysmal symptoms and neurological 
progression some of which are detailed below. 
Relapses 
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Acute focal MS lesions show demyelination, inflammation and neuroaxonal damage 
(Bruck et al 1995, Trapp et al 1998, Bitsch et al 2000, Luchinetti et al 2000, Barnett 
and Prineas 2004) and all three of these processes may contribute to relapse-related 
neurological impairment. 
 
In healthy white matter the intact myelin sheath provides an insulating layer that 
allows rapid propagation of the action potential. Voltage gated sodium channels are 
almost exclusively located at the nodes of Ranvier with very low levels on the 
internodal membrane (Ritchie and Rogert 1977). Acutely demyelinated internodes are 
therefore essentially devoid of sodium channels (Shrager 1989). Nodal sodium 
currents may be insufficient to depolarise the denuded axolemma, leading to a 
conduction block in affected axons and dysfunction in affected pathways (McDonald 
and Sears 1969, Waxman 1989, Youl et al 1991).  
 
Products of inflammation may also contribute to conduction block (Moreau et al 
1996). One of the more prominent inflammatory molecules implicated in conduction 
block is nitric oxide (NO) which is present in MS lesions (Bagasra et al 1995, Johnson 
et al 1995a), is raised in the cerebrospinal fluid (CSF) in MS (Giovannoni et al 1997) 
and has been shown to induce conduction block in vitro (Redford et al 1997). The 
mechanism by which NO may contribute to conduction block is not fully understood 
but possibilities include interaction with sodium channels (Ahern et al 2000, 
Renganatahan et al 2002), mitochondria (Bolanos et al 1997) or with the sodium-
potassium ATP-ase (Guzman et al 1995) with consequent axonal depolarization 
(Garthwaite et al 2002). 
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Recovery of function - remission  
Following the resolution of acute inflammation (Miller et al 1988, Larsson et al 1988) 
there is restored conduction but persistent electrophysiological evidence of conduction 
delay (Halliday et al 1972, Small et al 1978, Robinson and Rudge 1977, Youl et al 
1991).  
 
The resolution of oedema (Larrsson et al 1988, Miller et al 1988) with reduction in 
potentially harmful inflammatory products may contribute to restoration of 
conduction. Immunological studies in both EAE (Craner et al 2003, Craner et al 
2004a) and MS (Moll et al 1991, Craner et al 2004b) indicate that there may also be a 
proliferation and redistribution of voltage gated sodium channels on sections of 
chronically demyelinated axolemma which may help improve action potential 
propagation. Finally in new lesions there is evidence of partial remyelination (Prineas 
et al 1993, Patrikios et al 2006, Patani et al 2007, Goldshmidt et al 2009) which 
should contribute to restoring normal axonal function. 
 
Intermittent symptoms 
Paroxysmal functional deficit can occur in previously affected pathways, possibly 
through temporary conduction block. For example small increases in body 
temperature can shorten sodium channel opening time, decreasing the likelihood that 
the membrane will depolarise sufficiently to reach the firing threshold, potentially 
resulting in heat sensitive symptoms such as Uhthoff’s phenomenon (Uhthoff 1890). 
Sustained electrical activity may impair depolarization through induction of the 
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electrogenic Na/K ATPase pump which hyperpolarizes the membrane (Bostock and 
Grafe 1985) which may result in exercise induced neurological deficit.  
 
The restructured axolemma may also be prone to ectopic activity (Smith and 
McDonald 1982), leading to paroxysmal positive symptoms including: neurogenic 
pain, positive sensory phenomena and tonic spasms; mechanosensitive discharges 
such as Lhermitte’s phenomenon (Lhermitte 1920) or visual phosphenes. 
 
Progression 
The lesion burden seen on T2 weighted images increases with time (Rudick et al 
2006a, Fisniku et al 2008a) and there is a correlation of lesion burden with disability 
(Li et al 2006). Progressive disability may therefore arise partly from the progressive 
acquisition of a greater burden of focal demyelinated lesions. However there is a 
growing body of evidence indicating that progressive neuroaxonal loss may also be 
partly responsible for progressive disability.  
 
The correlation of focal lesion burden with disability is modest (Miller et al 2002) and 
is weaker in people who have higher levels of disability (Li et al 2006). Furthermore 
medications that have been shown to reduce the number of new focal lesions and 
relapses (Paty and Li 1993, Kappos et al 1998, Coles et al 1999, Jacobs et al 2000, 
Comi et al 2001a, Kappos et al 2001, Li et al 2001, Cohen et al 2002, Panitch et al 
2004, Kappos et al 2006) have limited effect on brain atrophy (Coles et al 1999, 
Molyneux et al 2000a) or progressive disability (Coles et al 1999, Kappos et al 2001). 
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Natural history studies also indicate that after the first few years, the impact of 
relapses on progressive disability is limited (Weinshenker et al 1989, Scalfari et al 
2010), raising the possibility that a second pathological process may in part be 
responsible for progressive MS. 
 
Pathological studies show axonal transection in focal lesions (Trapp et al 1998), 
diffuse axonal loss in normal appearing white matter (Evangelou et al 2000, 
Evangelou et al 2005) and gross generalized brain atrophy (Kutzelnigg et al 2005). 
Although brain atrophy occurs in even the earliest stages of MS (Dalton et al 2004) 
the extent of atrophy is greater in progressive forms of the condition (Kutzelnigg et al 
2005) and it correlates with the level of neurological deficit and disability (Miller et al 
2002). Although there is axonal damage in acute lesions (Ferguson et al 1997, Trapp 
et al 1998, Bitsch et al 2000) it is possible that there is also gradual progressive loss of 
chronically demyelinated axons. 
 
The possible role of nitric oxide, sodium and calcium metabolism in progressive 
disease 
A number of hypotheses have been developed to explain why chronically 
demyelinated axons could gradually degenerate. One of these involves the interaction 
between inflammatory molecules, including NO, and adaptive processes, particularly 
proliferation of sodium channels on the denuded axolemma. 
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In experimental models of inflammation, axons can degenerate when exposed to nitric 
oxide, particularly if they are electrically active (Smith et al 2001).  In models of 
ischaemia, axons loaded with sodium are at risk of degeneration because of the 
secondary influx of calcium ions through the reverse function of the membrane 
Na+/Ca2+ exchanger (NCX) (Stys et al 1992, Bechtold and Smith 2005). This may be 
exacerbated by the presence of nitric oxide and notably axonal degeneration due to 
nitric oxide can be blocked by inhibition of sodium channels or of the NCX (Kapoor 
et al 2003).    
 
It is known that there is a proliferation of sodium channels on chronically 
demyelinated axons (Craner et al 2004a) with colocalisation of NCX (Craner et al 
2004b) and it is possible that this can lead to increased intracellular sodium 
concentration, reversal of the NCX and an influx of cytotoxic calcium. While many 
other potentially cytotoxic processes have been identified that could also give rise to 
progressive disability in MS, the wide availability of relatively safe sodium channel 
blocking drugs means that inhibition of toxic sodium loading is an attractive target for 
potentially neuroprotective medication.  
 
1.4. Quantifying Neurological Deficit in MS 
Several clinical scales have been developed to quantify MS related neurological 
impairment based on disability, function and quality of life. A few of these are in 
widespread use and it is necessary to be familiar with them in order to make sense of 
much of the data published from MS studies. This section gives an introduction to the 
three clinical scales that have been used in this study. 
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Expanded Disability Status Scale (EDSS) 
The most commonly used tool for quantifying clinical disability in MS is the 
expanded disability status scale (EDSS) (Kurtzke 1983). This is a an ordinal scale in 
which an assessing clinician examines 8 functional systems – visual, brainstem, 
pyramidal, cerebellar, sensory, bowel/bladder, cerebral and ambulatory function - and 
assigns a score of 0-5 for each one (0-6 in the case of the visual system) according to 
defined examination findings. An overall score from 0-10 is assigned based on the 
combined scores from each functional system and an estimation of mobility and 
independent function: zero represents no detectable neurological deficit and 10 death 
due to MS.  
 
Despite being widely used, the EDSS is heavily weighted towards mobility and 
relatively insensitive to upper limb, cognitive and visual dysfunction (Cutter et al 
1999); has relatively poor intra- and inter-rater reproducibility (Noseworthy et al 
1990); and is vulnerable to subjective investigator bias (Noseworthy et al 1994). 
Because of this the National MS Society established a task force to develop a more 
objective and reproducible assessment scale. The result was the multiple sclerosis 
functional composite (MSFC). 
 
Multiple Sclerosis Functional Composite (MSFC) 
In 1999 the National MS Society Task Force on Clinical Outcomes Assessment 
analyzed 14 large treatment trials in MS, evaluating 10 separate measures of 
neurological impairment. Of these 3 were selected on the basis that they best fit the 
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criteria of: 
 reflecting the major dimensions of multiple sclerosis 
 avoiding redundancy 
 being simple to administer 
 being sensitive to change over time 
The three chosen outcome measures were: a measure of mobility, the 25 foot timed 
walk (TW); a measure of upper limb function, the 9-hole peg test (9HPT); and a 
measure of cognitive function, the paced auditory serial addition test – three minute 
version (PASAT-3). For each of these measures a score is calculated, reflecting how 
far an individual’s performance deviates from the mean (z-score) for either the study 
group in question or for the MS population used by the task force (Fischer et al 1999). 
A combined z-score can be calculated from all 3 components, the MSFC. 
 
The MSFC and component measures have since been validated by comparing scores 
against both the EDSS (Cutter et al 1999, Cohen et al 2001, Kalkers et al 2000, 
Fischer et al MS 1999) and a self reported quality of life questionnaire (Miller et al 
2000). Significant correlations have been found between the MSFC and EDSS (Cutter 
et al 1999, Fischer et al 1999, Kalkers et al 2000, Cohen et al 2001, Rudick et al 2001, 
Miller et al 2000) with moderate to strong associations of performance in the timed 
walk and the 9-hole peg test with EDSS and more modest correlation of performance 
in the PASAT-3 with the EDSS (Cutter et al 1999, Cohen et al 2001, Kalkers et al 
2000). In a longitudinal study, MSFC at baseline correlated with both EDSS and 
MSFC at 2 years and change in MSFC correlated with change in EDSS over the same 
time (Rudick et al 2001). 
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Although performance in components of the MSFC (PASAT-3 and 9HPT) are subject 
to a substantial learning effect (Cohen et al 2001, Solari et al 2005), inter-rater and 
intra-rater reproducibility was found to be good when compared to the EDSS (Cohen 
et al 2000).  
 
The range of values for the timed walk, the 9-hole peg test and the MSFC was greater 
in people with progressive MS than in those with relapsing-remitting MS (Kalkers et 
al 2000) and greater in people with higher EDSS (Miller et al 2000, Cutter et al 1999), 
while the range of the PASAT-3 was similar in all clinical phenotypes and EDSS 
groups, perhaps indicating that the MSFC may be the more sensitive measure. 
 
The MSFC does have some limitations. Notably the PASAT-3 is subject to a marked 
learning effect, which can make the interpretation of longitudinal data difficult 
(Polman and Rudick 2010); it is also relatively unpopular with subjects (Aupperle et 
al 2002) and the Symbol-Digit Modalities test has been considered as a possible 
replacement for this component of the MSFC (Drake et al 2010). The MSFC also does 
not include a test of visual function although future revisions may include the Low 
Contrast Letter Acuity Test (Balcer and Frohman 2010). 
 
Overall in it’s present form the MSFC is highly reproducible, correlates with 
established objective and subjective measures of disability, is predictive of and 
sensitive to change in neurological deficit and may be more sensitive than the EDSS 
in people with substantial motor disability and progressive forms of the condition. 
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However whereas the EDSS can be easily and intuitively interpreted by any clinician 
familiar with the standard neurological examination, the connection between MSFC 
and clinical status is not immediately apparent and the interpretation is not so 
straightforward. To allow data from clinical trials to be widely interpreted it is 
convention to include and compare both measures in clinical studies. 
 
Multiple Sclerosis Impact Scale (MSIS-29) 
Investigators’ assessment and patients’ perception of the impact of neurological 
impairment can differ (Rothwell et al 1997). When EDSS has been tested against 
quality of life measures the results have been mixed, some showing no correlation of 
EDSS with quality of life (Simeoni et al 2008) some showing correlations with 
elements specifically dealing with physical function (Amato et al 2001, Gold et al 
2001, Lobentanz et al 2004) and some showing correlation with several aspects of 
quality of life (Janhardan and Bakshi 2000, Nordvedt et al 2000, Benito-Leon et al 
2002, Isaksson et al 2005). Several MS specific questionnaires have been proposed all 
with the aim of evaluating the impact of MS on patient experience and quality of life 
(Mitchell et al 2005). 
 
The Multiple Sclerosis Impact Scale MSIS-29 consists of 29 items; 20 related to the 
physical impact of MS (MSIS-phys) and 9 related to the psychological impact (MSIS-
psych). It was generated through a combination of structured interviews and surveys 
of 1530 randomly chosen people with MS, identifying 29 key questions from an 
initial battery of 129. The questionnaire was compared with widely used generic 
health impact scales and validated with a second sample of 1250 people with MS with 
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responsiveness being gauged by studying 50 patients being treated for acute relapses 
(Hobart et al 2001). 
 
Subsequent studies have shown the MSIS-29 to correlate with: clinician assessed 
disability in patients being treated for acute relapses or for inpatient rehabilitation 
(Riazi et al 2002); and with objective measures of mobility, cognitive and upper limb 
impairment, the MSFC (Hoogervorst et al 2004, Costelloe et al 2008).  
 
1.5. Magnetic resonance imaging (MRI) in MS 
MRI allows investigators to detect and quantify pathology in vivo and so can provide 
extensive information regarding the natural history of MS and how different 
pathological processes may contribute to the development of neurological deficit. In 
clinical practice MRI has become an integral part of the diagnosis of MS (Polman et 
al 2005) and in the UK has been included as part of the decision making process for 
treatment with one of the disease modifying agents (Multiple sclerosis - natalizumab 
for the treatment of adults with highly active relapsing-remitting multiple sclerosis: 
Final appraisal determination – NICE 2007).  
 
Quantitative MRI has become one of the most widely used tools in both natural 
history studies and treatment trials. International consensus committees on the 
investigation and treatment of multiple sclerosis have recommended that MRI 
outcomes be used to evaluate the efficacy of new treatments (Miller et al 1991, 
Whitaker et al 1995, Miller et al 1996, Filippi et al 1998a, Filippi et al 2002). The 
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following section is a brief review of some of the quantitative MRI modalities used in 
MS. 
 
T2 weighted imaging 
The most commonly used diagnostic MRI modalities are T2-weighted fast spin echo 
and fast fluid attenuated inversion-recovery (FLAIR) imaging sequences. Combined 
pathological and radiological studies have shown high signal lesions on T2 weighted 
imaging to be sensitive for the detection of focal white matter lesions (Stewart et al 
1984, Ormerod et al 1987). The presence of T2 hyperintense lesions is central to the 
current, widely accepted diagnostic criteria for both primary progressive (Thompson 
et al 2000, McDonald et al 2001, Polman et al 2005, Polman et al 2011) and relapse-
onset MS (McDonald et al 2001, Polman et al 2005, Polman et al 2011).  
 
T2 hyperintense lesion burden, number or total volume, is also used as a quantitative 
measure of MS pathology. One long term follow up study of clinically isolated 
syndrome (CIS) suggestive of demyelination indicates that during the first 15 years of 
follow up there was a significant correlation between the increase in lesion volume 
and disability (Fisniku et al 2008a). However the correlation between lesion volume 
measures and measures of clinical impairment is poor and the discrepancy between 
lesion volume and disability, the so-called ‘radiological-clinical paradox’ gets more 
substantial as the condition progresses (Li et al 2006). Some cross-sectional studies 
comparing people with progressive MS with age and gender matched patients with a 
more benign disease course have shown that both groups can have similar lesion 
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volumes but radically different levels of disability (Thompson et al 1990, Filippi et al 
1994). Furthermore in a trial of interferon β-1b in 718 subjects with secondary 
progressive MS, the correlation between change in T2 weighted lesion volume and 
change in disability over 3 years was not significant (Kappos et al 1998, Molyneux et 
al 2001). 
 
T2 lesions can be histologically heterogeneous comprising varying levels of 
inflammation, axonal loss (Newcombe et al 1991) and remyelination (Barkhof et al 
2003). Thus if a person has a large volume of less severely damaged or remyelinating 
lesions they may be less neurologically compromised than an individual with a 
smaller number of more severe lesions. 
 
In addition detection of focal lesions on T2 weighted imaging gives limited 
information about surrounding white matter and, using a standard sequence at 1.5 
Tesla (the magnetic field strength of many standard MRI scanners), is relatively 
insensitive for grey matter lesions (Guerts et al 2005). Since extensive pathology is 
seen in both of these regions, particularly in secondary progressive MS (Kutzelnigg et 
al 2005), much of the brain pathology that may be contributing to neurological deficit, 
may be overlooked by basic T2 lesion burden measures. 
 
Although recent meta-analysis has identified that compound measures combining the 
number of new/active lesions and relapse rate can explain a large proportion of the 
variability in EDSS progression (Sormani et al 2009, Sormani et al 2011), much effort 
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has been invested in devising more sensitive and specific MRI markers of brain and 
cord pathology. 
 
Gadolinium DTPA enhancing lesions 
Gadolinium DTPA (Gd) is a paramagnetic contrast agent that crosses an abnormal 
blood-brain barrier (Grossman et al 1986, Miller et al 1988, Hawkins et al 1990, Katz 
et al 1993, Soon et al 2007) to give a high signal on T1 weighted imaging.  
 
The incidence of Gd enhancing lesions correlates with relapse rate in secondary 
progressive MS (Tubridy et al 1998)  and  the incidence of enhancing lesions over 6 
months is weakly predictive of disability at 24 months, but longitudinally there is no 
significant correlation between the incidence of enhancing lesions and change in 
disability (Kappos et al 1999). 
 
Gd enhancing lesion number is felt to be a good MRI marker of acute focal 
neuroinflammation, so is widely used in studies of immunomodulatory treatments (for 
recent examples see Polman et al 2006, CAMMS223 Trial Investigators 2008, 
Giovannoni et al 2010, Kappos et al 2010). However it is not thought to be a sensitive 
measure of neurodegeneration and so measures such as brain atrophy (see section 
1.5.4) have been recommended as more suitable MRI outcomes in studies of potential 
neuroprotective agents (Filippi et al 2005). 
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Magnetic Resonance (MR) Spectroscopy 
Magnetic resonance (MR) spectroscopy enables quantification of several specific 
organic compounds within a chosen region of the brain or spinal cord. Examples 
include compounds such as N-acetyl aspartate (NAA), an amino acid derivative that is 
relatively specific for neurons and axons (Tallan et al 1956, Petroff et al 1995, 
Urenjak et al 1993); creatine/phosphocreatine (Cr.), which is present in many cell 
types and gives a strong, easily detected signal (Urenjak et al 1993); and choline 
containing compounds (Cho) which are also detected in a range of neural cells 
(Urenjak et al 1993), but are found at high concentration in newly enhancing MS 
lesions and so are thought to represent acute demyelination or inflammation (Davie et 
al 1994, Brenner et al 1993). MR spectroscopy has the potential to give additional 
information about the level of demyelination and axonal loss in brain tissue, 
particularly that which is normal appearing on standard T2 weighted imaging, and 
may be more suitable than T2 lesion burden for monitoring neurodegeneration. 
 
Low global NAA/Cr ratio may reflect neuronal and axonal loss with relative 
preservation or increase of interstitial cells such as macrophages or reactive microglia. 
NAA/Cr ratio is low in people with MS compared with controls and is most marked 
among people with secondary progressive MS (De Stefano et al 1998, De Stefano et 
al 2001). In a study comparing chronic white matter lesions in people with relapsing 
remitting MS with a group of people with secondary progressive MS and significantly 
greater disability, NAA/Cr and NAA/Cho ratios were significantly lower in subjects 
with secondary progressive MS (Falini et al 1998) possibly indicating more severe 
axonal loss. However in other studies the cross-sectional and longitudinal correlations 
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with disability were stronger in the relapsing-remitting subgroup (De Stefano et al 
1998, De Stefano et al 2001).  
 
Overall normal appearing white matter (NAWM) NAA concentration has been 
investigated numerous times in relapsing-remitting (Chard et al 2002a, Helms et al 
2000, Schubert et al 2002, van Walderween 1999a, Vrenken et al 2005, Sarchielli et al 
1999) secondary progressive (Helms et al 2000, Schubert et al 2002, van Walderveen 
et al 1999a, Vrenken et al 2005, Sarchielli et al 1999) and primary progressive MS 
(Vrenken et al 2005, Davie et al 1997, Suhy et al 2000). Some studies show lower 
NAA levels in MS than in normal controls (Leary et al 1999a, Sarchielli et al 1999, 
van Walderween et al 1999a, Cucurella et al 2000), while others show no significant 
difference (Chard et al 2002a, Davie et al 1997, Helms et al 2000, Schubert et al 
2002). Sarchielli and colleagues reported that in their cohort of 40 people with MS, 
lower NAWM NAA correlated with higher EDSS (Sarchielli et al 1999). 
 
Grey matter NAA concentration has also been shown to be lower in secondary 
progressive MS than in relapsing-remitting subjects (Adalsteinsson et al 2003). 
However there was no significant correlation between grey matter NAA concentration 
and disability. 
 
MR spectroscopy has been shown to be reproducible across several centres (Geurts et 
al 2004, Benedetti et al 2007) so has generated interest as a potential marker for brain 
pathology in future treatment trials. However problems with low signal to noise ratio 
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(De Stefano et al 2007), questions over the specificity of NAA (Bhakoo and Pearce 
2000), the relatively limited correlation with disability in people with progressive MS 
(De Stefano et al 1998), and the observation that NAA/Cr ratio can increase following 
treatment (Narayanan et al 2001) indicating that observed decreases my be reversible, 
mean that it may not be the best technique for use in trials of possible neuroprotective 
agents in progressive MS.  
 
Brain atrophy  
Pathological studies have indicated that there may be significant brain and spinal cord 
tissue loss in MS (Evangelou et al 2000, Kutzelnigg et al 2005) which is more marked 
in progressive forms of the condition (Kutzelnigg et al 2005). To evaluate whether 
this tissue loss has any impact on disability, investigators have assessed brain and 
spinal cord atrophy on T1 weighted MRI. Techniques developed include regional two 
and three dimensional volume measures, global volume measures and more 
sophisticated techniques involving co-registration of serial images (Miller et al 2002). 
Whatever measure is used, rates of cerebral atrophy are higher in people with multiple 
sclerosis than in normal controls (Kalkers et al 2001a, Fox et al 2000, Anderson et al 
2006). 
 
MRI detectable brain atrophy has been observed in the very earliest stages of MS. For 
example in people with CIS there was significantly more brain atrophy in those 
subjects who subsequently went on to develop MS over one or three years compared 
to those who did not (Brex et al 2000, Dalton et al 2004). Although some studies have 
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suggested that the rate of atrophy is greater in people with relapsing-remitting MS 
than in those with secondary progressive MS (Redmond et al 2000, Pagani et al 2005, 
Filippi et al 2000a), the other studies indicate that rates of change are similar in both 
groups (Fox et al 2000, Kalkers et al 2002, Turner et al 2003). In the case of 
ventricular enlargement (a two dimensional measure of brain atrophy) the rate of 
change has been found to be greater in people with secondary progressive MS (Dalton 
et al 2006).  
 
Many studies have shown correlation between brain atrophy measures and measures 
of neurological deficit in MS. People with MS who show greater disease progression 
also show greater central cerebral atrophy (Losseff et al 1996a, Coles e al 1999, 
Molyneux et al 2000a, Ingle et al 2002) regional atrophy (Gasperini et al 2002) and 
whole brain atrophy (Rudick et al 1999). In a mixed group of 28 people with MS 
including six people with secondary progressive MS there was significant correlation 
between change in brain volume and change in EDSS (Fox et al 2000). A similar 
result was found in a large study assessing central cerebral volume in a group of 239 
people with relapsing-remitting MS (Rovaris et al 2001) while in a group of 160 
patients with relapsing-remitting MS, change in whole brain volume over two (Fisher 
et al 2000), six (Rudick et al 2001) and eight years (Fisher et al 2002) correlated with 
both EDSS and, at the six year timepoint, MSFC. 
 
Recently interest has been focused on grey matter atrophy (Bermel et al 2003, De 
Stefano et al 2003, Sailer et al 2003, Amato et al 2004, Houtchens et al 2007). 
Selective grey matter atrophy has also been observed in CIS (Dalton et al 2004) and 
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early relapsing-remitting MS (Chard et al 2002b, Chard et al 2004, Tiberio et al 
2005). Selective grey matter atrophy has also been identified in people with early 
primary progressive MS (Sastre-Garriga et al 2004) and secondary progressive MS 
(Sanfilipo et al 2005, Tedeschi et al 2005, Furby et al 2008). In addition grey matter 
atrophy correlates with both higher EDSS (Sanfilipo et al 2005, Tedeschi et al 2005) 
and neurological deficit measured with the MSFC (Furby et al 2008). 
 
Brain atrophy measures are responsive, reproducible, well correlated with disability, 
and in the case of newer techniques, semi- or fully automated (Anderson et al 2006). 
As a consequence brain atrophy techniques are now commonly included as an 
endpoint when testing the neuroprotective potential of any medication. In this study a 
number of regional and whole brain atrophy measures were used, both to evaluate the 
effect of presumed neurodegeneration on clinical function and to assess the 
neuroprotective potential of lamotrigine. 
 
Spinal cord atrophy  
Much of the clinical impairment in people with MS is thought to be due to pathology 
of the spinal cord, which is known to be a common site for neuroinflammation and 
axonal loss (Oppenheimer 1978, Lovas et al 2000). Pathological studies of human 
tissue and studies in animal models of MS have confirmed that axonal loss is 
responsible for much of the observed spinal cord atrophy (Lovas et al 2000, 
McGavern et al 2000).  
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There is considerable evidence that clinical disability, estimated using the EDSS, 
correlates with spinal cord cross-sectional area (SCCA) (Losseff et al 1996b) and that 
changes in SCCA over time correlate with changes in EDSS (Stevenson et al 1998, 
Lin et al 2003a, Lin et al 2003b). 
 
Measures of spinal cord atrophy have been identified as potentially sensitive marker 
of axonal loss in chronic MS. An international consensus group report has 
recommended that measures of spinal cord atrophy be included in trials evaluating 
proposed treatments in progressive MS (Filippi et al 2005).  
 
T1 hypointense lesions 
Part or all of some lesions that are high signal on T2 weighted MRI are hypo-intense 
on T1 weighted MRI. In a proportion of T2 lesions the hypointensity on T1 weighted 
imaging represents acute inflammation and is associated with Gd enhancement (van 
Waesberghe et al 1998a, Rovira et al 1999). A proportion of these lesions will become 
isointense as the enhancement wears off, a process that may represent a relative 
resolution of the inflammation and some remyelination (Bagnato et al 2003). 
Persistent T1 hypointensity, however, appear to characterize those focal lesions where 
the level of demyelination and axonal damage/loss is most severe (van Walderveen et 
al 1998, van Waesberghe et al 1999, Fisher et al 2007). 
 
Although it is difficult to identify T1 hypointense lesions on post-mortem imaging, 
one study of five samples from people with progressive MS demonstrated that the 
lesions which were most hypointense on T1 weighted imaging tended to be hypo-
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cellular, with a rim of reactive astrocytes (van Walderveen et al 1998). In combined 
pathological and radiological studies in progressive MS, lesions that were hypointense 
on T1 weighted imaging were more likely to be demyelinated (Fisher et al 2007), 
have lower axonal density (van Walderween 1998, van Waesberghe et al 1999, Fisher 
et al 2007) and have greater axonal cross-sectional area, possibly due to pathological 
swelling (Fisher et al 2007), than those which were isointense with normal appearing 
white matter.   
 
Finally an MR spectroscopic study of 12 people with secondary progressive MS and 
four with relapsing remitting MS found that NAA concentration was significantly 
lower in severely hypointense T1 lesions, whereas the concentration of Cho and Cr 
was relatively preserved (van Walderween et al 1999a). The authors felt that this 
indicated a reduction in axonal density with proliferation of inflammatory and glial 
cells. 
 
In cross-sectional studies the mean T1 lesion volume in subjects with secondary 
progressive MS was higher than in people with primary progressive (Stevenson et al 
1999) or relapsing-remitting MS (Rovaris et al 1999, Tortorella et al 2000). 
Significant correlations of T1 lesion volume with EDSS (van Walderveen et al 2001) 
and upper limb function have been observed (Stevenson et al 1999). However in the 
latter study the correlation of T1 lesion volume with clinical function was no stronger 
than that of T2 lesion volume. 
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In a longitudinal study, comparing 46 people with secondary progressive MS with 29 
people with relapsing-remitting MS who had an equivalent level of disability, T1 
lesion load and ratio of T1/T2 lesion volume correlated with EDSS at baseline and 18 
months. The increase in T1 lesion volume was significantly higher in the progressive 
group and this change correlated with change in EDSS. Finally both change in T1 and 
T2 lesion load were compared in multiple linear regression analysis and change T1 
lesion load was found to be the only MR variable that correlated independently with 
change in EDSS (Truyen et al 1996). Similar results were obtained in a mixed group 
of 19 people with relapse-onset MS (van Walderween et al 1995). In this case there 
was a significant correlation between increase in EDSS and increase in T1 lesion 
volume, but not T2 lesion volume. Furthermore T1 lesion volume at baseline 
correlated with change in EDSS over 24 months.  
 
T1 hypointense lesion burden may give a more specific measure of demyelination and 
neuroaxonal damage than T2 lesion volume so is potentially a better measure for use 
in studies of neurodegeneration and neuroprotection. However there are a number of 
factors which make brain volume measures more suitable as primary end-points: T1 
lesion volume remains a relatively localized measure, giving little direct information 
about neuronal loss at distant sites; lesions which are acutely hypointense sometime 
represent areas of acute neuroinflammation or remyelination (Waesberghe et al 1998a, 
Rovira et al 1999, Bagnato et al 2003) and as such may not be as specific for 
neurodegeneration as brain atrophy; finally although automated techniques for 
contouring T1 hypointense lesions exist (Fisher et al 2007) these are not widely 
available;  in this study a semi-automated technique was used, which was associated 
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with some intra-rater variability. T1 hypointense lesion volume measures were 
obtained to evaluate the correlation with other MRI measures, measures of clinical 
impairment and to quantify, what effect, if any, lamotrigine had on this measure.  
 
Magnetization transfer ratio (MTR) 
Magnetization transfer (MT) imaging is another quantitative MRI technique that, like 
MR spectroscopy, is thought to give a measure of the level of neuroaxonal damage 
and demyelination in a given tissue. MT imaging involves the use of an off-water-
resonance radiofrequency pulse to saturate the nuclei of hydrogen atoms bound to 
large complex molecules - the "bound pool" - which are invisible using conventional 
MRI techniques. Magnetization is transferred from the saturated hydrogen atoms in 
the bound pool to hydrogen atoms in adjacent free water - the "unbound pool". This 
reduces the intensity of the signal seen in the image as the atoms in the free pool 
which previously contributed to the returned signal are now saturated. The greater the 
concentration of complex molecules in a tissue, the greater the reduction of the 
returned signal (Wolff and Balaban 1989). The ratio of pre- to post- saturation signal 
intensity from a given tissue, the magnetization ratio (MTR) therefore gives a measure 
of the macro-molecular content of the tissue.   
 
An MRI study in early life demonstrated that MTR increases with maturation through 
childhood and that the sites of MTR increases corresponded to the sequence of 
myelination obtained from previous postmortem studies (Rademacher et al 1999). 
Furthermore pathological studies in MS have also shown that low MTR correlates 
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with low myelin content in both T2 high-signal lesions (Schemierer et al 2004, 
Barkhof  et al 2003, Fisher et al 2007) and white matter that appears normal on T2 
weighted MRI (van Waesberghe 1999, Vrenken et al 2006). MTR is also low in CNS 
demyelinating diseases other than MS, e.g. central pontine myelinolysis or 
adrenoleukodystrophy (Davie et al 1999, Fatemi et al 2005, Melhem et al 1996).  
 
However low MTR may also denote neuroaxonal loss. In pathological studies low 
MTR correlates with low axonal content in both T2 lesions and normal appearing 
brain tissue (van Waesberghe et al 1999). In vivo T1 hypointense lesions, those more 
likely to show higher levels of axonal damage, have been shown to have low MTR 
compared to surrounding tissue (Heihle et al 1995, Filippi et al 1999, Fisher et al 
2007), while low MTR has also been shown to correlate with other putative measures 
of axonal loss such as low NAA concentration (Davie et al 1999) and global and 
regional brain atrophy (Phillips et al 1998, Traboulsee et al 2003, Khaleeli et al 2007).  
 
Overall MTR in whole brain (Kalkers et al 2001a, Rovaris et al 2001), normal 
appearing brain tissue (Traboulsee et al 2003) NAWM (Cercignani et al 2001, Ge et al 
2002a, Dehmeshki et al 2003, Davies et al 2004, Beniek et al 2006, Vrenken et al 
2007) and grey matter (Agosta et al 2006, Cercignani et al 2001, Davies et al 2004, 
Davies et al 2005a, Dehmeshki et al 2001, Ge et al 2002a, Griffin et al 2002) is lower 
in people with MS than age and gender matched controls.  
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Although not all studies have found significant correlations between MTR measures 
and disability (Rovaris et al 2001, Tortorella et al 2000, Davies 2005a, Davies et al 
2005b Oreja-Guevara et al 2006), highly significant cross-sectional correlations have 
been identified of whole brain (Dehmeshki et al 2001, Kalkers et al 2001a, Inglese et 
al 2003), lesion (Gass et al 1994, Traboulsee et al 2003), normal appearing brain 
tissue (Traboulsee et al 2003, Rammio-Torrenta et al 2006), NAWM (Leary et al 
1999b, Ramio-torrenta et al 2006) and normal appearing grey matter (NAGM) 
(Dehmeshki et al 2003, Davies et al 2004, Ramio-torrenta et al 2006) MTR measures 
with EDSS.  Whole brain matter MTR measures have been found to correlate with 
cognitive function (Kalkers et al 2001a), grey matter MTR measures have been 
correlated with cognitive function (Ramio-torrenta et al 2006, Khaleeli et al 2007) 
upper limb function and mobility (Vrenken et al 2007, Davies et al 2004), while 
NAWM MTR has been shown to correlate with upper limb function and mobility 
(Ramio-torrenta et al 2006). MTR changes in normal appearing brain tissue and lesion 
MTR measures at baseline can predict later disability (Santos et al 2002, Rovaris et al 
2003a) and correlate with changes in disability over time (Filippi et al 2004, Santos et 
al 2002).  
  
In short, MTR appears to give a measure of both myelin and axonal content, is lower 
in people with MS than in age and sex matched controls with no known neurological 
deficit, changes with time, and correlates with disability and neurological deficits both 
cross-sectionally and longitudinally. MTR may be sensitive to change in subjects 
where a change in T2 lesion volume is not (Filippi et al 2000b). It is also a highly 
reproducible measure (Rovaris et al 1997, Sormani et al 2000, Inglese et al 2001) so is 
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appealing as a potential marker of disease progression. An international consensus 
conference has recommended that MTR measures be included as an adjunctive tool to 
monitor disease in clinical trials (Filippi et al 2005). In this study a large number of 
MTR measures have been acquired to evaluate the correlation with other MRI 
measures of pathology and to help elucidate the potential neuroprotective effects of 
lamotrigine in MS. 
 
Diffusion tensor imaging (DTI) 
Diffusion is the term used for the random motion of free water molecules. In intact 
neural tissue, particularly white matter, this motion is thought to be somewhat 
restricted and tends to be anisotropic with major axonal tracts. Pathological processes 
such as inflammation, demyelination and axonal transection will lift some of this 
restriction and allow localized relative istropic diffusion of free water molecules. This 
can be detected with and quantified using MRI sequences termed diffusion weighted 
imaging (DWI) (Le Bihan et al 2001) one of which is diffusion tensor imaging (DTI) 
(Pierpaoli et al 1996). 
 
The DTI characteristics of each tissue type – T2 hyperintense lesions, T1 hypointense 
lesions, grey matter and NAWM – differ from each other and the DTI characteristics 
of MS tissue differs from equivalent tissue types, where applicable, in non-MS 
controls (Rovaris et al 2005).  
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Studies have identified some correlation between diffusion imaging measures and 
clinical status and so it has the potential for use as an MRI endpoint in clinical trials 
(Rovaris et al 2005). However at the present time the exact nature of the pathological 
substrate underlying DTI abnormalities is not fully understood. DTI has not been used 
as an endpoint in this study, in which the principal focus is neurodegeneration, but 
may well appear as a secondary endpoint in future treatment trials.  
 
1.6. Treatment of MS 
At the moment the treatment of progressive MS is largely symptomatic. Although 
corticosteroids can accelerate recovery from acute relapses (Filippini et al 2008) and 
immunomodulatory drugs are used to effectively reduce relapse frequency, no 
medication has yet been developed which has been shown to provide long-term 
protection from progressive disability without the risk of serious side-effects (Edan et 
al 1997,  Hartung et al 2002, Marriott et al 2010).  
 
One of the aims of this study was to evaluate lamotrigine as a potential 
neuroprotective drug, with the hope that it could be shown to ameliorate some of the 
pathological processes that are thought to give rise to progressive disability. The 
following section is a brief review of the immunomodulatory drugs that are currently 
available followed by a summary of rationale behind testing the neuroprotective 
potential of lamotrigine.  
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Immunomodulatory drugs 
Interferon β 1a and 1b have been tested extensively in both relapsing-remitting and 
progressive MS. Both compounds reduce the frequency of acute relapses in relapsing-
remitting and secondary progressive MS by about 30% (Paty and Li 1993, Kappos et 
al 1998, Jacobs et al 2000, Comi et al 2001a, Li et al 2001, Cohen et al 2002, Panitch 
et al 2004, Kappos et al 2006) and reduce the number of new, radiologically 
detectable inflammatory lesions during the trial period (Panitch et al 2004, Li et al 
2001, Cohen et al 2000, Leary et al 2003) and can reduce the proportion of subjects 
with sustained progression to a higher EDSS (Kappos et al 1998, Kappos et al 2004). 
Unfortunately neither have been shown to have any effect on the rate of progression 
of irreversible disability in entirely progressive forms of the condition (Panitch et al 
2004, Li et al 2001, Cohen et al 2000, Leary et al 2003) and the apparent effect on 
disability in the relapsing cohorts may in fact be due to an effect on disability due to 
relapse (Ebers et al 2008). 
 
One of the proposed MRI markers of neurodegeneration is brain atrophy (see 
section1.7.4). People with relapsing-remitting MS in the verum arm of a trial of 
interferon β 1a had significantly less brain atrophy over the course of the study than 
those in the placebo group (Zivadinov et al 2007). However in a similar cohort these 
differences were not sustained in the long-term (Kappos et al 2006) and have not been 
seen in studies of primary (Montalban et al 2009) or secondary MS (Molyneux et al 
2000a). 
  
A second compound, glatiramer acetate, has also been shown to reduce relapse rate 
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and MRI activity in people with relapsing-remitting MS (Johnson et al 1995b, 
Johnson et al 1998, Comi et al 2001b) but, like interferon, has yet to be shown to 
ameliorate progressive disability (Wolinksy et al 2007) 
 
Mitoxantrone, an antineoplastic agent, has been shown to reduce relapse rate in 
relapsing remitting and secondary progressive MS by approximately 66-76% 
(Hartung et al 2002, Edan et al 1997) with an associated mean improvement in EDSS 
compared with baseline (Hartung et al 2002). However potentially serious side-effects 
such as cardiotoxicity with a lifetime cumulative dose of >100mg/m
2
 (Ghalie et al 
2002) and the risk of promyelocytic leukaemia (Voltz et al 2004) have meant that in 
the UK the use of mitoxantrone is limited to people with rapidly progressive MS with 
both clinical and MRI evidence of active inflammation. 
 
Several new compounds have been developed in recent years which may be more 
effective than interferon, with a less prohibitive side-effect profile than mitoxantrone. 
Natalizumab is a monoclonal antibody to the α4 subunit of α4β1 and α4β7 integrins, 
molecules that facilitate binding of leukocytes to inflamed brain endothelium 
(Yednock et al 1992). It is thought to limit the migration of T cells across the blood 
brain barrier and hence has been shown to reduce frequency of relapses by up to 68% 
over two years (Polman et al 2006). A trial of monotherapy with natalizumab in 942 
people with MS reported a generally favourable safety profile (Polman et al 2006). 
However in a parallel trial of combined therapy in 1171 people with MS, where 
natalizumab was administered with interferon β 1a, 2 subjects developed progressive 
multifocal leukoencephalopathy (PML), a potentially fatal and rapidly progressive 
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demyelinating condition (Rudick et al 2006b, Yousry et al 2006). At the time of 
writing (October 2011) 170 further cases of PML have been reported from the 88,100 
people treated with Natalizumab worldwide (data supplied by Biogen Idec Inc.). At 
the present time in the UK the use of natalizumab is restricted to people with rapidly 
evolving severe relapsing–remitting multiple sclerosis or those who were previously 
participating in clinical trials of natalizumab.  
 
Promising results have been obtained with several other immunomodulatory 
compounds. Alemtuzumab, a monoclonal antibody directed towards the lymphocyte 
surface protein CD52, which causes prolonged lymphocyte depletion (Coles et al 
2006), has been shown to reduce the frequency of relapses in early relapse-onset MS 
by up to 74%  with an associated improvement in EDSS over the course of the trial 
(CAMMS223 Trial Investigators 2008). However an earlier study in secondary 
progressive MS showed that the effect was principally on acute inflammatory activity, 
with less effect on progressive disability, or on MRI measures of neurodegeneration 
(Coles et al 1999). 
 
A monoclonal antibody that causes depletion of CD20+ B cells, Rituximab, has been 
tested in a small cohort of people with relapsing-remitting MS over a short time-scale 
and been shown to reduce relapse rate by approximately half (Hauser et al 2008). 
However larger, longer studies will be needed to evaluate the efficacy and safety 
profile of Rituximab, particularly since there are case reports of PML in patients being 
treated with rituximab albeit for conditions other than MS 
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(http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients
andProviders/ucm126519.htm).      
 
All of the above medications are parenterally administered, which limits their 
acceptability to some patients. Positive trials have recently been published for several 
oral compounds: cladribine and fingolimod both reduce relapse rate by approximately 
half compared to placebo (Giovannoni et al 2010, Kappos et al 2010), although 
concerns over safety mean that cladribine is unlikely to be granted marketing 
authorization by the Committee for Medicinal Products for Human Use 
(http://guidance.nice.org.uk/TA/Wave20/69). Teriflunomide has been found to reduce 
relapse rate by approximately 30% (O’Connor et al 2011); phase III trials of 
laquinimod and dimethyl fumarate have recently been completed with initial reports 
suggesting annualized relapse reduction rates of approximately 30 and 50% 
respectively (Comi et al 2011, 
http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1
621631). People in the verum arm of the fingolimod and teriflunomide trials had 
significantly less brain volume loss and a smaller increase in T1 hypointense lesion 
volume than the placebo group perhaps suggesting that these substances may have 
some neuroprotective effect. 
 
Neuroprotection 
Based on the fact that the majority of immunomodulatory compounds that have been 
tested in MS have significant effect on both the clinical and radiological stigmata of 
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acute neuroinflammation without seeming to influence clinical and radiological 
evidence of progressive neurodegeneration (see section 1.3a). Investigators have 
therefore started to consider whether other compounds, with a primary action that is 
not immunomodulatory, may be neuroprotective and hence slow down the 
development of progressive disability.   
 
A large number of different compounds are currently under investigation as potential 
neuroprotective agents. Among these are drugs which block voltage gated sodium 
channels since it is possible that intracellular sodium accumulation can damage 
chronically demyelinated axons (see section 1.3.5). 
 
In EAE, the rodent model of MS, several sodium channel blockers including 
lamotrigine, flecainide and phenytoin have been shown to prevent axonal loss and 
reduce disability (Lo et al 2003, Bechtold et al 2004, Bechtold et al 2006). Of these 
lamotrigine was felt to be the most suitable candidate for the first clinical trial in 
human subjects; compared to phenytoin, lamotrigine had a greater effect on 
preserving axonal density and clinical statius in EAE (Kapoor, personal 
correspondence), while flecainide was felt to have an unfavorable side-effect profile 
which would limit its widespread use (CAST investigators 1989).  
 
A phase II clinical trial of neuroprotection with lamotrigine in people with secondary 
progressive MS at the Institute of Neurology in London forms the basis of this thesis. 
The trial was completed in early 2009. 
 
 55 
1.7. Conclusion 
 
MS is a chronic neurological condition that in many cases is associated with 
significant disability. It is associated with inflammation, demyelination and 
neurodegeneration, the last of which may be largely responsible for progressive 
neurological disability. Although a range of treatments have been developed that can 
reduce the incidence of acute inflammatory lesions and relapses, there is little 
evidence that they confer any significant protection against the development of 
progressive disability. 
 
Some evidence exists suggesting that sodium loading of chronically demyelinated 
axons may give rise to some neurodegeneration and that sodium channel blockers 
such as Lamotrigine could be neuroprotective. 
 
A number of clinical assessment tools have been developed which allow investigators 
to quantify levels of neurological function, disability and MS related reduction in 
quality of life. However even the most reliable clinical measures in MS are subject to 
a high degree of longitudinal variability, both between and within individuals. 
 
Quantitative MRI is a powerful tool which gives investigators in vivo measures of 
brain pathology. MRI is reproducible, carries little risk, is well tolerated and can be 
used to obtain serial data points making it ideal for longitudinal monitoring. Even 
when trials are blinded, clinical measures are vulnerable to investigator and subject 
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bias (Noseworthy et al 1994). By contrast MRI analysis can be blinded and, provided 
adequate quality assurance procedures are followed, can be standardized 
longitudinally and between centres. 
 
In this study clinical and MRI data was collected from a large group of people with 
secondary progressive MS who were taking part in a double-blinded, randomized, 
placebo-controlled trial of lamotrigine. The MRI techniques chosen were those that 
were felt to best capture neurodegeneration. Cross-sectional and longitudinal 
correlations between the MRI and clinical data were assessed to gain further insight 
into which pathological changes give rise to clinical impairment and which MRI 
modalities are most useful for monitoring progressive MS. The main focus of this 
thesis is the clinical correlation of MTR and T1 hypointense lesion measures. 
However atrophy and T2 hyperintense lesion volume data is presented where relevant. 
The effect of lamotrigine on MRI and clinical measures was also assessed to evaluate 
the neuroprotective potential of this compound. 
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2. Methods 
2.1. Introduction: A randomized, double-blind, placebo-controlled trial of 
neuroprotection with lamotrigine in secondary progressive MS. 
Data presented in this thesis are taken from a randomized, double-blinded, placebo-
controlled, parallel arm trial of neuroprotection with lamotrigine in secondary 
progressive MS. Central cerebral volume (CCV) (see section 1.5) has been shown to 
be a reproducible and sensitive measure (Losseff et al 1996a) which changes in 
secondary progressive MS over 24 months (Molyneux et al 2000a) so was chosen as 
the primary end-point. The study was powered to detect a difference in change in 
CCV between verum and placebo arms.  
 
Several other MRI endpoints, which were felt may be more sensitive (Anderson et al 
2006), or to give different information, including MTR and T1 hypointense lesion 
volume (see section 1.5), were also measured.  
 
Informed consent was taken from all subjects prior to the acquisition of any clinical or 
MRI data. Ethical approval for the lamotrigine trial was given by the Joint 
UCL/UCLH Committee on the Ethics of Human Research (Committee A). The trial 
was registered with the US National Institute of Health 
(http://clinicaltrials.gov/ct2/show/NCT00257855?term=lamotrigine+multiple+sclerosi
s&rank=1) and the UK Medicines and Healthcare Regulatory Authority and was 
conducted according to  International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Good Clinical 
Practice (ICH-GCP) guidelines. Recruitment and data collection was monitored by 
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UCL Research and Development Department and was reviewed by an independent 
data and ethics monitoring committee. 
 
The trial was funded by the MS Society of Great Britain and Northern Ireland and 
Sponsored by University College London. Neither party had any involvement in data 
collection, analysis, interpretation or the dissemination of results. 
 
2.2. Subjects 
The subjects in this study comprised 118 people with secondary progressive MS who 
were recruited into a randomised, placebo controlled trial of neuroprotection with 
lamotrigine. 
 
A sample size of 120 subjects, 60 in the verum arm and 60 in the placebo arm was 
calculated. This was based on a power of 80%, to detect a 60% reduction in the 
change of CCV, with a significance level of 5% and combined loss to follow up and 
non-compliance of 20%. The sample size calculation was based on change in CCV 
from 17 people who took part in a natural history study (data from Professor Alan 
Thompson) and 46 people from the placebo arm of a trial of beta-interferon in 
secondary progressive MS (Molyneux et al 2000a, Molyneux et al 2000b). The mean 
rate of brain atrophy from these two groups was estimated at approximately 1% per 
annum. A treatment effect of 60% was extrapolated from EAE data, in which 
lamotrigine treatment gave rise to a 50% reduction in axonal loss. The 20% drop-out 
rate was estimated from clinical experience of sodium channel blocker treatment in 
MS (RK and DHM). ANCOVA and multi-level, random-intercept linear regression 
models were simulated and gave sample sizes of n=57 and n=48 respectively for each 
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arm, thus a sample size of n=60 in each arm was felt to be sufficient for the more 
powerful model, allowing for equal drop-out in each arm. 
 
The sample size calculations were done by DA. 
 
Recruitment into the lamotrigine trial was conducted by two investigators (myself and 
JF). A list of 354 potential subjects was generated from consultant referrals and by 
surveying all the hospital letters of three of the multiple sclerosis specialists at the 
National Hospital for Neurology and Neurosurgery (NHNN), London (DHM, RK and 
GG); two specialists at the Royal Free Hospital Hampstead (RFH) (RB and AG) and 
one at St Albans Hospital Hertfordshire (RB) 
 
Subject information leaflets were posted to all potential subjects. All subjects were 
then contacted by telephone and screened to ensure that they met the 
inclusion/exclusion criteria for the trial. The inclusion criteria were: 
 Age 18-60 years.  
 Subjects should have a clinical history including one or more episodes of 
acute neurological deficit with full or partial recovery and a subsequent 
history of progressive neurological deterioration, the latter being the main 
cause of disability over the preceding 24 months. Evidence of clinical 
progression was taken from medical records or from prospective subjects 
reporting a reduction in mobility equating to a one point increase in EDSS 
over two years. 
 EDSS 4 to 6.5 – this was checked by determining that a subject had some 
limitation of mobility (a limited exercise tolerance – EDSS 4.0) but were 
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able to walk at least 10m with bilateral assistance (EDSS 6.5) (See 
appendix 3). 
 
The exclusion criteria comprised:  
 Eligibility for disease-modifying treatment under 2001 recommendations 
of the Association of British Neurologists. 
 Pregnancy. 
 Progression of ≥ 2 EDSS points over the preceding 12 months. 
 The use of sodium or calcium channel blockers during the two weeks 
preceding the baseline scan; corticosteroids in the preceding two months; 
beta interferon, glatiramer acetate or other immunomodulatory drugs in the 
preceding six months or mitoxantrone in the preceding year. 
 History of serious systemic illness other than multiple sclerosis or any 
evidence of abnormal renal or hepatic function. 
 Previously documented adverse reaction to lamotrigine. 
 Disabling temperature dependent exacerbations of neurological 
impairment. 
 Contraindications to MRI scanning e.g. pacemakers, cerebrovascular 
aneurysm clips or a previous penetrating injury with metal objects. 
 
A total of 130 eligible subjects were invited for interview of whom 10 declined or 
were rendered unsuitable because of abnormal blood test results. 
 
120 subjects gave informed consent were randomly assigned to either active treatment 
or placebo using minimization. Minimization is a form of stratified randomization 
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process, whereby the probability of an individual being assigned to a given group is 
weighted according to the characteristics of the subjects who have already been 
allocated to each group. Although less suitable for large studies, in smaller trials, such 
as the lamotrigine trial, it improves the likelihood that the two groups will be 
balanced. The minimization criteria used in the lamotrigine trial were: 
 Sex 
 Age ≥ 50 
 EDSS ≥ 5.5 
 Site recruited from (NHNN or RFH) 
 Clinical fellow seen at screening 
 
By including the recruiting clinical fellow in the minimization criteria any differences 
in patient outcome related to the intervention of the treating physician (see section 
2.3) or to inter-rater differences in clinical assessment or MRI analysis should be 
evenly spread between the two groups. 
 
Minimization was done with concealed allocation using a fully automated, web-based 
protocol www.SealedEnvelope.com. (Sealed Envelope Ltd. London. UK). Patients 
were given a randomization number which was matched to a confidential treatment 
number by the study pharmacist assigning patients to either lamotrigine (in a 
sustained release form, Lamictal XR, GlaxoSmithKline, UK) or to a visually identical 
placebo tablet. Only the pharmacist was aware of the treatment allocation throughout 
the study; both subjects and investigators were blinded to treatment allocation for the 
complete duration of the trial. All MR images were analyzed and all statistical 
analysis protocols were established prior to unblinding.  
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Following randomization, two subjects experienced acute neurological deterioration 
which meant that they were unable to attend for baseline assessment. One subject was 
unable to tolerate MRI scanning. 117 subjects underwent the full MRI and clinical 
assessment at baseline. A summary of the recruitment and screening process is shown 
in Table 1. 
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Figure 1. A summary of the recruitment and screening process for the lamotrigine 
trial. One subject discovered that she was too claustrophobic to tolerate the full MRI 
protocol. 
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After randomization subjects attended for baseline assessment, which included 
clinical assessment (see section 2.3) and acquisition of MRI images.  
 
The investigational medicinal product (IMP) was dispensed by the treating physician. 
The dose of the IMP was escalated using the following regime, which was 
recommended by the Department of Epilepsy at NHNN (Prof John Duncan): 
 
25mg daily for two weeks, 50mg daily for two weeks, 100mg daily for one week, 
200mg daily for one week, 300mg daily for one week, 400mg daily for one week.  
 
Subjects were encouraged to find the highest dose at which they did not suffer un-
acceptable side-effects and this was established as the maintenance dose for the rest of 
the trial. Subjects met with their treating physician at three-monthly intervals until the 
end of the trial to report on side-effects, return un-used IMP and collect a new supply 
for the following three months. Once established on the maintenance dose of the IMP, 
subjects continued with that dose until a date approximately 24 months after the 
baseline visit, at which point the IMP was de-escalated over three months.  
 
 
When assessing the effects of lamotrigine treatment on MRI and clinical measures 
both intention to treat (including all subjects randomized) and per-protocol (including 
only those subjects who were judged to be compliant) analyses were employed.  
 
Compliance with treatment was evaluated in two ways: 
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1. By calculating the number of tablets that a subject should have consumed 
since the preceding visit, calculating the number of tablets that should be 
returned, counting back the number of tablets that were actually returned and 
comparing the two values. Subjects were considered to be ‘tablet compliant’ if 
they appeared to have consumed ≥80% of the tablets and were still taking the 
tablets at 24 months. An 80% threshold for treatment adherence is widely used 
in clinical trials (Robiner 2005) and is in line with the lower levels of 
adherence seen with established disease modifying treatments in MS (Bruce et 
al 2010).    
2. By measuring serum lamotrigine levels at 6, 12, 18 and 24 months. Subjects 
were considered to be ‘serum compliant’ if they had detectable serum 
lamotrigine levels at 24 months. 
 
A study, published after all the subjects in the lamotrigine had been started on the trial 
medication, showed that in experimental allergic encephalomyelitis sudden 
withdrawal of two sodium channel blockers, carbamazepine and phenytoin, lead to 
rebound CNS inflammation and clinical deterioration (Black et al 2007).  
 
To evaluate whether a similar response may have been occurring the subjects on the 
active arm of the lamotrigine trial, further MRI and clinical data were acquired  at 27 
months, after subjects had withdrawn from the trial medication. In the absence of Gd 
enhancing lesion number, T2 lesion volume and the incidence of new T2 lesions were 
felt to be the best MRI markers of new inflammatory activity and so were acquired at 
27 months.  
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There was also concern that lamotrigine may have direct, osmotic effect reducing 
overall brain and spinal cord volume in the subjects in the verum arm, which could 
potentially obscure a positive treatment effect. To evaluate this possibility CCV and 
whole brain atrophy estimated using Structural Image Evaluation using Normalisation 
of Atrophy – longitudinal method (SIENA) (see section 2.4) were also calculated at 
27 months.  
 
In total 69 subjects consented to have an MRI scan and full clinical assessments at 27 
months. MTR and T1 lesion volume data were not acquired at 27 months.  Data from 
the 27 month timepoint has been published elsewhere (Kapoor et al 2010).  
 
2.3. Clinical data in the lamotrigine trial. 
Clinical data comprised: baseline demographic details and clinical history, i.e. age, 
sex, date of first neurological symptom, and date of diagnosis; EDSS; MSFC and 
component measures; and MSIS-29. All adverse events experienced during the 24 
month trial period, including clinical relapses, were also recorded. On four occasions 
clinical data were collected by colleagues (AH and SG), otherwise all clinical data 
were collected by the same two investigators (myself and JF) 
 
To ensure, as far as possible, that the objective clinical endpoints were not influenced 
by the investigators knowledge of how a subject was reacting to the trial medication 
each subject was assigned a treating and assessing physician.  
 
The treating physician was the investigator who saw the subject at screening, 
collected the demographic and clinical data at baseline, prescribed the trial medication 
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and saw the subject on a three monthly basis to discuss clinical problems, e.g. side-
effects, relapses and other adverse events. The assessing physician’s only role was to 
collect the EDSS, MSFC and MSIS-29 at baseline, six, 12, 18 and 24 months. In a 
subset of subjects (see above) these measures were also acquired at 27 months. 
 
Each investigator was responsible for screening 60 subjects and so was automatically 
assigned as assessing physician for the other 60 subjects.  
 
EDSS 
The EDSS comprises a structured clinical history and examination performed by an 
investigator who had undergone prior training using a web based training protocol 
(www.neurostatus.net).  
 
The range of EDSS values was narrow – 4.0 to 7.5 at baseline (see table 4). Therefore 
for cross sectional analysis subjects were classified as being in either a low disability 
group (EDSS ≤ 6.0) or a high disability group (EDSS ≥ 6.5), which ensured a 
relatively even split of subjects.  
 
For longitudinal analysis patients were divided into groups depending on whether or 
not they had experienced sustained disability, defined as an increase of ≥0.5 points 
from baseline observed at two consecutive assessment visits in subjects with a 
baseline EDSS of ≥ 6.0 or a sustained increase of 1.0 in subjects with a baseline 
EDSS of ≤ 5.5 (Weinshenker et al 1991a, Weinshenker et al 1991b).  
 
MSFC  
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The MSFC was conducted and recorded using an internationally agreed protocol 
(Fischer et al 2001; http://nationalmssociety.org/for-professionals/researchers/clinical-
study-measures/msfc/index.aspx). Both investigators received training in 
administering the MSFC from an experienced practitioner (DS and RF) prior to 
collecting any data. The MSFC comprises three component tests: a test of ambulation 
- TW; a test of upper limb function – 9HPT and a test of cognitive function – the 
PASAT-3.  
 
The PASAT-3 is known to be subject to a measurable learning effect which attenuates 
after three or four repetitions (Cohen et al 2001, Solari et al 2005). All subjects 
completed three iterations of the PASAT over a two week period prior to the 
collection of the baseline data. Results of these ‘Practice’ PASAT tests are shown in 
figure 2. The score in the first attempt was significantly lower than score used as the 
baseline PASAT value (t= 4.832, p<0.0001). 
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Figure 2. The effect of practice on PASAT-3 scores. The dots and black line indicate 
the mean PASAT-3 score for the whole SPMS study group. The red lines show the 
standard error of the mean at each iteration. 
 
 
 
When a subject was unable to complete the 9HPT due to disability a score of 777 
seconds was allocated (Cutter et al 1999). Where a subject was unable to complete the 
TW due to disability a score of 180 seconds was allocated. The latter was chosen 
because it is similar to the maximum time observed in the pooled dataset used by the 
National MS society to create the MSFC (Fischer et al 2001). None of the subjects 
were unable to complete the PASAT-3. 
 
The three component measures were combined to generate the MSFC combined score 
using the following formula: 
 
MSFC = (Z 1/9HPT + Z -TW +Z PASAT-3)/3 
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Where Z is: (the mean score for a subject at a given timepoint - the mean score for the 
whole study group at baseline)/ the standard deviation of the scores for the whole 
study group at baseline. 1/9HPT here refers to: (1/mean score for the dominant hand + 
1/mean score for the non-dominant hand)/ 2. 
 
In addition to the overall MSFC score, the component scores were considered 
individually. For cross-sectional statistical analysis the PASAT-3 was treated as a 
continuous variable. Reciprocals of the TW and 9HPT were used for all analysis, 
meaning that a higher score represented a better performance in the test and making 
the results easier to interpret.  
 
Longitudinal change in MSFC or any of the component measures was calculated as 
the value at the second timepoint minus the value at the first, so a negative value 
represented a fall in that measure over time. 
 
 
MSIS-29 
The MSIS-29 is a self reported questionnaire about the impact of a subject's MS over 
the preceding two weeks. This was completed by the subject, with the assistance of 
one of two investigators (myself and JF) where the subject had marked upper limb 
impairment. It comprises 20 questions relating to physical impairment (MSIS-phys) 
and nine questions relating to psychological wellbeing (MSIS-psych) (See appendix 
1). The physical and psychological scores for the MSIS-29 were recorded separately. 
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Relapses 
Relapses were defined as a new neurological symptom, or deterioration of an existing 
neurological symptom, in the absence of any concurrent potentially confounding 
systemic medical conditions, such as infection, with an acute or sub-acute onset, 
duration of greater than 24 hours and partial or total recovery. Subjects were 
encouraged to contact the investigators as and when they experienced any 
neurological symptoms and the number of relapses was totalled at 24 months.  It was 
decided that relapse rate should be converted to a binary variable with subjects 
divided into those who had experienced one or more relapses during the two year 
follow up period and those who had none. 
 
2.4. MRI data in the lamotrigine trial 
Five MRI sequences were used in the lamotrigine trial; a list of these with the 
acquisition parameters is shown in Table 1. All of these sequences have been 
previously used in human studies and been shown to have good reproducibility. 
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Table 1. MRI characteristics and acquisition parameters used in the lamotrigine 
trial. PD = proton density, TR = repetition time, TE = echo time, μT = micro tesla, TI 
= inversion time, 2D = two dimensional, 3D = three dimensional, FOV = field of 
view. 
 Sequence MRI Characteristics 
1 2D T1 weighted* - Brain 
(Losseff et al 1996a) 
46 contiguous 3mm slices – 
TR 550ms, TE 15ms; FOV 240x180mm; Matrix 
256x256; voxel size 1.98mm
3
 
2 2D PD weighted/T2 dual fast 
spin echo* - Brain 
(Molyneux et al 2001) 
2 interleaved sequences PD and T2 each 46 
contiguous 3mm slices 
 TR - 2500 ms, TE – PD 20ms T2 80m; , FOV 
240x180mm; Matrix size 256x256; voxel size 
1.98mm
3
 
3 MTR* - Brain 
(Barker et al 1996) 
4 interleaved sequences each of 28 x 5mm 
contiguous slices: PD, T2 weighted, with and 
without MT saturation – a total of 112 images. 
TR 1730ms, TE 30/80ms 
MT saturation pulse 14.6 μT,                                      
64ms in duration, 1 kHz off resonance; FOV 
240x180mm; Matrix 256x128; voxel size 
6.59mm
3
 
4 3D T1 weighted fast-spoiled 
gradient recall inversion 
recovery (FSPGR-IR)†- Brain 
(Fox et al 2000) 
124 contiguous 1.5mm slices  
TR 10.9ms, TE 4.2ms,  TI 450ms; FOV 
250x190mm; , matrix 256x192 1.28 ; voxel size 
1.28mm
3
 
5 T1 FSPGR-IR – Cervical and 
upper thoracic spinal cord‡ 
(Losseff et al 1996b)  
60 contiguous 1mm slices 
TR 13.2ms, TE 4.2ms; FOV 250x250mm; Matrix 
256x256 ; voxel size 1.95mm
3
 
*acquired in the axial oblique plane to pass along the inferior borders of both the 
anterior genu and posterior splenium of the corpus callosum (Gallagher et al 1997). 
†acquired in the coronal plane, not oblique to any subject landmarks 
‡acquired in the sagittal plane following an axial pilot at the level of the C7 vertebral 
body  
 
All MRI data were acquired using the same Signa 1.5 Tesla scanner (General Electric, 
Milwaukee, WI, USA). Scan data was transferred from the scanner via a secure 
network and stored in a dedicated library. All subject identification data - name, date 
of birth, date of scan - was removed from the images prior to analysis.  
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All analysis was performed using Sun Blade 150 Workstations (Sun Microsystems, 
Mountainview, Ca, USA). All post acquisition MRI analysis for this study was 
performed by two investigators (myself and JF).  
 
In accordance with departmental policy, control subjects with no known neurological 
condition and specially designed ‘phantoms’ with a set shape and proton density were 
scanned on a regular (monthly) basis for quality control and to ensure that there was 
no change in MRI derived measures.  
 
Part way through the trial, between the 12 and 24 month timepoints, a major 
component of the scanner, the gradient coil, was replaced. To identify whether this 
was associated with any step-change in absolute values of any of the MRI measures 
three volunteers (AB, KC and MY) agreed to be scanned 10 times over a four month 
period before and after the replacement of the gradient coil. There was no significant 
change in the absolute values or the variability of any of the volume measures or 
normal appearing brain tissue MTR measures.  
 
It was not possible to test in the controls whether lesion measures – volume, activity 
or MTR - changed significantly following the replacement of the gradient coil. An 
unselected sub-group of 27 lamotrigine trial subjects did agree to undergo a further 
scan at 18 months, with lesion volume and MTR analysis, to try and evaluate the 
effects of the equipment change on lesion measures. It was not possible to detect any 
significant change in these measures which could be attributed to the gradient coil 
replacement.  
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T2 hyperintense lesion volume (T2LV) 
T2 hyperintense lesions were identified using the two dimensional (2D) T2/proton 
density (PD) weighted sequences (see table 1 row 2). Lesions were contoured on the 
PD images from using a semi-automated intensity-thresholding programme 
Dispimage (Plummer 1992, University College London, London, UK). An area of 
high signal was considered a lesion if it was within the brain parenchyma, was higher 
intensity than grey matter on both the T2 weighted and PD images, was visible on 
more than one slice and was felt to be in an anatomical region where MS lesions 
commonly occur (Polman et al 2005).  
 
T2LV was calculated by multiplying the area within the resulting ‘T2 lesion map’ by 
the slice thickness. Investigators analyzed the T2LV of the subjects for whom they 
were the treating physician – approximately half each of the analysis was done by 
myself and JF 
 
T1 hypointense lesion volume (T1LV)  
T1 hypointense lesions were identified using the 2D T1 weighted sequence (see table 
1 row 1) with the ‘T2 lesion map’ as a reference. T1 hypointense lesions were also 
contoured using Dispimage (Plummer 1992). An area of low signal on the 2D T1 
images was designated T1 hypointense lesion if it corresponded to a contoured area 
on the 'T2 lesion map' and had lower signal intensity that the surrounding brain 
parenchyma. T1 lesion volume was calculated by multiplying the area within the ‘T1 
lesion map’ by the slice thickness.  
This analysis was done by me alone.  
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New and enlarging – ‘active’-  T2 lesions 
New and enlarging lesions were identified after 12 months and 24 months by 
comparing the corresponding slices from two serial 2D T2 weighted scans taken from 
the same subject (see table 1 row 2). They were marked on the PD images. The 
definition of what constituted new and enlarging lesions were taken from a previous 
consensus paper which allows good intra- and inter-rater reproducibility (Molyneux et 
al 1999). A sample of 30 subjects (15 from each investigator) was repeated by a 
consultant radiologist (KM) and concordance was found to be 100%. Investigators 
analyzed the new and enlarging lesion counts of the subjects for whom they were the 
treating physician – approximately half each of the analysis was done by myself and 
JF 
 
Central cerebral volume (CCV)  
Central cerebral volume was calculated from the 2D T1 weighted sequence (see table 
1 row 1) the using a modified version of the ‘Losseff central cerebral volume 
technique’ (Losseff 1996a). Six contiguous slices were isolated, the most caudal at the 
level of the velum interpositum. A semi-automated intensity thresholding tool – 
Medical Image Display and Analysis System (MIDAS) (Freeborough et al 1997) – 
was used to extract brain tissue only. MIDAS allows investigators to select the largest 
contiguous region within a given intensity range. The upper and lower limits of this 
intensity range are chosen by a trained investigator. The resulting region of interest 
was then corrected manually. The volume was then calculated by multiplying the area 
of the extracted slices by slice thickness.  
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Investigators analyzed the CCV of the subjects for whom they were the treating 
physician – approximately half of the analysis was done by myself and JF 
 
Normalized brain volume (NBV) 
Normalized brain volume (NBV) is a technique which allows comparison of brain 
volumes between subjects with different head sizes. It was calculated using 
‘Structural Image Evaluation, using Normalization of atrophy – Cross sectional 
method’ (SIENAX; FSL software Oxford UK) on the three dimensional (3D) T1 
weighted fast-spoiled gradient recall inversion recovery (FSPGR-IR) sequence (see 
table 1 row 4). It is a fully automated technique that uses a two step process to 
identify brain and non-brain tissue, the Brain Extraction Tool (BET; Smith 2002, 
Smith et al 2002).  
 
Step 1: the largest contiguous region is selected bounded by maximum and minimum 
brain tissue intensity thresholds. However rather than being chosen by a trained 
investigator, the thresholds are identified by a computer algorithm that generates a 
compound histogram of intensity of all the voxels in the image and sets the thresholds 
as approximately the 10
th
 and 90
th
 centiles. This region of interest is used to estimate 
the rough size of the brain and the centre of gravity. 
 
Step 2: a spherical mesh of tessellating triangles is gradually expanded and deformed 
until the vertices of the triangles cross into CSF at which point local threshold and 
smoothing protocols are used to create a 3D brain map.  
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The BET derived region of interest and the subject’s skull are registered to a standard 
space brain image. In the case of SIENAX the template used is the based on 152 
normal controls scanned by the Montreal Neurological Imaging group (MNI152) 
(Evans et al 1993). The skull of a given subject is also segmented by BET, by 
projecting lines from the surface of the BET brain region of interest and using an 
intensity gradient to identify the (low intensity) skull and the (high intensity) scalp. 
 
Where extra-axial structures, such as the optic nerve, are mis-identified as brain 
parenchyma by the BET, these can be manually removed. This analysis was 
conducted by a single investigator (JF).  
 
Whole brain atrophy (SIENA) 
Whole brain atrophy was calculated using Structural Image Evaluation, using 
Normalization of Atrophy – Longitudinal protocol (SIENA) (Smith et al 2002). This 
is a fully automated technique which employs stereotactic co-registration of serial 
images and identification of regions of change. It was conducted by a single 
investigator (JF) using the 3D T1 weighted FSPGR-IR images (see table 1 row 4).  
 
The brain and skull are segmented using the BET. These regions of interest are then 
co-registered, not with a standard template, but rather with a skull and generated 
region of interest from the same subject at a different timepoint. Regions where the 
two brains do not correspond exactly are identified as positive or negative change in 
brain volume. Results are expressed as a percentage of the volume of the earlier 
image.  
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Grey matter fraction (GMF) and white matter fraction (WMF) 
The proportions of intracranial volume occupied by white matter and grey matter 
were calculated using Statistical Parametric Mapping (SPM; University College 
London, London, UK) – segmentation. This employed the 3D T1 weighted FSPGR-
IR images, which had been reformatted into 28 5mm axial slices as part of the MTR 
analysis protocol (see section 2.4). SPM is a fully automated system in which images 
are co-registered into MNI152 standard space brain template. The intensity and 
position of each voxel is compared to adjacent voxels and the MNI152 template and 
assigned a probability of being white matter, grey matter, CSF or extra-axial tissue 
based on site and intensity (Ashburner and Friston 1997, Ashburner and Friston 
2000).  
 
Binary masks for white matter, grey matter, CSF and other tissue can then be 
generated using a probability cut-off. In this study a value of 75% was assigned. The 
volume of each segment can then be calculated by multiplying the area of the binary 
mask by the slice thickness.  
 
Grey matter and white matter parenchymal fraction (GMF;WMF) were calculated by 
dividing the grey matter and white matter volumes by the total intracranial volume 
(the sum of grey matter, white matter and CSF volumes).  
 
Several versions of the SPM programme are available (see 
www.fil.ion.ucl.ac.uk/spm). At the start of this study SPM99 (Ashburner and Friston 
1997) was used and some baseline data was published using this programme. Later 
SPM05 was made available, which was felt to be superior (Ashburner and Friston 
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2005) so all data used in longitudinal analysis was analyzed using this. This involved 
re-analyzing the baseline images with SPM05 
 
Even moderate lesion volumes are known to effect segmentation and give rise to 
significantly different grey matter and white matter volumes (Chard et al 2002c). In 
order to try to minimize the effect of this, T2 high-signal lesions were ‘masked-out’ 
prior to segmentation. The lesion mask was then added back into the white matter 
mask post segmentation. This is the same technique that was used to generate the 
NAGM and NAWM masks as part of the MTR analysis and is described in more 
detail in the relevant section (see below). 
 
Spinal cord cross-sectional area (SCCA) 
This analysis was using the 3D T1 weighted FSPGR-IR images of the spinal cord (see 
table 1 row 5). The protocol used was a modified version of the ‘Losseff cervical 
spinal cord technique’ (Losseff et al 1996b). 
 
The scan was acquired in the sagittal plane. From the sagittal images, five contiguous 
pseudo-axial 3mm thick slices were created using the scanner console with the centre 
of the C2/3 intervertebral disc as the caudal landmark. Around the circumference of 
the cord there is a spectrum of intensity values, ranging from high (cord parenchyma) 
to low (CSF), and it is difficult to determine where the true boundary between cord 
and CSF lies.  
 
Using Dispimage two regions of interest, one within the cord and one within the CSF 
were manually selected for each slice. The mean signal intensity for cord and CSF 
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were duly estimated from the two regions and the cord CSF threshold set as midway 
between these two values.  The largest contiguous region with signal intensity greater 
than the threshold value was then selected automatically and non-cord material 
removed manually using a mouse driven cursor. The spinal cord cross sectional area 
was the mean of the five slices. 
 
All the SCCA analysis was done by JF. 
 
Brain MTR 
The MTR image (see table 2 row 3) was analyzed using histogram analysis. This 
involved the generation of a binary mask, corresponding to a region of interest or 
tissue type – lesions, NAGM, NAWM, normal appearing brain tissue (NABT) or 
whole brain parenchyma – which was then applied to the with- and without- 
saturation pulse images. 
 
1. Lesion masks were created by contouring T2 high-signal lesions on the PD images 
of the MTR sequence with the T2 images of the MTR sequence as a reference; this 
was done using Dispimage and the same rules as for T2LV analysis. The regions of 
interest were converted into an intrinsically co-registered binary mask and MTR 
histograms were derived from any voxels which were covered by the mask. 
 
2. Normal appearing grey and white matter masks were created using SPM. The 
intention at the outset was to segment the T2-weighted images from the MTR 
sequence (see table 1 row 3). However in eight of 20 scans in which segmentation of 
the T2-images was attempted, the resulting tissue masks were clearly incorrect (an 
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example of this is shown in figure 3).  The 3D T1-weighted FSPGR-IR images (see 
table 1 row 4) had a higher grey matter-white matter contrast and so a technique was 
devised whereby the NAGM and NAWM masks could be generated using this 
sequence and then applied to the MTR sequence. 
 
The 3D T1 weighted FSPGR-IR sequence was first re-formatted into the same virtual 
space as the MTR images using a specially written programme (DT and KH). This 
process converted the 124 x1.5mm coronally oriented slices into 50x5mm axially 
oriented slices. These images were qualitatively reviewed by a single rater (myself) 
and the 28 slices which most closely corresponded to the 28 slices of the MTR 
sequences were isolated and co-registered with the MTR sequence. It was these 
images that were segmented with SPM. A minimum tissue probability threshold of 
75% was used. 
 
Because even moderate lesion volumes are known to affect segmentation and give 
rise to significantly different grey matter and white matter volumes (Chard et al 
2002c) the T2 lesion mask was applied to the re-formatted, co-registered T1 images 
prior to segmentation. A signal intensity of 0 was allocated to the lesion mask which 
meant that it could not be identified as grey matter or white matter. 
 
In order to minimize the contribution of partial volume voxels, a two voxel erosion 
was applied to the white matter mask and a one voxel erosion was applied to the grey 
matter masks. On a subset of 10 scans I removed two voxels from the grey matter 
mask and calculated the volume change; the mean value was 66.37% (standard 
deviation 3.13%) so it was felt that a one voxel erosion would be more suitable.  
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Examples of the SPM output generated using this protocol are shown in figure 3. 
 
Figure 3. The outcome of segmentation with SPM99. Using the T2-weighted images 
from the MTR sequence (left hand column) and the re-formatted, co-registered 3D T1 
weighted FSPGR-IR sequence (right hand column) 
 Segmentation of T2 weighted 
images from the MTR sequence 
Segmentation of the re-formatted, co-
registered 3T1-weighted FSPGR-IR 
sequence 
Grey 
Matter 
 
 
White 
matter 
 
 
 
3. NABT masks were generated by combining the NAGM and NAWM output from 
SPM and then applying a one voxel erosion to the whole mask.  
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Example of the binary masks used to generate MTR histograms are shown in figure 4. 
 
Figure 4. Examples of regions used to generated MTR histograms  
Lesions NAGM NAWM 
   
NABT   
 
  
NAGM – normal appearing grey matter, NAWM – normal appearing white matter, NABT- normal 
appearing brain tissue. 
 
MTR, expressed as per cent units (pu) was then calculated for each voxel in the region 
covered by the mask, using the formula: 
 
MTR = ([MO-MS]/[MO]) x 100 pu  
 
where MO is the intensity of the image with no saturation and MS is the intensity of 
the with saturation image. Histograms were then generated, with MTR values along 
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the x-axis at a resolution, or bin width, of 0.1 pu and the proportion of the total 
number of voxels at a given MTR value on the y-axis. To circumvent the problem of 
variable brain size, and to make values between individuals comparable, the 
histogram was normalized by dividing all the values by the total number of voxels. 
Thus the units of the y-axis are normalized brain volume units (or percentage of brain 
volume per pu).  
 
Although it is possible to generate values which describe the overall shape of the 
histogram (Dehmeshki et al 2001), several localized descriptors are typically used to 
summarize the histogram. These are: histogram mean; peak location (PL) (the modal 
MTR value); peak height (PH) (the number of normalized brain volume units at the 
modal MTR value); and 25
th
, 50
th
 and 75
th
 centiles.  
 
The initial MTR histogram appears spiky. These spikes arise in part from noise in the 
images, but also come from the use of a division in the formula for MTR and the 
integer signal intensities in the images. This results in an uneven distribution of MTR 
values (Tozer and Tofts 2003).  It is important to smooth out the histogram as much as 
possible because spikes could give rise to erroneous localized descriptors, with peak 
height and peak location being particularly vulnerable to this.  
 
To smooth out spikes caused by the division of integers, random noise with a value 
within the range -0.5/+0.5 was added to each voxel (Tozer and Tofts 2003). Spikes 
caused by non-uniformity in the magnetic field were removed by applying a moving 
average smoothing window of 0.7 pu to the histogram. For more details see Tofts et al 
2003.    
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To minimize the contribution from partial volume voxels containing CSF or other 
non-brain tissue, any voxels with an MTR value of <10pu were excluded from the 
analysis.  
 
A typical final MTR histogram is shown in figure 5. 
 
Figure 5. A typical MTR histogram of the whole brain. Taken from one of the 
subjects in the lamotrigine trial. The dotted line indicates the value of the peak height.  
 
MTR – magnetization transfer ratio 
 
 
 
 
 
Typical MTR histogram: whole brain
0
0.005
0.01
0.09 10.09 20.09 30.09 40.09 50.09
MTR (pu)
N
o
rm
al
iz
ed
 b
ra
in
 v
o
lu
m
e 
u
n
it
s
 86 
Validation of semi-automatic analysis techniques. 
For all techniques that include manual editing, investigators (myself and JF) received 
training from experienced practitioners: T2LV (DS, DHM); T1LV (DS, DHM); CCV 
(VA); SCCA (WR).  
 
The MTR analysis included lesion contouring, for which training was provided by DS 
and DHM, and selecting the slices of the re-formatted, co-registered images which 
corresponded to the MTR sequence, which was essentially a new technique.   
 
To quantify intra-rater and inter-rater variability a set of five test scans was analyzed 
on two separate occasions and the data were used to calculate coefficients of variance. 
 
Intra-rater variability values were quite high for techniques that required the highest 
level of manual input –T2LV, T1LV, CCV – and for NAWM PH. However for the 
majority of the MTR measures the coefficient of variance was reassuringly small (see 
table 2). 
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Table 2. Coefficients of variance for semi-automated MRI analysis. Data shown is 
the coefficient of variance as a percentage of the mean value for each measure.  
MRI measure Intra-rater coefficient of 
variance.  
Inter-rater coefficient of 
variance.  
T2LV 6.63% 8.61% 
T1LV 10.09% n/a 
CCV 0.82% 1.40% 
 SPM99 SPM05 
NAGM PH 7.58% 7.52% 
PL 1.88% 2.78% 
Mean 0.47% 0.28% 
NAWM PH 11.08% 11.28% 
PL 1.26% 1.42% 
Mean 3.89% 3.87% 
Lesions PH 4.14% 4.15% 
PL 1.43% 1.43% 
Mean 1.37% 1.37% 
MRI – magnetic resonance imaging, T2LV – T2-weighted high signal lesion volume, T1Lv – T1 
hypointense lesion volume, CCV – central cerebral volume, NAGM – normal appearing grey matter, 
MAWN – normal appearing white matter, PH - peak height, PL – peak location, SPM – statistica 
parmetric mapping. 
 
A summary of the data collected during the trial is shown in table 3. 
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Table 3. Summary of clinical and MRI collected from subjects in the SPMS study 
group at each timepoint. Month 0 is baseline.data collected on all subjects, s 
data collected on a sub-set of patients. 
                     Month              
          Data 
0  1 2 3 6 9 12 15 18 21 24 27 
Clinical Data             
Adverse events new relapses 
Compliance data 
EDSS, MSFC and MSIS-29         s 
Serum lamotrigine levels           
MRI Data             
CCV         s 
T2LV; T1LV; T1 to T2 lesion 
volume ratio 
       s  s 
Active T1 and T2 lesions            s 
NBV, GMF, WMF        s  s 
Brain MTR        s    
SCCA         s    
EDSS – expanded disability status scale, MSFC multiple sclerosis functional composite, MSIS-29 – 
multiple sclerosis impact scale, CCV – central cerebral volume, T2LV – T2-weighted high signal lesion 
volume, T1Lv – T1 hypointense lesion volume, NBV – normalized brain volume, GMF – grey matter 
fraction, WMF – white matter fraction, MTR-  magnetization transfer ratio, SCCA – spinal cord cross 
sectional area 
 
2.5 Statistical analysis and dissemination of results 
Statistical analysis of the effects of lamotrigine on CCV, whole brain, white and grey 
matter volume, T1 and T2 lesion volume and all clinical measures was designed and 
performed by DA. Details of these analyses were published, following peer review, in 
2010 (Kapoor et al 2010). Additional statistical analysis regarding the effect of 
lamotrigine treatment on MTR measures, T1 and T2 lesion volume were designed and 
conducted by me and are detailed in chapters 3.2 and 3.3 of this thesis. 
 
Cross-sectional and longitudinal correlation of whole brain and regional volume and 
atrophy measures with clinical measures in the placebo group were evaluated by JF 
and have been published following peer review (Furby et al 2008, Furby et al 2010). 
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The correlation of baseline lesion measures with grey matter MTR and volume 
measures was also performed by JF and has been published following peer review 
(Furby et al 2009). The cross-sectional and longitudinal correlation of MTR measures 
with clinical measures and the cross-sectional and longitudinal correlation of all MRI 
measures with MSIS-29 scores were performed by me, are detailed in chapters 3.1, 
3.2 and 3.4 and have been published following peer review (Hayton et al 2009, 
Hayton et al 2011a, Hayton et al 2011b).  
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3. Results 
The main aims of this study were: 
 to evaluate the correlation of brain MTR measures and T1 hypointense 
lesion measures with measures of clinical status in secondary progressive 
MS and so derive some insight into the types of pathological processes that 
give rise to disability in this condition. 
 To evaluate the neuroprotective potential of lamotrigine in secondary 
progressive MS by observing the effects of treatment with this drug 
compared to a placebo on brain MTR and T1 lesion volume measures. 
With regard to the first aim, both cross-sectional and longitudinal correlations were 
considered. A strength of cross-sectional studies is that they provide an indication of 
all the MS pathology that has accumulated over each subject’s clinical course. 
Longitudinal studies are potentially more specific, showing that change in one 
measure can be directly correlated with change in another, and may also be more 
sensitive, showing pathological change before a subject manifests relevant clinical 
changes. 
 
For quantifying the effect of lamotrigine treatment only longitudinal analysis is 
suitable, comparing the verum arm with the placebo arm. 
 
To get some indication of how MTR and T1 lesion volumes are related to 
neurodegeneration and neuroinflammation respectively, brain volume or atrophy 
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measures and T2 hyperintense lesion measures were frequently included in the 
analysis. Furthermore by using ‘best-predictor’ stepwise multiple regression analysis 
to compare the clinical correlates of all the MRI measures it was possible to determine 
to what extent MTR and T1 lesion volumes measured clinically relevant pathological 
processes that were not captured by brain atrophy or T2 hyperintense lesion volume. 
 
In addition to testing the correlation of MRI measures with ‘objective’ clinical 
measures such as EDSS and MSFC, the relationship with the MSIS-29 was also 
assessed. This gives an indication of how the identified pathological processes 
impacted on quality of life. 
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4. Grey matter magnetization transfer ratio independently 
correlates with neurological deficit in secondary progressive 
multiple sclerosis 
 
4.1. Introduction 
Grey matter involvement in MS is well recognised (Brownell and Hughes 1962, 
Lumsden 1970). It affects deep brain nuclei (Cifelli et al 2002) and cortical grey 
matter, (Bo et al 2003a, Geurts et al 2005, Kidd et al 1999, Kutzelnigg et al 2005, 
Peterson et al 2001). A recent quantitative pathological study has suggested that 
cortical lesion load is much greater in progressive MS than in relapsing remitting MS 
(Kutzelnigg et al 2005).  
 
Limited correlations have been observed between grey matter MTR and measures of 
neurological deficit in early relapsing-remitting MS (Davies et al 2004), primary 
progressive MS (Dehmeshki et al 2003, Ramio-Torrenta et al 2006) and a mixed 
group including  19 people with SPMS (Traboulsee et al 2003). However there are as 
yet no large-scale, single centre and MTR sequence studies examining the correlation 
between grey matter MTR measures and neurological deficit in SPMS. 
 
In this study the correlation was assessed of brain grey matter MTR measures with the 
EDSS and MSFC.  To establish whether or not grey matter pathology had a greater 
impact on clinical status than white matter or lesion pathology, the correlation of 
NAWM and lesion MTR measures with EDSS and MSFC was also calculated. 
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Established measures of neuro-axonal loss (NBV) and focal neuroinflammation 
(T2LV) were also included in this study to identify how closely related these 
measures are and perhaps give some indication of the pathological process that gives 
rise to low MTR. 
 
4.2. Methods  
Subjects  
This study comprises 113 people with secondary progressive MS, taking part in the 
lamotrigine trial (see section 2.1.1), who had MTR imaging at baseline.   
 
Clinical data 
Clinical data included here are EDSS and MSFC. For details of how these measures 
were collected see section 2.2. 
 
MRI acquisition and analysis 
Details of the MRI acquisition parameters used in this study are given in table 1. Data 
presented here are: 
 T2LV 
 NBV 
 MTR histograms for T2 hyperintense lesions, NAWM and NAGM. The 
data presented here were generated from tissue segments derived using 
SPM99 (Ashburner and Friston 1997)  
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Statistics 
Statistical analyses were performed using the statistical package for social sciences 
(version 11.5; SPSS Inc. Chicago, IL, USA) and Stata 9.2 (Stata Corporation, College 
Station, TX, USA). 
 
Within-patient differences between NAWM, grey matter and lesion MTR measures 
were assessed using multiple paired Student's t-tests. To evaluate the association 
between different MRI values and the MSFC and its components, we used multiple 
linear regression of the clinical variable as the outcome for each MTR measure with 
age, gender, disease duration and duration of secondary progressive MS as covariates.  
 
A two-stage set of multiple linear regression models was used also to determine best 
predictors of MSFC and its components, using the following potential predictors: 
mean, peak location and peak height from each of NAWM, grey matter and lesion 
MTR; NBV; T2 lesion volume; age; gender; disease duration and duration of 
secondary progressive MS.  In the first stage best predictors were obtained separately 
within each of the NAWM, grey matter and lesion MTR measures, retaining 
significant variables (p<0.05); in a manual forward stepwise procedure, the best 
predictors from each of these tissue classes were then entered together, and after 
removing non-significant variables, the remaining covariates were added singly.  
Discarded variables were then re-entered singly in the final models, and retained only 
if significant.  
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We used binary logistic regression to assess whether MRI variables could predict 
whether a subject would be in the lower (EDSS ≤6.0 n=45) or higher (EDSS ≥6.5, 
n=68) disability group. Age and gender were covariates in the model.  
Spearman-rank coefficients were used to assess the correlation between MSFC 
components and EDSS and between MRI measures and EDSS. 
 
4.3. Results 
Clinical features 
The clinical features of the subject group are detailed in table 4. There were 
significant correlations between the EDSS and the MSFC composite, 1/TW and 
1/9HPT (rs -0.39 p<0.0001, rs -0.81 p<0.0001, rs -0.36 p<0.0001). There was no 
significant correlation between the EDSS and the PASAT-3. 
 
Table 4. Clinical characteristics for subjects in baseline analysis. Values expressed 
as mean (standard deviation; range) unless otherwise stated 
Characteristics Secondary Progressive MS 
subjects, n=113 
Sex, F/M (%) 
Age, yrs (range) 
Disease duration, yrs (range) 
Duration of secondary 
progressive MS, yrs (range) 
EDSS, median (IQR; range) 
PASAT-3 
1/9HPT 
1/TW 
80/33 (70.8/29.2) 
50.2 (29 to 60) 
19.9 (3 to 41 yrs) 
7.8 (1to 26 yrs) 
 
6.0 (6.0 to 6.5; 4.0 to 7.5)  
43.44 (13.65; 2 to 60) 
0.034 (0.010; 0.001 to 0.052) 
0.092 (0.061; 0.006 to 0.25) 
EDSS – expanded disability status scale, PASAT-3 paced auditory serial addition test, 9HPT  - 9 hole 
peg test, TW – timed 25 foot walk. 
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MRI findings 
Mean MTR for NAWM was 37.36 pu (standard deviation 1.06, range 33.15 to 38.97), 
for grey matter was 32.43 (standard deviation 1.03, range 29.37 to 34.04) and for 
lesions was 30.70 (standard deviation 1.98, range 24.90 to 35.09). Histogram profiles 
for grey matter, NAWM and lesions are shown in figure 6.  NAWM peak height, peak 
location and histogram mean were significantly higher than the corresponding grey 
matter or lesion measures (p<0.0001). Grey matter MTR histogram mean was 
significantly higher and peak height significantly lower than the corresponding lesion 
measures (p= 0.010, p<0.0001) but there was no significant difference between grey 
matter and lesion peak location.  
 
 
 
 
 
 
 
 
 
 
 
 97 
Figure 6. Histogram profiles for NAWM, grey matter and lesions at baseline. These 
comprise the average MTR histograms for lesions (dotted line), NAWM (dashed line) 
and grey matter (solid line) for all subjects. The peak location is the modal MTR 
value in pu. The peak height is the number of normalized brain volume units at the 
modal MTR value. 
 
The mean NBV was 1478.915 ml (SD99.87 ml, range 1215.79 to 1712.97 ml) and 
mean T2 lesion volume was 25.44 ml (SD18.0 ml, range 0.35 to 87.97 ml). There 
were significant correlations between all MTR measures and both T2 lesion volume 
and NBV (Table 5). 
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Table 5. Cross-sectional correlation between magnetization transfer (MTR) 
measures for normal appearing white matter (NAWM) grey matter and T2 high-
signal lesions, normalized brain volume (NBV) and T2 high-signal lesion volume. 
Significant correlations are shown in bold 
 
NBV, Pearson correlation 
coefficient (p value) 
T2LV, Pearson correlation 
coefficient (p value) 
T2 lesion volume -0.478 (<0.0001) - 
NAWM peak height 0.319 (0.008) -0.36 (<0.0001) 
NAWM peak 
location 
0.381 (<0.0001) -0.445 (<0.0001) 
NAWM histogram 
mean 
0.417(<0.0001) -0.420(<0.0001) 
NAGM  peak height 0.379 (<0.0001) -0.481(<0.0001) 
NAGM  peak 
location 
0.355 (<0.0001) -0.506 (<0.0001) 
NAGM  histogram 
mean 
0.625 (<0.0001) -0.713 (<0.0001) 
Lesion peak height 0.511(<0.0001) -0.635 (<0.0001) 
Lesion peak location 0.350 (<0.0001) -0.523 (<0.0001) 
Lesion histogram 
mean 
0.567  (<0.0001) -0.692 (<0.0001) 
NAWM - normal appearing white matter, NAGM – normal appearing grey matter 
 
Correlation between EDSS and MRI variables 
Significant inverse correlations existed between EDSS and grey matter peak location 
(rs -0.19, p<0.046). No other MRI measures significantly correlated with EDSS.  
 
Logistic regression analysis for EDSS using MRI variables 
None of the MRI measures significantly predicted whether a subject was in the higher 
EDSS group. 
 
Linear regression analyses for MRI measures with MSFC measures (Table 6) 
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Table 6. Linear regression analysis with MSFC-based clinical measures as the 
outcome variable and a single MR measure as the predictor, adjusted for age, 
gender, disease duration and duration of secondary progressive MS at baseline. 
Statistically significant results in bold * p≤0.01, **p≤0.001, ***p<0.0001 
 
 MSFC 
standardised β  
PASAT-3 
standardised β   
1/9 HPT 
standardised β  
1/TW  
standardised β 
NAWM 
MTR 
PH 0.280*  0.338***  0.201  0.076  
PL 0.337***  0.368*** 0.285* 0.194  
Mean 0.327*** 0.399*** 0.283* 0.163  
NAGM 
MTR 
PH 0.265*  0.435***  0.182  -0.032  
PL 0.354** 0.280* 0.250 * 0.225*  
Mean 0.460*** 0.543***  0.391*** 0.144 
Lesion 
MTR 
PH 0.304** 0.334*** 0.279* 0.057 
PL 0.368***  0.374***  0.371***  0.116 
Mean 0.394***  0.429*** 0.376***  0.135  
T2LV -0.360***  -0.425***  -0.295** -0.062  
NBV 0.447*** 0.373*** 0.505***  0.177 
MSFC – multiple sclerosis functional composite, PASAT-3 – paced auditory serial addition test, 9HPT 
– 9 hole peg test, TW – 25 foot timed walk, NAWM – normal appearing white matter, MTR – 
magnetization transfer ratio, NAGM – normal appearing grey matter, T2LV – T2 weighted 
hyperintense lesion volume, NBV – normalized brain volume 
 
NAWM MTR 
NAWM MTR peak height, peak location and histogram mean correlated with MSFC 
score, PASAT-3 and 1/9HPT. There was a significant, though weaker, correlation 
between NAWM MTR peak location and 1/TW.  
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NAGM MTR 
There were significant correlations between grey matter MTR peak height, peak 
location and histogram mean and MSFC score and PASAT-3. A significant 
correlation was also found for grey matter MTR histogram mean and peak location 
with 1/9HPT. Grey matter MTR peak location correlated modestly with 1/TW. Figure 
7 shows a scatter plot with regression line of grey matter histogram mean vs. MSFC 
composite. 
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Figure 7. Scatter plot of grey matter histogram mean vs. MSFC composite showing 
regression line at baseline. Regression coefficient =0.446, p<0.0001 (note there was 
no adjustment for other variables, so the r value differs from that shown in table 6) 
 
MSFC – multiple sclerosis functional composite 
Lesion MTR 
Lesion MTR peak height, peak location and histogram mean all correlated 
significantly with MSFC score, PASAT-3 and 1/9HPT, but not with 1/TW.  
 
NBV 
There were significant correlations between NBV and MSFC score, PASAT-3 and 
1/9HPT.  
T2LV 
Significant inverse correlations existed between T2LV and MSFC score, PASAT-3 
and 1/9HPT. There was no significant correlation between T2LV and 1/TW. 
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Best predictor analysis (multiple linear regression) (table 7)  
 
Table 7. Multiple linear regression models for predicting the MSFC and its 
components with MTR peak height, peak location and histogram mean for grey 
matter, NAWM and lesions; NBV, T2LV disease duration, duration of secondary 
progressive MS, age and gender as independent variables. Only significant 
independent predictors are described in the table. 
MSFC PASAT-3 1/9 HPT 1/TW 
Variable rp; p Variable rp; p Variable rp; p Variable rp; p 
NAGM 
mean 
0.462; 
<0.0001 
NAGM 
mean 
0.537; 
<0.0001 
NBV 0.361; 
<0.0001 
Duration 
of SPMS 
-0.344; 
<0.0001 
Duration 
of SPMS 
-0.178; ; 
0.035 
Female 
gender 
-0.168; 
0.036 
Lesion 
peak 
location 
0.215; 
0.019 
Female 
gender 
-0.241; 
0.006 
      NAWM 
peak 
location 
0.209; 
0.014 
      NAGM 
peak 
location 
0.198; 
0.021 
R
2
=0.248, 
p<0.0001 
R
2
=0.342, 
p<0.0001 
R
2
=0.231, 
p<0.0001 
R
2
=0.245, p=0.004 
MSFC – multiple sclerosis functional composite, PASAT-3 – paced serial addition 
test, 9HPT – 9 hole peg test, TW – timed 25 foot walk, NAGM – normal appearing 
grey matter, SPMS – secondary progressive MS, NBV – normalized brain volume, 
NAWM – normal appearing white matter
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MSFC 
NAGM histogram mean and duration of SPMS were the only independent predictors 
of the MSFC score, accounting for approximately 25% of the variance in the score. 
 
PASAT-3 
For the PASAT-3 the best independent predictors were NAGM histogram mean and 
female gender which accounted for approximately 34% of the measure’s variance. 
 
 1/9HPT. 
The best independent predictors of 1/9HPT were NBV and lesion peak location, 
which accounted for approximately 23% of the variance of the clinical measure. 
 
1/TW 
The best model for predicting 1/TW contained NAGM peak location, NAWM peak 
location, duration of secondary progressive MS and female gender. This model 
accounted for 25% of the variation in 1/TW. 
 
4.4. Discussion 
The aim of this study was to determine the correlation between brain grey matter 
MTR measures and neurological deficit in people with secondary progressive MS. 
This is the only large single centre investigation of such MTR findings in secondary 
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progressive MS and has the advantage of measuring MTR using a single stable 
acquisition sequence 
 
There were significant correlations between lesion, NAWM and grey matter MTR 
measures and the overall MSFC score, as well as with component tests of upper limb 
and cognitive function (1/9HPT and PASAT-3) such that a higher MTR measure was 
associated with less impairment. The best predictor analysis in this study identified 
grey matter histogram mean as an independent predictor of clinical impairment in 
MSFC and PASAT-3 and grey matter peak location as an independent predictor of the 
timed walk. These findings suggest that brain grey matter pathology contributes to 
motor or cognitive dysfunction in this study group. 
 
Previous MTR studies of whole brain, normal appearing brain tissue and lesions in 
MS 
Previous studies have demonstrated limited cross-sectional correlation between 
disability and whole brain MTR mean in both a group of 79  people with MS 
including 26 subjects with secondary progressive MS (Kalkers et al 2001a) and a 
group of 82 subjects with exclusively secondary progressive MS (Inglese et al 2003). 
In the mixed study group, whole brain peak height and peak location also correlated 
with EDSS (Kalkers et al 2001a).  In a similar study, including 16 people with 
secondary progressive MS in a mixed group of 83 with MS, whole brain MTR peak 
height correlated with EDSS (Dehmeshki et al 2001). Whole brain MTR mean and 
peak height have also been shown to correlate with PASAT-3 (Dehmeshki et al 2003) 
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These correlations may be partly due to MTR detectable pathology in T2 lesions. 
Lesion mean MTR has been shown to correlate with EDSS in mixed groups including 
10 subjects with secondary progressive MS from a mixed group of 43 subjects (Gass 
et al 1994) and in a larger group of 25 people with secondary progressive MS from a 
study group of 95 people with different types of MS (Traboulsee et al 2003). However 
MTR mean and peak height for normal appearing brain tissue, comprising grey matter 
and NAWM, has also been shown to correlate with EDSS (Traboulsee et al 2003). 
 
MTR and grey matter abnormalities in MS 
Previous studies have reported correlation between MSFC and MTR measures from 
segmented grey matter in MS, though not always with multivariate analysis (Davies et 
al 2004, Rovaris et al 2001, Vrenken et al 2007). A study of 43 people with primary 
progressive MS found strong correlations between: grey matter measures and MSFC 
composite and grey matter histogram mean and the PASAT (Rovaris et al 2001). In a 
group of 38 people with early relapsing-remitting MS there were borderline 
correlations between upper limb function and grey matter histogram mean (Davies et 
al 2004) and deep grey matter histogram mean and the TW. Another study comparing 
a heterogeneous group of 66 people with MS, including 19 with SPMS, found 
significant correlations between grey matter peak location and MSFC composite; grey 
matter peak height and 9HPT; grey matter peak location and TW; but no correlation 
between any MTR measure and PASAT-3 (Vrenken et al 2007). 
 
In this study grey matter MTR measures also correlated with the measure of whole 
brain volume, NBV. While this may partly reflect an increase in partial volume pixels 
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with lower MTR at grey matter tissue edges in the presence of greater atrophy, the 
erosion of the outer voxel in the grey matter segments and exclusion of pixels with 
MTR < 10pu in this study should have minimized this effect.   
 
MRI studies of relapsing remitting MS (Chard et al 2002b, Miller et al 2002) and a 
group including 10 subjects with secondary progressive MS (Santos et al 2002) have 
shown a correlation between T2 lesion measures and brain grey matter atrophy. There 
are also correlations reported between T2 lesion volume and grey matter MTR 
measures (Cercignani et al 2001, Davies et al 2004, Ge et al 2002) and the results of 
present study echoed these findings. One possible mechanism linking reduced grey 
matter MTR with T2 lesion volume is neuronal loss following retrograde degeneration 
of axons transected or damaged in white matter lesions (Bjartmar and Trapp 2001). 
An association might also exist if there is a correlation between grey matter 
demyelinating lesion load and white matter (T2) lesion load. Grey matter in MS may 
contain a large number of focal demyelinated lesions (Brownell and Hughes 1962, 
Kutzelnigg et al 2005); particularly in progressive MS (Kutzelnigg et al 2005). 
Almost all grey matter lesions are invisible on conventional T2 weighted scans at 1.5 
Tesla (Geurts et al 2005). MTR is very sensitive to loss of myelin (Barkhof et al 2003, 
Schmierer et al 2004, Vrenken et al 2007) and a reduction in grey matter MTR would 
be compatible with an effect of demyelinating lesions. That the best predictor analysis 
in this study identified the grey matter histogram mean as an independent predictor of 
clinical impairment suggests that grey matter pathology – whether due to 
demyelinating lesions and/or neuroaxonal loss - contributes to disability in secondary 
progressive MS. 
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Limited correlation between MTR measures and EDSS 
The only MRI measure that significantly correlated with EDSS was grey matter MTR 
PL. Although the EDSS is well validated, widely understood and gives a measure of 
both impairment and disability, it has been criticized for being heavily weighted 
towards mobility and relatively insensitive to upper limb and cognitive dysfunction. 
The findings from this study group of strong correlations between EDSS and 1/TW, a 
direct measure of mobility, less pronounced correlation between EDSS and 1/9HPT 
and no significant correlation between EDSS and PASAT-3 would support this. 
 
Much of the clinical impairment in people with MS is thought to be due to pathology 
of the spinal cord, which is known to be a common site for neuroinflammation and 
axonal loss (Lovas et al 2000, Oppenheimer 1978). It is possible that cord MRI 
measures may correlate better with EDSS and measures of mobility than brain 
measures do (Furby et al 2008). 
 
However, even though the EDSS range was narrow, 3.5 points, the overall range of 
mobility, as measured using the TW was relatively broad. Comparing the ratio of 
standard deviation to mean for 1/TW, PASAT-3 and 9HPT, the ratio was highest for 
1/TW. This suggests that even as a measure of mobility the EDSS is simply not 
sensitive enough to differentiate between different subjects in this secondary 
progressive group.  
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5. Longitudinal changes in magnetization transfer ratio in 
secondary progressive multiple sclerosis: data from a 
randomised placebo controlled trial of lamotrigine. 
5.1. Introduction 
Higher MTR has been shown to correlate with the higher myelin and axonal content 
in both MS lesions and NAWM in post-mortem samples (van Waesberghe et al 1999, 
Scmierer et al 2004) and  is therefore of particular interest in progressive MS, where 
neuroaxonal loss and grey matter damage have been shown to be prominent 
(Kutzelnigg et al 2005), and is a potentially useful marker of pathology in the 
evaluation of putative neuroprotective treatments.  
 
One possible neuroprotective agent is lamotrigine, a sodium channel blocker that has 
been shown to ameliorate neurological dysfunction and prevent neuroaxonal loss in 
the EAE animal model (Bechtold et al 2006). 
 
This study comprises data from a randomized, double-blinded, placebo-controlled 
trial of lamotrigine in secondary progressive MS comparing change in MTR measures 
in brain NAWM, NAGM and T2 hyperintense lesions over two years in a group of 
subjects with secondary progressive MS. The hypothesis being that, if lamotrigine 
were neuroprotective, one would see a greater reduction in MTR in the placebo group. 
 
The data from the trial was also used to assess the utility of MTR as a measure of 
clinically relevant pathology in secondary progressive MS by calculating the 
responsiveness of MTR measures to change over a 24 month period i.e. the 
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longitudinal correlation of MTR measures with MSFC and the association of MTR 
measures with a sustained increase in EDSS. 
 
5.2. Methods 
Subjects  
This study comprises 117 people with secondary progressive MS, taking part in the 
lamotrigine trial (see section 2.1). 
 
Clinical data 
Clinical data included here are EDSS and MSFC. For details of how these measures 
were collected see section 2.2. 
 
MRI acquisition and analysis. 
Details of the MRI acquisition parameters used in this study are given in table 1. Data 
presented here are: 
 MTR histograms for T2 hyperintense lesions, NAWM and NAGM. The 
data presented here were generated from tissue segments derived using 
SPM05 (Ashburner and Friston 2005). 
 
Statistics 
Change in MRI and clinical measures  
The change in MRI and clinical measures were calculated by subtracting baseline 
values from the values at 24 months; thus a negative value indicated a fall in that 
measure over 24 months; a negative value for the MSFC measure indicated 
neurological deterioration. Paired Student’s t-tests were used to determine whether 
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any changes measured over 24 months were significant. To account for the fact that 
the change in MTR may not be normally distributed, Wilcoxon signed-rank tests were 
also used to identify potentially significant changes. 
 
The effect of treatment with lamotrigine  
Differences in change in MTR measures between the placebo and verum arms were 
assessed using independent samples Student’s t-tests. Intention to treat analysis was 
used in this study, with all randomized subjects invited for every scan irrespective of 
whether they were still taking the investigational medicinal product (IMP). Two 
additional, post-hoc, per protocol analyses were employed: a comparison of tablet 
adherent subjects, defined as those who had taken 80% of prescribed tablets and were 
still being prescribed tablets at 24 months; and a serum adherent comparison, which 
compared subjects in the verum arm who had detectable serum lamotrigine at 24 
months with the entire placebo arm. Mann-Whitney U tests were also used to account 
for possible skewed distribution of change in MTR measures. 
 
Reliability of the MTR measures 
The scan-reposition-rescan reproducibility of the MRI measures was estimated using 
MRI scans from three healthy controls, each of whom was scanned on five occasions 
over a four week period. Coefficients of variability were calculated for the MTR 
measures.  
 
Longitudinal correlation between MTR measures and MSFC 
Longitudinal correlation of MTR measures with MSFC and component scores was 
assessed in the placebo arm using a random intercept mixed effect linear regression 
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model with age, gender, disease duration and time as covariates. A second model was 
calculated evaluating the correlation of MSFC with an interaction variable - [MTR 
measure]x time. The first model shows the correlation of MTR and clinical measures 
at any given timepoint. The second shows the correlation of the clinical measure with 
the change in the MTR measure.  
 
The association between MTR measures and EDSS  
Subjects in the placebo arm were divided into those who did or did not experience a 
sustained increase in EDSS over 24 months, defined as an increase of ≥0.5 points 
from baseline observed at two consecutive assessment visits over six months in 
subjects with a baseline EDSS of ≥ 6.0 or of 1.0 points in subjects with a baseline 
EDSS of ≤ 5.5. Differences in baseline MTR values and change in MTR were 
assessed using binary logistic regression with age, gender and disease duration as 
covariates. 
 
5.3. Results 
Recruitment started in January 2006 and lasted eight months. The final 24 month 
scans were completed in September 2008. MRI data were collected on all subjects at 
baseline, 105 subjects (55 placebo, 50 verum) at 12 months and 108 subjects (56 
placebo, 52 verum) at 24 months. Figure 8 is a participant flow diagram showing 
reasons for withdrawal and loss to follow-up. Baseline clinical and MRI measures are 
shown in table 8; some of the demographic data has previously been published 
(Kapoor et al 2010). The mean absolute and annualized change in MTR measures are 
shown in table 9. The change in clinical measures have been published previously 
(Kapoor et al 2010). 
 112 
 
Figure 8. Trial participant flow chart. 
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Table 8. Clinical and MRI measures for both verum and placebo arms at baseline. 
Data shown are mean values (standard deviation - SD) unless otherwise specified. 
Characteristics Placebo arm, n = 57 Verum arm, n=61 p-value for difference 
Sex, F/M (%)  40/17 (70/30) 45/16 (76/24) 0.839* 
Age, years -  mean (SD; 
range)  
49.6 (6.7; 37 to 60) 51.4 (7.2; 30 to 61) 0.139† 
Disease duration, years -  
mean (SD; range)  
19.0 (8.3; 3 to 36) 21.2 (9.2; 5 to 41) 0.135† 
EDSS, median (inter 
quartile range)  
6.0 (0.5) 6.0 (0.5) 0.717‡ 
PASAT-3 44.7 (13.6) 41.7 (14.52) 0.255† 
TW, sec  20.5 (21.2) 20.5 (25.7) 0.693† 
9HPT, sec  32.3 (15.6) 31.7 (10.6) 0.836† 
NAWM PH - % 
volume/pu 
16.35 (2.57) 16.70 (2.29) 0.452† 
PL – pu 37.88 (0.78) 37.99 (0.68) 0.508† 
Mean - pu 37.22 (1.23) 37.43 (0.78) 0.264† 
NAGM PH - % 
volume/pu 
9.36 (1.08) 9.38 (1.13) 0.398† 
PL – pu 33.79 (0.71) 33.71 (0.87) 0.887† 
Mean - pu 32.08 (1.08) 32.10 (1.02) 0.588† 
Lesions PH - % 
volume/pu 
9.75 (2.41) 10.01 (2.55) 0.217† 
PL – pu 33.82 (1.43) 34.10 (1.60) 0.323† 
Mean - pu 30.58 (2.02) 30.83 (1.94) 0.484† 
 NAWM - normal appearing white matter, NAGM - normal appearing grey matter, PH - peak height, 
PL - peak location, EDSS - expanded disability status scale, PASAT-3 - paced auditory serial addition 
test, TW-  timed 25 foot walk, 9HPT - 9 hole peg test, pu - percentage units, *Chi Squared test, 
†unpaired Student’s T-test, ‡Mann-Whitney U test. 
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Table 9. Change in MTR measures over 24 months. Significant results are 
highlighted in bold. 
 Mean 
annual 
change - 
% 
Mean absolute 
change over 24 
months; median 
(standard error; 
range)
 ‡
 
Significance of 
change – t value (p 
value)*; z value (p 
value)
~
 
Difference between 
placebo and verum 
arms  - p value for 
Student’s T-test; p 
value for Mann-
Whitney U test 
NAWM PH 
placebo 
-0.61 
(1.37) 
-0.40; -0.70 (0.29; -
6.89 to 3.63) 
1.37 (0.177); 2.03 
(0.043)  
0.104; 0.269 
PH 
verum 
-3.33 
(1.23) 
-1.15; -0.80 (0.35; -
5.86 to 6.08)
 
3.29 (0.002); 2.75 
(0.006) 
PL  
placebo 
-0.14 
(0.14) 
-0.12; -0.10 (0.10;-
1.70 to 1.10 ) 
1.13 (0.264); 0.97 
(0.332) 
0.342; 0.199 
PL 
verum 
-0.006 
(0.11) 
0.01; 0.01 (0.08; -
1.70 to 1.10) 
0.14 (0.889); 0.67 
(0.504) 
Mean  
placebo 
-0.05 
(0.18) 
-0.06; -0.05 (0.13; -
3.78 to 1.48) 
0.486 (0.641); 0.04 
(0.969) 
0.624; 0.445 
Mean  
verum 
-0.25 
(0.20) 
-0.15; -0.09 (0.15; -
3.69 to 3.00) 
1.05 (0.301); 0.96 
(0.339) 
NAGM PH  
placebo 
-0.79 
(0.62) 
-0.18; -0.40 (0.10; -
2.91 to 0.94) 
1.76 (0.085); 2.36 
(0.018) 
0.036; 0.078 
PH 
verum 
-2.84 
(0.68) 
-0.51; -0.30 (0.12; -
2.13 to 1.63) 
4.25 (<0.0001); 
6.10 (<0.0001) 
PL  
placebo 
-0.20 
(0.15) 
-0.15; -0.10 (0.09; -
1.20 to 2.10) 
1.54 (0.123); 0.97 
(0.332) 
0.456; 0.510 
PL 
verum 
-0.09 
(0.14) 
-0.05; -0.10 (0.09; -
3.00 to 2.20)  
0.50 (0.618); 0.83 
(0.405) 
Mean  
placebo 
-0.19 
(0.06) 
-0.13; -0.10 (0.04; -
1.06 to 0.98) 
3.54 (0.001); 3.36 
(0.001) 
0.713; 0.505 
Mean  
verum 
-0.21 
(0.07) 
-0.11; -0.11 (0.05; -
0.76 to 0.63) 
3.29 (0.002); 2.12 
(0.034) 
Lesions PH  
placebo 
1.25 (0.60) 0.16; -0.1 (0.12; -
4.12 to 1.40) 
1.30 (0.200); 1.17 
(0.243) 
0.004; 0.025 
PH 
verum 
-1.48 
(0.83) 
-0.44; -0.10 (0.17; -
2.47 to 2.38) 
2.63 (0.011); 2.05 
(0.040) 
PL  
placebo 
0.80 (0.31) 0.49; 0.50 (0.20; -
2.39 to 4.29) 
2.44 (0.018); 2.62 
(0.009) 
0.617; 0.515 
PL 
verum 
0.65 (0.28) 0.36, 0.60 (0.18; -
4.80 to 3.60) 
1.96 (0.055); 1.96 
(0.051) 
Mean  
placebo 
0.70 (0.16) 0.40; 0.30 (0.09;-
1.90 to 2.34) 
4.21 (<0.0001); 
3.84 (<0.0001) 
0.418; 0.445 
Mean  
verum 
0.51 (0.19) 0.28; 0.39 (0.11; -
1.58 to 2.17) 
2.55 (0.011); 2.48 
(0.013) 
NAWM - normal appearing white matter, NAGM  - normal appearing grey matter, PH -  peak height, 
PL  - peak location * paired Student’s t-test baseline vs. 24 month measures ,~ Wilcoxon signed-rank 
test baseline vs. 24 months  † Independent samples Student’s t-test for change over 24 months; placebo 
vs. verum. ‡ values for PH are % per pu, values for PL and mean are pu.  
  
 
Responsiveness and reproducibility 
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In the placebo arm NAGM mean decreased over 24 months, but lesion PL and mean 
MTR both increased significantly; none of the other MTR measures changed over 
time – see table 9. The standardized response means (mean change/standard deviation 
of the change) were relatively low ranging from 0.05 to 0.56, indicating limited 
responsiveness and signal to noise ratio.   
 
The scan-reposition-rescan reproducibility of the MTR measures in the control group 
is shown in table 10. The coefficient of variation was small, ranging from 0.16 to 
2.54% with NAWM mean MTR the most reliable parameter. However the variability 
still exceeded the mean annualized change in the trial study group – see table 10. 
 
Table 10. Scan-reposition-rescan reproducibility of the MTR measures  
 Coefficient of variation % 
NAWM Peak height 2.00 
Peak location 0.53 
Mean 0.16 
NAGM Peak height 2.54 
Peak location 0.76 
Mean 0.22 
NAWM - normal appearing white matter, NAGM - normal appearing grey matter 
 
The effect of treatment with lamotrigine: intention to treat analysis.  
The results of Student’s t-tests comparing change in MTR measures in the placebo 
and verum arms with intention to treat analysis are shown in table 9. There were 
significant differences between the two groups in two parameters, NAGM PH and 
lesion PH. Both measures decreased in the verum arm, but did not change 
significantly in the placebo arm.   
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NAWM, NAGM and lesion PH also decreased significantly in the verum arm while 
no significant change was seen in the placebo arm (See figure 9). However the 
difference in change between the two groups was not significant for any of the three 
measures. Finally, there was a significant increase in lesion mean MTR in the verum 
arm; this was smaller than the corresponding increase seen in the placebo arm, but the 
difference between the two groups was not significant.  
 
None of these results would support the hypothesis that lamotrigine was 
neuroprotective.  
 
Figure 9. MTR peak height.  Mean values for MTR peak height at baseline, 12 and 
24 months for lesions (panel A), NAWM (panel B) and NAGM (panel C). The dashed 
line is the verum arm, the solid line placebo. Error bars show one standard deviation. 
 
 
A 
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B 
 
C 
NAWM – normal appearing white matter, NAGM – normal appearing grey matter 
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The effect of treatment with lamotrigine: per protocol analysis 
At 24 months, 32 of 52 subjects in the verum arm were receiving lamotrigine (mean 
dose 78mg) and 45 of 56 in the placebo arm (mean dose 240mg) were tablet 
compliant (χ2 p=0.018). Twenty five of 52 subjects in the verum arm were serum 
compliant (mean serum concentration 14.1mg/L [standard deviation 8.6]).  
 
The results of the per protocol analysis were similar to the intention to treat analysis. 
In the ‘tablet-adherent’ analysis there was a significantly larger reduction of NAGM 
PH in the verum arm compared to the placebo arm (mean change -0.55 %/pu vs. 0.19 
%/pu, p=0.005). There was mean decrease in lesion PH in the verum arm, compared 
with an increase in the placebo arm (-0.63 %/pu vs. -0.125/pu, p=0.013); but there 
was a significantly smaller reduction of NAWM PH in the verum arm compared with 
placebo arm (mean change - 0.17pu vs. -1,44pu, p=0.028).  
 
In the ‘serum-adherent’ analysis the only significant difference observed was for 
mean lesion PH, with a reduction in the verum arm (-0.52 %/pu) compared to an 
increase in the placebo arm (0.16 %/pu, p=0.008). 
 
Longitudinal correlations of MTR and MSFC measures 
Longitudinal correlations of MTR measures with MSFC and component scores are 
shown in table 11. The model used shows the correlation of the MTR measure with 
the clinical measure at any given timepoint, adjusting for age, sex and disease 
duration. There were significant correlations of PL and mean for all three tissue types 
with MSFC, PASAT-3 and 1/9HPT. NAGM mean was the only MTR parameter 
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which correlated with 1/TW. In all cases the correlations were positive; i.e. the higher 
the MTR measure, the better the performance in the clinical measure.   
 
Table 11. Longitudinal correlation of MTR measures with MSFC and component 
measures in the placebo arm. Age, sex and disease duration were covariates in the 
model. Significant results are shown in bold. Β is standardized beta i.e. the number of 
standard deviations of change in clinical measure for every standard deviation 
increase in MTR measure. 
 Lesion NAGM NAWM 
Peak 
Height 
Peak 
Location 
Mean Peak 
Height 
Peak 
Location 
Mean Peak 
Height 
Peak 
Location 
Mean 
MSFC β -0.002 0.123 0.093 0.178 0.590 0.454 0.022 0.467 0.233 
p 0.912 0.016 0.001 0.044 0.001 <0.0001 0.148 0.001 <0.0001 
PASAT-
3 
β 0.006 0.223 0.125 0.150 0.569 0.469 0.022 0.672 0.315 
p 0.669 <0.0001 <0.0001 0.032 <0.0001 <0.0001  0.062 <0.0001 <0.0001 
1/9HPT β -0.016 0.143 0.106 0.082 0.568 0.425 0.003 0.459 0.206 
p 0.378 0.002 <0.0001 0.314 <0.0001 <0.0001 0.828 <0.0001 <0.0001 
1/TW β -0.018 -0.005 0.004 -0.001 0.213 0.134 0.007 0.170 0.080 
p 0.187 0.889 0.824 0.982 0.079 0.022 0.491 0.098 0.060 
NAWM - normal appearing white matter, NAGM - normal appearing grey matter, PASAT-3 - paced 
auditory serial addition test, TW – timed 25 foot walk, 9HPT - 9 hole peg test 
 
Using the second model significant correlations were seen of change in NAWM PH 
and mean with PASAT-3 (β= 0.009, p=0.035, β=0.011, p=0.044) and of NAWM 
mean with 1/9HPT (β=0.009, p=0.026). In all cases the correlations were positive 
indicating an increase in the MTR measure was associated with better performance in 
the clinical task and a reduction in MTR with a poorer performance in the clinical 
task. 
 
Relationship of MTR measures with a sustained increase in EDSS 
Eleven subjects in the placebo arm (20%) experienced a sustained increase in EDSS 
during the 24 month follow up period. Change in two MTR variables was found to 
significantly predict those subjects who experienced an increase in EDSS: lesion 
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MTR PL (p=0.049, standardized odds ratio (OR)= 0.924) and lesion mean MTR were 
associated with a sustained increase in EDSS (p=0.002, OR= 1.699). In both cases the 
baseline value was lower, although not significantly so, in the group that experienced 
a sustained increase in EDSS: PL 33.07pu (standard error [SE] 0.22) vs 33.97pu (SE 
0.42, p=0.07); mean 29.74pu (SE 0.33) vs 30.71pu (SE 0.35, p=0.16); with a larger 
increase over 24 months in the group who did experience a sustained increase in 
EDSS: PL 0.97pu (SE 0.42) vs 0.39pu (SE 0.22, p=0.25), mean 0.79pu (SE 0.18) vs 
0.30 (SE 0.10, p=0.035). Graphs illustrating the change in lesion PL and mean in the 
two groups are shown in figure 10.  
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Figure 10. Mean lesion MTR measures. Panel A shows MTR mean, panel B shows 
MTR peak location. The dotted line represents those subjects who experienced a 
sustained increase in EDSS during the 24 month study period, the solid line 
represents those who did not. The error bars show one standard error. 
 
A 
 
B 
MTR – magnetization transfer ratio 
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5.4. Discussion  
The aim of this study was two-fold: firstly to evaluate the neuroprotective potential of 
lamotrigine in secondary progressive MS and secondly to assess the utility of brain 
MTR measures (reproducibility, responsiveness to change and the longitudinal 
correlation of MTR measures with neurological function and disability) as a marker of 
brain pathology in clinical trials of MS.  
 
Overall the results of the study do not show that lamotrigine has a neuroprotective 
effect. While the scan-reposition-rescan reproducibility in the non-MS controls was 
good, the magnitude of the change over time in the MS group was small compared 
with the variability, perhaps indicating that the responsiveness of MTR measures to 
change was relatively limited. There were significant correlations of MTR measures 
with measures of neurological impairment, indicating that MTR does detect clinically 
relevant brain pathology. 
 
The effect of treatment with lamotrigine 
The only measures differing significantly between the two treatment arms were lesion 
and NAGM MTR PH. In both cases there was a significantly greater decrease in MTR 
in the verum arm (in fact there was a non significant increase in lesion PH in the 
placebo group). Since higher MTR is thought to represent higher myelinated axon 
content (van Waesberghe et al 1999, Schmeirer et al 2004, Barkhof et al 2003, 
Vrenken et al 2006, Fisher et al 2007) treatment with a neuroprotective drug should 
have the opposite effect; a greater decrease in the placebo group. It is possible that 
lamotrigine is neurotoxic rather than neuroprotective and causes increased 
neuroaxonal damage. However, clinical data from this trial suggests relative 
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preservation of neurological function in the verum arm (Kapoor et al 2010) which 
would tend to refute this explanation.  
 
Another possible explanation is that lamotrigine has another physiological effect on 
brain tissue, which results in a fall in MTR without a reduction in axonal number. For 
example MTR has been shown to correlate with axonal expression of Na
+
/K
+
 ATPase 
in MS lesions (Young et al 2008). Reduced axonal sodium content brought about 
through lamotrigine mediated channel blockade could potentially lead to reduced 
expression of this enzyme and hence a fall in MTR. It would be interesting to evaluate 
this possibility in EAE for example. 
 
Responsiveness of MTR measures to change and reliability 
The changes in MTR measures seen in this study were small compared to those 
reported from previous studies (Rocca et al 1999, Inglese et al 2003, Rovaris et al 
2003a). To minimize the contribution of partial volume voxels to the MTR histograms 
in this study, all voxels with an MTR value of <10pu were excluded and an erosion 
was imposed on NABT masks. The exclusion of this tissue from the histogram 
analysis may partly explain why MTR changes in this study were smaller than those 
in previously published reports.  
 
The scan-reposition-rescan variability of MTR measures in the non-MS controls was 
good; comparable to previously published values for whole brain MTR measures 
acquired using a similar MRI sequence (Inglese et al 2001). However the period over 
which over scans were acquired in the MS group was markedly greater than that in the 
control group and it is known that increasing lesion volume can also lead to changes 
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in segmentation (Chard et al 2002c) so the variability caused by positioning and 
segmentation was likely to be somewhat higher in the MS subject group than in the 
non-MS controls.  
 
Longitudinal association of MTR measures with MSFC and component measures 
Despite the relatively limited sensitivity of MTR changes there were still significant 
longitudinal correlations with clinical measures in the placebo arm.  
 
Greater reduction of MTR in NABT and lesion MTR was associated with poorer 
performance in the PASAT-3 and the 9HPT. Consistent correlation of NAGM and 
NAWM MTR with cognitive and arm function was previously seen in the baseline 
cross-sectional analysis (Hayton et al 2009) and has been observed in other study 
groups (Barkhof et al 2003, Rovaris et al 2000, Ramio-Torrenta et al 2006, Deoire et 
al 2005, Davies et al 2004). It may represent neurological impairment due to 
neuroaxonal loss, particularly since grey and white matter volume and atrophy have 
also been shown to correlate with deficits in these areas of neurological function 
(Filippi et al 2000b, Amato et al 2007, Sanfilipo et al 2006. Morgen et al 2006  Sastre-
Garriga et al 2009). 
 
Correlation of MTR measures with mobility have also previously been reported 
(Barkhof et al 2003, Ramio-Torrenta et al 2006, Fisniku et al 2009). Where tissue 
types have been analyzed in isolation it is primarily grey matter MTR measures which 
have been found to correlate with and predict mobility (Rocca et al 1999, Fisniku et al 
2009, Agosta et al 2006). This study corroborates these findings with only NAGM 
MTR mean correlating with TW. The consistent correlation of changing NAGM mean 
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MTR with change in all three components of the MSFC highlights the likely 
importance of grey matter pathology in determining neurological dysfunction in 
secondary progressive MS. 
 
Using the second model, looking at the association between change in MTR measures 
with performance in the MSFC and component measures there were significant 
correlations observed of change in NAWM MTR mean and PH with performance in 
the PASAT-3 and 9HPT. These were all positive correlations indicating that an 
increase in MTR was associated with better performance in the clinical test and a 
reduction in MTR with a poorer performance. However the β values were very small, 
indicating that a very large reduction in MTR would be associated with a very small 
decrease in the clinical measure and of 36 comparisons made, only three were 
significant, so one should not put too much weight on these findings. 
 
Change in lesion MTR measures is associated with a sustained increase in EDSS 
A larger increase in mean lesion MTR over 24 months was associated with an 
increased probability of a sustained increase in EDSS. This is a surprising result for 
two reasons: firstly one would not expect lesion MTR to increase in people with 
secondary progressive MS: secondly it is the opposite of what of what one would 
expect if lesion MTR mean is a measure of myelinated axon content; a fall in mean 
MTR should correspond to an increase in disability.  
 
One possible explanation for the increase in lesion MTR PH and PL in the placebo 
arm and MTR mean in both arms is that within lesions factors other than just the 
myelinated axon content, such as resolution of oedema or changes to the structure or 
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function of axons may influence MTR. In addition to low myelinated axon content 
low MTR in lesions has been shown to be associated with: larger axonal diameter 
(Fisher et al 2007) lower expression of the Na
+
/K
+
 ATPase in demyelinated axons 
(Young et al 2008) and the presence of parenchymal T-cell and chemokine expression 
in microglia and macrophages (Moll et al 2009). Hence, it is possible that those 
subjects who experienced a sustained increase in disability had higher levels of 
inflammation, axonal oedema and axonal dysfunction at baseline and that the increase 
in MTR represents resolving oedema and attrition of dysfunctional axons. The mean 
lesion MTR mean and PL were lower at baseline in those patients who experienced a 
sustained increase in EDSS than in those who did not, which would be consistent with 
this sort of process. However the differences were not statistically significant so one 
should not place too much emphasis on this result. 
 
Limitations of the study 
The main limitation of this study was the relative insensitivity of the MTR measures. 
MTR was a secondary endpoint and the power calculations for the study’s sample size 
were based on CCV change which is more reproducible (Losseff et al 1996a) and 
responsive (Furby et al 2010). Replicating the study with a larger population may 
generate more reliable results, but the magnitude of the change in MTR measures 
would probably remain very small. A recent study in relapsing-remitting MS suggests 
that specifically targeting new lesions may improve the sensitivity of MTR measures 
(van del Elksamp et al 2010). The lamotrigine trial was not optimized to detect 
inflammatory activity, one of the eligibility criteria was that subjects should be 
relatively free of disabling relapses for at least two years prior to recruitment and no 
Gd was given, making the identification of new lesions somewhat less certain. 
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However future studies of potentially neuroprotective drugs in relapsing-remitting MS 
employing MTR as one of the MRI measures, would be advised to consider treating 
new and chronic lesions separately and in phase 3 trials with larger sample sizes, 
measurement of grey and white matter MTR changes may also be useful to evaluate 
putative neuroprotective treatments in secondary progressive MS. 
 
As previously reported (Kapoor et al 2010) non-adherence in the verum arm was 
higher than expected and disproportionate to the placebo arm. This may have 
influenced the outcome of the study, but it is difficult to envisage a good way to 
prevent this. 
 
Finally the design of the study failed to take into account the possible unintended 
effects of the drug on the outcome measures. This is increasingly recognized as a 
problem in MS studies (Zivadinov et al 2008). The use of cross-over study design or 
multiple assessments prior to the introduction of the IMP or after its withdrawal may 
allow investigators to differentiate the drug effects on neuroaxonal volume or 
inflammation, which one would expect to occur rapidly, from any effects on 
neuroaxonal survival, which one would expect to be a much slower process. 
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6. Clinical and radiological correlates of t1 and t2 lesion 
volume measures in secondary progressive multiple sclerosis 
 
6.1. Introduction 
The detection of T2 hyperintense lesions in specific regions of the central nervous 
system is useful in the diagnosis of MS (Polman et al 2005) and the number and 
volume of T2 lesions present in the early stages of the condition can partially predict 
later disability (Tinotore et al 2006, Rudick et al 2006a, Fisniku et al 2008a). There is 
a correlation between T2LV and neurological impairment, but the strength of this 
relationship diminishes with increasing disability, especially in people with secondary 
progressive MS (Li et al 2006).  
 
A proportion of T2 lesions are hypointense on T1 weighted imaging representing 
inflammation in the acute phase (van Waesberghe et al 1998a, Rovira et al 1999, 
Bagnato et al 2003) or, if persistent, a relative reduction in myelinated axon content 
(Rovira et al 1999, van Waesberghe et al 1999, van Walderveen et al 1999). T1LV 
may therefore be a relatively specific measure of focal MS pathology and so be a 
useful tool for monitoring brain pathology in clinical studies. 
 
Clinical status in MS has been shown to correlate with brain and spinal cord atrophy 
(Losseff et al 1996a, Miller et al 2002, Anderson et al 2006), perhaps indicating that 
chronic neuroaxonal loss may be partly responsible for progressive disability. One 
possible mechanism is toxic sodium accumulation following up-regulation of voltage 
gated sodium channels on demyelinated axons (Smith et al 2001, Craner et al 2003, 
Moll et al 2009). Sodium channel blockers such as lamotrigine have been found to 
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ameliorate progressive neurological dysfunction and axonal loss in the animal model 
EAE (Bechtold et al 2006) and so a recent clinical trial has been conducted to evaluate 
the neuroprotective potential of lamotrigine in MS (Kapoor et al 2010). 
 
The purpose of this study was to compare T1LV with T2LV and  the ratio of T1 to T2 
lesion volume in a group of people with secondary progressive MS who were taking 
part in a clinical trial of neuroprotection with lamotrigine, evaluating the 
responsiveness of both measures to change; the cross-sectional and longitudinal 
correlation with clinical status and MRI measures of NABT pathology and global 
atrophy (suggesting neuro-axonal loss); and the effects of lamotrigine treatment on 
T1LV and T2LV. 
 
4.2. Methods 
Subjects  
This study comprises 118 people with secondary progressive MS, taking part in the 
lamotrigine trial (see section 2.1). 
 
Clinical data 
Clinical data included here are EDSS, MSFC and the presence or absence of relapses. 
For details of how these measures were collected see section 2.2. 
 
MRI acquisition and analysis 
Details of the MRI acquisition parameters used in this study are given in table 1. Data 
presented here are: 
 T1LV  
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 T2LV  
 The presence or absence of new and enlarging (active) T1 and T2 lesions 
 NBV and percentage brain volume change (PBVC) calculated using 
SIENA 
 Mean MTR for NABT. The data presented here were generated from 
tissue segments derived using SPM5 (Ashburner and Friston 2005)  
 
Statistics 
Change in MRI and clinical measures  
The change in MRI and clinical measures were calculated by subtracting baseline 
values from the values at 24 months; thus a negative value indicated a fall in that 
measure over 24 months; a negative value for the clinical measure indicated 
neurological deterioration. Single sample Student’s t-tests were used to determine 
whether any changes measured over 24 months were significant.  
 
The effect of treatment with lamotrigine 
Differences in change in MRI measures between the placebo and verum arms were 
assessed using independent samples Student’s t-tests. Intention to treat analysis was 
used in this study, with all randomized subjects invited for every scan irrespective of 
whether they were still taking the investigational medicinal product. Two additional, 
post-hoc, per protocol analyses were employed: a comparison of tablet adherent 
subjects, defined as those who had taken 80% of prescribed tablets and were still 
being prescribed tablets at 24 months; and a serum adherent comparison, which 
compared subjects in the verum arm who had detectable serum lamotrigine at 24 
months with the entire placebo arm.  
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Reliability of the MRI measures 
It was not possible to estimate scan-reposition-rescan reproducibility for the lesion 
measures. Scan-reposition-rescan reproducibility for MTR and NBV was estimated 
using MRI scans from three healthy controls, each of whom was scanned on five 
occasions over a four week period. To quantify intra-rater variability for T1 and 
T2LV and inter-rater variability for T2LV a set of five randomly selected, 
anonymized test scans taken from the lamotrigine trial library was analyzed on two 
separate occasions. In all cases coefficients of variability were calculated. The values 
for T1 and T2LV are shown in table 2. 
 
Longitudinal correlation between lesion volume measures and MSFC 
Longitudinal correlation of lesion volume measures with MSFC and component 
scores was assessed in the placebo arm using a random intercept mixed effect linear 
regression model with age, gender, disease duration and time as covariates. A second 
model was calculated evaluating the correlation of MSFC with an interaction variable 
- [lesion volume measure] x time. The first model shows the correlation of lesion 
volume and clinical measures at any given timepoint. The second shows the 
correlation of the clinical measure with the change in the lesion volume measure.  
 
The association between lesion measures and EDSS 
Subjects in the placebo arm were divided into those who did or did not experience a 
sustained increase in EDSS over 24 months, defined as an increase of ≥0.5 points 
from baseline observed at two consecutive assessment visits over six months in 
subjects with a baseline EDSS of ≥ 6.0 or of 1.0 points in subjects with a baseline 
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EDSS of ≤ 5.5. Differences in baseline lesion volume values and change in lesion 
volume were assessed using binary logistic regression with age, gender and disease 
duration as covariates. 
 
Treatment effect 
Differences in change in lesion volume measures between verum and placebo arms 
were tested using independent samples Student’s t-tests. Intention to treat analysis 
was employed, so all subjects were invited for scanning at every timepoint, and every 
subject who attended for scanning at baseline and 24 months was included in the 
analysis.  In addition two per protocol comparisons were also carried out: 1) Tablet 
Compliant (TC), within the subgroup of participants who consumed at least 80% of 
prescribed tablets and were still being prescribed tablets at 24 months; 2) Serum 
Compliant (SC), comparing participants in the active group with detectable serum 
lamotrigine at 24 months with the whole placebo group.   
 
6.3. Results 
Demographic characteristics of the subjects shown in tables 4 and 8. Baseline lesion 
volume measures are shown in table 12.  
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Table 12. Lesion volume measures at baseline. Data shown are: mean values 
(standard deviation - SD) unless otherwise specified. 
Characteristics Placebo arm, n=57 Verum arm n=61 p-value (Student’s T-
test) 
T1LV, ml -  median 
(range)  
9.94 (0.18 to 43.67) 9.91 (0.21 to 46.96) 0.526 
T2LV, m-  median (range) 23.02 (0.82 to 87.97) 25.35 (0.35 to 71.62) 0.706 
T1 to T2 lesion volume 
ratio 
0.47 (0.21) 0.44 (0.21) 0.377 
Mean NABT MTR, pu 34.26 (1.27) 34.47 (0.92) 0.374 
NBV, ml 1480.51 (99.77) 1471.09 (101.09) 0.616 
T1LV - T1 hypointense lesion volume, T2LV - T2 hyperintense lesion volume, PBVC - percentage brain 
volume change, NABT MTR normal appearing brain tissue mean magnetization ratio. 
 
Change in lesion measures and treatment effect 
The results of the intention to treat analysis are shown in table 13. There was a 
significant increase in mean T1LV and T2LV in both verum and placebo arms but no 
significant difference in the size of this change between the two groups. There was no 
significant change in T1 to T2 lesion volume ratio over 24 months in either trial arm. 
The z-score is an indication of the responsiveness of the measures – the higher the z-
score the more responsive the measure is to change. In this study the responsiveness 
of T1 and T2 lesion volumes was similar. 
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Table 13. Mean change in lesion volume measures.  Significant results highlighted 
in bold 
  Mean 
annual 
change  
 
Mean absolute 
change over 24 
months 
(standard error) 
Significance of 
change over 24 
months 
Significance of 
difference between 
verum and placebo 
arms
‡ 
T1LV Placebo 1.83ml 
(15.3%) 
3.67ml (0.61) z=5.40* 
p<0.0001 
p=0.46 
Verum 2.01ml 
(19.9%) 
3.96ml (0.54) z=5.13* 
p<0.0001 
T2LV Placebo 2.93ml 
(18.2%) 
5.87ml (1.09) z=5.47* 
p<0.0001 
p=0.28 
Verum 2.94ml 
(17.5%) 
5.96ml (1.09) z=5.55* 
p<0.0001 
T1 to T2 
lesion 
volume 
ratio 
Placebo -0.003 (-
2.67%) 
-0.01 (0.18) t= 0.37
† 
p=0.71 
p=0.49 
Verum 0.005 
(6.49%) 
0.01 (0.18) t= 0.60
† 
p=0.55 
PBVC Placebo -0.59% -1.19% (0.10) t=12.00
†
, 
p<0.0001 
p=0.16 
Verum -0.70% -1.34% (0.11) t=12.28 
p<0.0001 
NABT 
mean MTR 
Placebo -0.06pu (-
0,16%) 
-0.12pu (0.06) t= 1.92
† 
p=0.60 
p=0.77 
Verum -0.09pu (-
0.27%) 
-0.15pu (0.08) t= 1.97
† 
p=0.54 
T1LV T1 hypointense lesion volume, T2LV T2 hyperintense lesion volume, PBVC percentage brain 
volume change, NABT mean MTR normal appearing brain tissue mean magnetization ratio. *paired 
sample Wilcoxon sign rank test baseline vs. 24 months; †paired sample Student’s t-test; ‡ independent 
sample student’s t-test comparing change over 24 months in the placebo vs. the verum arms. 
 
 
Similar results were seen with both forms of per protocol analysis with no significant 
differences between the two groups in the change of any of the lesion measures using 
either tablet compliance (T1LV p=0.50, T2LV p=0.47, T1 to T2 lesion volume ratio 
p=0.83); or serum compliance (T1LV p=0.40, T2LV p=0.41, T1 to T2 lesion volume 
ratio p=0.58). 
 
Reliability of the MRI measures 
The scan-reposition-rescan reproducibility for mean NABT MTR and PBVC were 
very high with coefficients of variability of 0.31% and 0.22% respectively. 
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Correlation with MSFC: cross-sectional correlation 
The correlation of lesion measures with clinical measures at baseline are shown in 
table 14. There were significant negative correlations of all three lesion volume 
measures with MSFC, PASAT-3 and 1/9HPT. The best lesion predictor for all three 
was lnT1LV, explaining approximately 19%, 18% and 9% of the variability of MSFC, 
PASAT-3 and 1/9HPT respectively. None of the lesion measure correlated 
significantly with 1/TW.  
 
When NBV and NABT mean MTR were included in the regression models the best 
predictor model for MSFC comprised NBV (rp=0.20, p=0.038) and NABT mean 
MTR(rp= 0.26, p= 0.006; R
2
=0.21), while NABT mean MTR was a lone best 
predictor for PASAT-3 (rp=0.53, p<0.0001; R
2
=0.28) and NBV the lone best predictor 
for 1/9HPT (rp= 0.45, p<0.0001; R
2
=0.20). 
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Table 14. Cross-sectional correlation of lesion volume measures with other MRI 
measures, MSFC and component measures. The results of linear regression analysis 
with NBV, mean NABT MTR, MSFC or component measure as a product of lesion 
volume measure, age, sex and disease duration. Significant results highlighted in 
bold.  
 MRI measure Clinical measure 
NBV Mean 
NABT 
MTR 
MSFC PASAT-3 1/9HPT 1/TW 
lnT1LV  
 
rp=-0.52, 
p<0.0001 
 rp=-0.57, 
p<0.0001 
rp=-0.31, 
p=0.001 
rp=-0.42, 
p<0.0001 
rp=-0.31, 
p=0.001 
rp=0.076, 
p=0.736 
lnT2LV  
 
rp=-0.46, 
p<0.0001 
 rp=-0.54, 
p<0.0001 
rp=-026, 
p=0.004 
rp=-0.35, 
p<0.0001 
rp=-0.28, 
p=0.003 
rp=0.01, 
p=0.916 
T1 to T2 
ratio 
 
rp=-0.41, 
p=0.001 
rp=-0.41, 
p=0.002 
rp=-026, 
p=0.005 
rp=-0.31, 
p=0.001 
rp=-0.25, 
p=0.009 
rp=-0.13, 
p=0.168 
Best 
predictor 
model 
lnT1LV and 
disease 
duration R
2
 
= 0.35 
lnT1LV R
2
 
= 0.33 
lnT1LV R
2
 
= 0.19 
lnT1LV and 
sex R
2
 = 
0.21 
lnT1LV R
2
 
= 0.09 
n/a 
T1LV T1 hypointense lesion volume, T2LV T2 hyperintense lesion volume, PBVC percentage brain 
volume change, NABT mean MTR normal appearing brain tissue mean magnetization ratio. 
 
Correlation with MSFC: longitudinal correlation 
There were no significant correlations of change in any lesion volume measure with 
change in MSFC or any of the component measures.  
 
The results of random intercept mixed effect linear regression model are shown in 
table 15. These models show that at any given timepoint there were significant 
negative correlations of change in: lnT1LV and T1 to T2 lesion volume ratio with 
MSFC; lnT1Lv and lnT2LV with PASAT-3; and all three lesion measures with 
1/9HPT; none of the lesion measures correlated significantly with 1/TW.  
 
There was no significant correlation of any of the lesion measures with an interaction 
variable [MSFC/component measure]*time. 
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Table 15. Longitudinal correlation of lesion measures with other MRI measures, 
MSFC and components. Data shown are standardized β – the number of standard 
deviations of change in the MRI or clinical measure for every standard deviation 
increase in lesion measure. Statistically significant results are highlighted in bold.   
 Clinical measures 
 MSFC PASAT-3 1/9HPT 1/TW 
lnT1LV β=-0.20, p=0.013 β=-0.19, p=0.015 β=-0.30, 
p<0.0001 
β=-0.113, 
p=0.159 
lnT2LV β=-0.14, p=0.057 β=-0.19, p=0.011 β=-0.25, 
p=0.002 
β=-0.05, 
p=0.485 
T1 to T2 
lesion 
volume 
β=-0.06, p=0.009 β=-0.05, p=0.054 β=-0.09, 
p<0.0001 
β=-0.04, 
p=0.073 
MSFC – multiple sclerosis functional composite, PASAT-3 – paced auditory serial addition test, 9HPT 
– 9 hole peg test, TW – timed 25 foot walk 
 
 
The association of lesion volume measures with disability or markers of inflammatory 
activity. 
In the placebo arm, 30 subjects (54%) had one or more active T2 lesions, 23 (41%) 
had one or more active T1 lesions and 26 (46%) experienced one or more relapses 
during the trial period. In the verum arm 23 subjects (38%) had one or more active T2 
lesions, 17 (28%) had one or more active T1 lesions and 25 (41%) experienced one or 
more relapses. There were no significant differences in any of these measures between 
the two groups. 
 
In the placebo group, neither change in T1 or T2 lesion volume predicted whether or 
not a subject was likely to experience a relapse during the 24 month follow up period.  
26 subjects in the placebo group were in the higher disability group at baseline none 
of the baseline lesion measures significantly predicted whether a subject would be in 
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the higher EDSS group. 11 subjects in the placebo group experienced a sustained 
increase in EDSS during the trial period. Change in T1, T2LV or T1 to T2 lesion 
volume ratio did not significantly predict a sustained increase in EDSS. 
 
6.4. Discussion 
These data do not show that treatment with lamotrigine has any effect on the rate of 
change of lesion volume measures. The data confirm cross-sectional correlation of 
both T1 and T2LV with MSFC and component measures and that these correlations 
are consistent across all three timepoints. At baseline T1LV emerged as the only 
independently significant correlate of the clinical measures, perhaps suggesting that it 
may be the more specific measure of clinically important brain pathology. However 
even though both T1 and T2LV did change significantly over the 24 months of the 
study there was no significant correlation of change in lesion volume measures with 
change in any of the clinical measures, raising the question of whether either measure 
is sufficiently responsive to be useful in clinical trials. 
 
The effects of lamotrigine 
In this study lamotrigine had no significant effect on any lesion measure, using either 
intention to treat or per-protocol analysis. If lamotrigine does indeed prevent 
degeneration of chronically demyelinated axons one would hope to see a slower 
increase in T1 lesion volume in the verum arm compared with the placebo arm, which 
unfortunately was not the case here.  
 
It is also possible that either lamotrigine is not neuroprotective in MS, or that the 
neuroprotective effect is too small to be detected using the sample size, follow up time 
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or assessment measures used in this study. The in vitro and animal studies on which 
the trial was based do suggest that sodium channel blockade has the potential to be 
neuroprotective (Garthwaite et al 2002, Lo et al 2002, Kapoor et al 2003, Bechtold et 
al 2004, Bechtold et al 2006) and it is tempting to suggest longer, larger trials with 
additional biomarkers – optical coherence tomography (Fisher et al 2006), 
neurofilament light chain etc. (Semra et al 2002). However when conducting clinical 
trials one has to consider the welfare of the subjects taking part and the value of 
effective treatment – is it worth exposing large numbers of patients to prolonged or 
unproven investigations for a medication that offers a very small benefit? 
 
Responsiveness of T1 and T2LV 
In this study the responsiveness of T1 and T2 lesion volumes are very similar (see 
table 13.). Both compare well to NABT mean MTR (there was no significant change 
in this measure over the two years) but less well compared to PBVC.  
 
In previously published studies there is a wide range for change in T1 and T2LV (van 
Walderveen et al 1995, van Walderveen et al 1999a, Truyen et al 1996, Simon et al 
2000, Barkhof et al 2001, Wolinsky et al 2001, Zivadinov et al 2001, Rovaris et al 
2003a, Sailer et al 2003, Mesaros et al 2008, Korteweg et al 2009) and the absolute 
values recorded in this study are at the higher end of this range. However the 
variability of the lesion volume changes in this study was relatively wide, perhaps 
limiting the responsiveness of these measures. It was not possible to measure the 
scan-reposition-rescan variability of the lesion measures, but the inter- and intra-rater 
variability of these measures was quite large (see table 2) highlighting the influence of 
human error.  
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The process for deriving PBVC is almost completely automated, substantially 
improving the reproducibility (Smith et al 2002). The other advantage of SIENA (the 
process by which PBVC is calculated) is that by coregistering sequential images it 
very sensitively identifies areas of volume change, which may not be apparent using 
localized thresholding techniques on individual scans.  
 
Some centres have developed automated techniques for identifying and contouring T1 
lesions, which cuts down on the variability in this measure due to human judgment. 
However this technique still requires reference to a previously identified T2 lesion 
mask (Fisher et al 2007). To produce a robust comparison of T1 and T2 lesion 
measures, what is really needed are fully automated techniques for acquiring both 
measures independently, i.e. the T1LV without reference to the T2 lesion maps. If this 
also involved interpolation and coregistration of sequential scans, in a similar fashion 
to SIENA, the sensitivity of both measures would probably also increase. 
 
Correlation with clinical measures 
Previously published cross-sectional studies in subjects with secondary progressive 
MS have shown significant correlations of T1LV with MSFC (Kalkers et al 2001b) 
and PASAT-3 (Kalkers et al 2001a). In this study there were cross-sectional 
correlations of both T1LV and T2LV with PASAT-3 and 1/9HPT with T1LV the only 
independently significant cross-sectional correlate of both measures.  
 
The amount of variance in the clinical measures explained by T1LV (21% and 9% for 
cognitive and arm function respectively) suggests that other aspects of brain 
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pathology which may not be directly related to focal lesion burden, such as grey 
matter damage, may also contribute to neurological dysfunction. Previous MRI 
studies correlating abnormalities in NABT with neurological impairment and the 
correlation of grey matter atrophy with neurological impairment would corroborate 
this (Filippi and Agosta 2007, Fisher et al 2008, Fisniku et al 2008b, Furby et al 
2010). Additional corroboration would be the finding from this study that introducing 
NABT mean MTR into the model correlating MRI values with PASAT-3 scores and 
NBV into the corresponding model for 1/9HPT rendered lnT1LV association non-
significant. 
 
Previous studies have shown correlations of both T1 hypointense and T2 hyperintense 
lesion measures with EDSS (van Walderveen et al 1995, Truyen et al 1996, Lycklama 
y Nijeholt et al 1998, van Waesberghe et al 1998b, Ianucci et al 1999, Rovaris et al 
1999, van Walderveen et al 1999b Simon et al 2000, Rovaris et al 2003b). In this 
study, none of the lesion measures were associated with either a higher EDSS at 
baseline or a sustained increase in EDSS over two years. Furthermore none of the 
lesion measures correlated with mobility, either cross-sectionally or longitudinally. In 
this study subjects were selected to have an EDSS of 4.0 to 6.5 at baseline; a range at 
which variation in EDSS is almost exclusively determined by mobility (Kurtzke et al 
1983). It is possible that brain lesions have a relatively limited effect on mobility and 
so a relatively limited effect on EDSS in this subject group. Previous studies which do 
show correlations of both T1 hypointense and T2 hyperintense lesion measures with 
EDSS have subjects with a wider range of EDSS scores, where arm and cognitive 
function may be more influential (van Walderveen et al 1995, Truyen et al 1996, 
Lycklama y Nijeholt et al 1998, van Waesberghe et al 1998b, Ianucci et al 1999, 
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Rovaris et al 1999, van Walderveen et al 1999b Simon et al 2000, Rovaris et al 
2003b). 
 
Although the correlations of lesion volume measures with MSFC and component 
measures were consistent across all three time-points, there was no correlation of 
change in lesion volume with change in any of the MSFC measures. Nor was a model 
correlating lesion measures with the interaction variable of [clinical measure]*time 
statistically significant. It is possible that while the burden of focal lesions 
accumulated over the whole timecourse of MS does correlate with the degree of 
neurological dysfunction, new changes in lesion volume in established SPMS do not 
contribute to concurrent progressive impairment. It is known that there is axonal 
transection in lesions (Trapp et al 1998) and it has been proposed that this may lead to 
subsequent brain atrophy and neurological impairment. It would be interesting to 
follow this study group up after a longer time interval to see if those subjects who had 
the largest increase in lesion volume over the course of this study subsequently  
showed a greater change in clinical status. 
 
The effects of inflammatory activity 
Change in T1LV may not simply represent axonal degeneration; acute T1 hypointense 
lesions may represent focal oedema associated with inflammatory demyelination (van 
Waesberghe et al 1998a, Rovira et al 1999, Bagnato et al 2003). Recent evidence 
suggests that sodium channel blockers may have some immunomodulatory potential 
(Black et al 2007) and differences between the two groups in terms of new 
inflammatory activity is a potentially confounding factor. There was no significant  
difference between the two groups in terms of the presence of active T1 or T2 lesions. 
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However the best established marker of new focal neuroinflammation is Gd enhanced 
lesion load (Tubridy et al 1998) and, because of concerns about the duration of the 
scanning protocol, we did not acquire this. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 144 
7. CLINICAL AND IMAGING CORRELATES OF THE 
MULTIPLE SCLEROSIS IMPACT SCALE IN 
SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS. 
 
7.1. Introduction 
The correlation of MRI measures of pathology with clinician assessed neurological 
function is subtotal (Miller et al 2002, Li et al 2006, Filippi and Agosta 2007) but 
clinicians’ assessment of the severity of a patient’s MS and patients’ perception of the 
impact of MS on their quality of life (QoL) can also differ (Rothwell et al 1997) and it 
remains to be established whether MRI detected brain pathology may have an impact 
on QoL which is independent of clinically detected neurological dysfunction. 
  
In this study we tried to establish whether MRI detectable brain and spinal cord MS 
pathology and clinical measures of neurological function and disability correlated 
independently with patient’s assessment of the impact MS on their lives and which 
aspects of both seem to be most important.  
 
7.2. Methods 
Subjects  
This study comprises 118 people with secondary progressive MS, from the 
lamotrigine trial (see section 2.1). 
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Clinical data 
Clinical data included here are EDSS, MSFC the presence or absence of relapses and 
MSIS-29. For details of how these measures were collected see section 2.2. Two 
scores were derived from the MSIS-29 questionnaire MSIS-phys and MSIS-psych. 
Higher scores are awarded for greater impact on QoL. 
 
MRI acquisition and analysis 
Details of the MRI acquisition parameters used in this study are given in table 1. Data 
presented here are: 
 T2LV 
 T1LV 
 Active lesions, i.e. new and enlarging T2 and T1 lesions 
 NBV 
 PBVC derived using SIENA 
 CCV  
 MTR histograms for T2 lesions, NAGM and NAWM The data presented 
here were generated from tissue segments derived using SPM05 
(Ashburner and Friston 2005)  
 GMF and WMF 
 SCCA 
Statistics 
The aim of this study was to identify which measures, clinical and MRI, were 
independently significant correlates of MSIS-29 measures. In order to keep each 
regression model as small as possible, while including as many variables as possible a 
two stage process was used. In the first stage, variables which were thought a priori to 
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be likely to be intercorrelated were grouped together.  The following categories were 
used: 1. Baseline demographic characteristics – age, sex, disease duration; 2 Tests of 
neurological function - MSFC and component measures; 3. Disability - EDSS; 4. 
Lesion volume measures; 5. Brain volume and atrophy measures; 6. MTR measures; 
7. SCCA. For the longitudinal analysis two further categories were included: binary 
variables denoting the presence or absence of clinical relapses and the presence or 
absence of active lesions.  
 
Because of the limited range of values, EDSS was converted to a binary variable. For 
cross-sectional analysis subjects were divided into higher (EDSS≥6.5) and lower 
(EDSS≤6.0) disability groups, and for longitudinal analysis divided according to 
whether or not they experienced an increase in EDSS from baseline observed at two 
consecutive assessment visits (≥1.0 points in subjects with a baseline EDSS of ≤ 5.5 
or ≥0.5 points from in subjects with a baseline EDSS of ≥ 6.0. The decision to treat 
the EDSS as a binary variable was made prior to conducting any statistical analysis. 
 
For each group of variables linear regression analysis was used to identify the ‘least 
significant correlate’ (the one with highest p-value). This variable was ‘discarded’ and 
the regression analysis repeated to identify the ‘next least significant correlate’. This 
process was repeated until only independently significant variables were left, then, to 
make sure no independently significant correlate had been erroneously discarded due 
to collinearity, each of the discarded variables were tested against the final model. For 
all binary variables Student’s T-tests, rather than regression analysis, were used to 
identify whether the MSIS measures were different between the two groups.  For 
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SCCA, which was considered on its own, Pearson correlation coefficient was 
calculated.  
 
In the second stage of the statistical analysis a ‘multimodal best predictor model’ was 
established by repeating the stepwise multiple regression analysis including all the 
independently significant correlates from the first stage in a single model. Again, all 
previously discarded variables are checked against the final model, including those 
discarded in the first stage of the analysis.  
 
Cross-sectional analysis 
Cross-sectional analysis was done using baseline MSIS-29, clinical and MRI 
measures. Baseline T1 and T2 lesion volumes were not normally distributed so were 
log transformed prior to statistical analysis.  
 
Longitudinal analysis 
For all continuous variables longitudinal associations were evaluated by comparing 
the change in a given clinical or MRI value over the 24 months with the change in 
MSIS-29 values over 24 months. Change in a continuous variable was calculated by 
subtracting the baseline value from the value at 24 months, so a negative change 
represented a reduction in that parameter. Single sample Student’s t-tests were used to 
identify those variables that changed significantly over 24 months. Because of the 
potentially confounding effects of lamotrigine, only subjects from the placebo group 
were included in the longitudinal analysis. 
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7.3. Results 
Baseline demographic details are shown in table 16. Two patients experienced an 
increase in EDSS between screening and the baseline visit meaning that the range of 
baseline values was wider than would be expected from the trial inclusion criteria. 
 
Table 16. Baseline demographic characteristics for the both the placebo and verum 
arms combined. (demographic data for the placebo and verum arms is shown in table 
9).    
Characteristics Whole group, n= 118 
Sex, Female/Male (%)  85/33 (72/28) 
Age, years -  mean (SD; 
range)  
 
50.6 (7.0; 30 to 61) 
Disease duration, years - 
mean (SD; range)  
20.1 (8.8; 3 to 41) 
EDSS, median (inter 
quartile range; range)  
 
6.0 (0.5; 4 to 7.5) 
SD - standard deviation, EDSS – expanded disability status scale. 
 
In the placebo arm: 27 subjects (47%) experienced one or more relapses during the 
study period (range 1 to 4). 30 subjects (53%) in the verum arm had one or more 
active T2 lesions during follow up period; the median number of active lesions 
detected was 3 (range 1 to 13 active lesions), with a median annualized active lesion 
rate for the whole group of 0.75 (range 0 to 6.5). 13 subjects (23%) experienced a 
sustained increase in EDSS. Other clinical and MRI data are summarized in table 17.  
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Table 17. Clinical and MRI characteristics at baseline and change over 24 months. 
Characteristics Whole group 
Baseline values, 
mean (SD) 
Placebo arm 
Baseline values, 
mean (SD) 
Placebo arm 
Change over 24 
months, mean 
(SD) 
Significance of 
change over 24 
months*, t-
value (p-value) 
MSIS-phys 60.86 (15.15) 60.98 (15.44) 2.08 (14.38) 1.09 (0.28) 
MSIS-psych 24.10 (8.71) 24.07 (8.89) -0.30 (7.91) 0.29 (0.78) 
PASAT-3 43.1 (13.6) 44.7 (13.6) -2.5 (9.6) 1.96 (0.06) 
TW, sec  36.0 (47.9) 20.5 (60.0) 7.8 (18.2) 2.99 (0.004) 
9HPT, sec  57.1 (106.5) 32.3(25.0) 13.1 (66.3) 1.47 (0.15) 
T2LV, ml 25.96 (17.80) 26.61 (18.39) 5.87 (8.06) 5.40 (<0.0001) 
T1LV, ml 13.51 (12.08) 14.25 (12.85) 3.67 (6.19) 4.34 (<0.0001) 
T1 to T2 lesion 
volume ratio 
0.46 (0.20) 0.48 (0.21) -0.01 (0.13) 0.37 (0.71) 
CCV, ml 254.89 (23.79) 255.04 (23.62) -7.30 (5.30) 10.44 (<0.0001) 
GMF 0.45 (0.03) 0.46 (0.03) -0.002 (0.007) 5.19 (<0.0001) 
WMF 0.29 (0.02) 0.29 (0.02) -0.008 (0.01) 2.24 (0.03) 
Whole brain 
atrophy, ml 
NBV 1475.6 (SD 
100.1) 
NBV 1480.5ml 
(SD 99.8ml) 
PBVC -1.18% (SD 
0.74%) 
12.00
†
 
(<0.0001) 
Lesion MTR, pu 30.70 (1.98) 30.58 (2.02) 0.40 (0.70) 4.21 (<0.0001) 
NAGM MTR, pu 32.05 (1.07) 31.99 (1.12) -0.13 (0.26) 3.54 (0.001) 
NAWM MTR, pu 37.37 (1.08) 37.27 (1.33) -0.06 (0.92) 0.49 (0.64) 
SCCA, mm2 63.59 (8.62) 66.29 (9.06) -2.05 (2.47) 6.20 (<0.0001) 
MSIS-phys – MSIS-29 physical component, MSIS-psych – MSIS-29 psychological component, PASAT-3 
– Paced Auditory Serial Addition Test, TW – 25 foot timed walk, 9HPT – 9 hole peg test, T1LV – T1 
hypointense lesion volume, T2LV, T2 hyperintense lesion volume, CCV – central cerebral volume, 
GMF – grey matter fraction, WMF – white matter fraction, MTR – magnetization transfer, NAWM – 
normal appearing white matter, NAGM, normal appearing grey matter, SCCA – spinal cord cross 
sectional area, NBV – normalized brain volume, PBVC – percentage brain volume change. *two- 
tailed Student’s  t-test comparing baseline with 24 months. † calculated using a single sample Student’s 
t-test against a test variable of 0. 
 
Cross-sectional association: stage 1. 
The results of the first stage analysis are shown in table 18. 
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Table 18.  The results of stage 1 cross-sectional analysis. Unless otherwise stated 
shows the results of multiple linear regression analysis showing the correlation of 
baseline MSIS-29 with baseline clinical and MRI measures. Only independently 
significant correlates of are shown.  
 MSIS-phys MSIS-psych 
Independently significant 
variables 
Independently significant 
variables 
Clinical measures 
1. Demographic 
characteristics*: 
Age, sex, disease duration 
None Female sex 
rp=0.20,  p=0.035 
2. MSFC and component 
measures*:  
MSFC, 1/TW, 1/9HPT, PASAT-
3 
1/TW  
rp=-0.38,  p<0.0001 
PASAT-3 
rp=-0.31,  p=0.001 
3. EDSS†: 
EDSS high or low   
None None 
MRI measures 
4. Lesion measures*: 
lnT1LV, lnT2LV, T1 to T2 ratio 
T1 to T2 ratio 
rp=0.24, p=0.009 
T1 to T2 ratio 
rp=0.31, p=0.001 
5. Brain volume measures: 
CCV, NBV, GMF, WMF* 
CCV 
rp=-0.22, p=0.015 
CCV 
rp=-0.21, p=0.025 
6. MTR measures*: 
NAGM, NAWM and lesion (PH, 
PL, mean) 
None  None  
7. SCCA‡ None None 
*Multiple linear regression analysis. † Two tailed Student’s t-test. ‡ Pearson correlation coefficient. 
MSIS-phys – MSIS-29 physical component, MSIS-psych – MSIS-29 psychological component, PASAT-3 
– Paced Auditory Serial Addition Test, TW – 25 foot timed walk, 9HPT – 9 hole peg test, T1LV – T1 
hypointense lesion volume, T2LV, T2 hyperintense lesion volume, CCV – central cerebral volume, 
GMF – grey matter fraction, WMF – white matter fraction, MTR – magnetization transfer ratio, 
NAWM – normal appearing white matter, NAGM, normal appearing grey matter, SCCA – spinal cord 
cross sectional area. 
 
1/TW was the only independently significant clinical correlate of MSIS-phys whereas 
PASAT-3 was the only independently significant correlate of MSIS-psych.  
 
Of the lesion measures, T1/T2 lesion volume ratio was the only independently 
significant correlate of MSIS phys and MSIS-psych. CCV was the only one of all the 
brain volume measures to independently correlate with MSIS phys and MSIS-psych. 
None of the other MRI measures correlated independently with either of the MSIS 
measures. 
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Cross-sectional association: stage 2. 
The results of stage 2, the multi-modal analysis, are shown in table 19. 
 
Table 19.  The results of stage 2 cross-sectional analysis. Shows the results of 
multiple linear regression analysis correlating baseline MSIS-29 with of all the 
independently significant correlates from stage 1 analysis.  
 MSIS-phys MSIS-psych 
Variables included in the model 1/TW, T1 to T2 ratio, 
CCV 
Female sex, PASAT-3, T1 to T2 ratio, 
CCV  
Independently significant 
variables 
1/TW  
 
rp=-0.36, 
p<0.0001 
T1 to T2 ratio 
 
rp=0.24, p=0.009 
  PASAT-3 
 
rp=-0.18, p=0.041 
R
2
=0.13 R
2
=0.13 
MSIS-phys – MSIS-29 physical component, MSIS-psych – MSIS-29 psychological component, TW –  
timed 25 foot walk, CCV – central cerebral volume. 
 
1/TW accounted for approximately 13% of the variability in MSIS-phys. T1 to T2 
lesion volume ratio was not an independently significant correlate in this model (rp = 
0.127, p=0.051).  
 
However T1 to T2 lesion volume ratio was also the closest independently significant 
correlate of MSIS-psych, accounting for approximately 9% of the variability of the 
latter measure. The inclusion of PASAT-3 increased the proportion of the variability 
of MSIS-psych accounted for by the model to 13%.  
 
Longitudinal association:  Stage 1 
Of the clinical measures 1/TW was the only independently significant correlate with 
MSIS-phys (rp=-0.27, p=0.047) and MSIS-psych (rp=-0.36, p=0.007)  
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Change in NAGM MTR peak height (rp=0.29, p=0.022), NAGM peak location (rp=-
0.45, p=0.001) and mean NAWM MTR (rp=0.26, p=0.041) all correlated 
independently with change in MSIS-psych together accounting for 22.2% of the 
variability of that measure.  
 
Longitudinal association:  Stage 2 
The results of the multi-modal analysis are shown in table 20. 
 
Table 20. The results of stage 2 longitudinal analysis. Shows the results of multiple 
linear regression analysis correlating change in MSIS-29 measures with all the 
independently significant correlates from stage 1 analysis. 
 MSIS-phys MSIS-psych 
Variables included in the 
model 
∆1/TW  
 
∆1/TW, ∆NAGM peak height, ∆NAGM peak 
location, ∆NAWM mean MTR  
Independently 
significant variables  
∆1/TW  
 
rp=-0.27, 
p=0.047 
∆1/TW 
 
rp=-0.334, p=0.007 
 ∆NAWM mean  rp=0.371, p=0.003 
∆NAGM peak height  rp=-0.242, p=0.048 
R
2
=0.09 R
2
=0.32 
Δ - change in a given variable, MSIS-phys – MSIS-29 physical component, MSIS-psych – MSIS-29 
psychological component, TW – 25 foot timed walk, NAGM – normal appearing grey matter, NAWM – 
normal appering white matter,  MTR – magnetization transfer ratio, CCV – central cerebral volume. 
 
For change in MSIS-phys change in 1/TW was the only variable included in the 
model; it accounted for approximately 9% of the variability of change in MSIS-phys. 
For change in MSIS-psych change in 1/TW, change in NAWM mean and change in 
NAGM peak height were all independently significant correlates with a multimodal 
model accounting for approximately 32% of the variability.  
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7.4. Discussion 
The aim of this study was to investigate the relationship between a range of clinical 
and imaging measurements with the MSIS-29, a measure of the impact of MS on 
QoL, in secondary progressive MS. Data from this study do show that in people with 
higher levels of MRI detected brain pathology and poorer clinician assessed 
neurological function, MS has a greater impact on QoL. However the associations, 
even from the best models, were modest, indicating that even when using a wide 
range of different clinical and MRI modalities, there may still be factors influencing 
QoL in MS, which are not adequately captured. 
 
The contribution of neurological impairment to impact on QoL 
There was no association of EDSS with MSIS-29 scores in this subject group. There 
is some evidence that changes in EDSS scores in the context of clinical trials may 
partly represent temporary fluctuation in function or variations in measurement rather 
than sustained disability due to irreversible myelin and neuroaxonal loss (Ebers et al 
2008) and it is possible that the EDSS has a limited sensitivity for detecting 
neurological dysfunction in secondary progressive MS. However a number of 
previous studies which have shown good correlation between EDSS and the physical 
component of QoL measures (Rothwell et al 1997, Hoogervorst et l 2004, Benito-
Leon et al 2003, Janhardan and Bakshi 2000, Lobentanz et al 2004, Isaksson et al 
2005, Simeoni et al 2008, Nordvedt et al 2000, Gold et al 2001, Benito-Leon et al 
2002, Benedict et al 2005, Mitchell et al 2005, Ytterberg et al 208, Mowry et al 2009) 
and so the lack of a correlation in this study may reflect the limited sensitivity of 
EDSS in this subject group in particular, in whom the selection criteria ensured a 
narrow baseline range.  
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Significant correlation of MSIS-29 measures with components of the MSFC were 
found. TW was the only independently significant clinical correlate of MSIS-phys in 
the cross-sectional analysis, change in TW was the only measure of any kind that 
correlated with change in MSIS-phys over 24 months while PASAT-3 was the single 
best clinical predictor of MSIS-psych in the cross-sectional analysis. These findings 
would suggest that physician assessed neurological dysfunction does have an impact 
on QoL in MS.  
 
Correlation of MRI measures with MSIS measures 
It is well recognized that the correlations between T2 lesion volume and disability in 
MS are modest, particularly in the secondary progressive form of the condition 
(Miller et al 2002, Li et al 2006, Filippi and Agosta 2007). The pathological 
heterogeneity of T2 hyperintense lesions (Trapp et al 1998, Kutzelnigg et al 2005) 
may partly explain this phenomenon, with lesions comprising a higher level of 
neuroaxonal loss and more severe chronic demyelination contributing more to 
neurological dysfunction. Chronically hypointense T1 lesions are known to be 
relatively specific for neuroaxonal loss (van Walderveen et al 1998, van Waesberghe 
et al 1999, Fisher et al 2007) and so one would expect that, all other things being 
equal, people with a higher T1 to T2 lesion ratio, would have more severe 
neurological deficit. In this study cross-sectionally T1 to T2 lesion volume ratio was 
the most consistent MRI correlate of both MSIS-measures suggesting that a higher 
burden of lesion-associated neuroaxonal loss may also have an impact on QoL. 
Previously published studies comparing MRI measures with QoL questionnaires have 
reported a higher T1 lesion volume being associated with lower QoL would support 
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this (Janhardan and Bakhi 2000, Mowry et al 2009). There are reports of correlation 
between T1 lesion volume and depression (Bakshi et al 2000) which may partly 
explain why T1 to T2 lesion volume ratio was an independently significant correlate 
in the multimodal model for MSIS-psych.  
 
In the longitudinal analysis there were no correlations of change in MRI measures 
with change in MSIS-phys, but changes in NAWM mean MTR and NAGM peak 
height did correlate significantly with change in MSIS-psych. MRI detectable 
changes, possibly neuroaxonal loss, in normal appearing brain tissue may have an 
independent role in determining level of neurological impairment (Miller et al 2002, 
Filippi and Agosta 2007). Data from this study suggest that pathological changes in 
the normal appearing brain tissue may also have an impact, albeit limited, on 
psychological QoL. A preliminary study evaluating the link between MTR and fatigue 
failed to find a significant association (Codella et al 2002) but it would be interesting 
to revisit this using a larger cohort and longitudinal measurement. 
 
No significant correlations of MSIS-29 measures with measures of inflammatory 
activity 
There was no observed association of either clinical or MRI markers of active 
neuroinflammation – relapses and active lesions – with change in MSIS-29 measures. 
Gradual deterioration in neurological function, rather than acute relapse is thought to 
be the predominant cause of disability in secondary progressive MS (Confavreux et al 
2000, Leray et al 2010, Scalfari et al 2010) while MRI measures such as atrophy, that 
are thought to represent neuroaxonal loss, are more closely correlated with 
progressive disability than measures focal lesion volume are (the latter thought to be 
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measures of focal neuroinflammation) (Miller et al 2002). Data from this study would 
suggest that in progressive forms of the condition new focal inflammatory activity has 
a limited impact on QoL when compared to measures of neuroaxonal damage and 
loss. 
 
However one should be cautious about over interpreting this result. Because the data 
in this study were taken from a trial of a potentially neuroprotective drug the MRI 
measures used were not optimized to detect neuroinflammation. Inclusion of the 
MSIS-29 in future trials of immunomodulatory therapies, where Gd enhanced scans 
of the brain, and T2 weighted images of the cord (allowing an estimation of cord 
lesion burden) would be a convenient way to correct this omission.  
 
Limitations of the study 
Overall the correlations of clinical and MRI measures acquired in this study with 
MSIS-29 were relatively modest. There are factors such as fatigue and depression 
which are known to have a substantial impact on QoL in MS (Bakshi et al 2000) that 
may not be captured well using either the clinical or MRI tools that have been 
included in this study. Future studies should include appropriate questionnaires 
quantifying the impact of fatigue and depression. 
 
The statistical methods used in this study assume a linear relationship between 
continuous variables and the MSIS-29 measures. This may not be the case, which 
could mean the correlation coefficients derived in this study under estimate the true 
strength of the associations. Repeating the study with a larger patient cohort may 
allow the investigation of the possibility of non-linear associations.  
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Some of the variables used in the models are quite closely linked, for example the 
descriptors of the MTR histograms, and substantial multicollinearity can also lead to 
under estimation of correlation coefficients. However the statistical methods 
employed, grouping the variables for the first stage of the analysis and re-testing all 
discarded variables against the final model, ensure that the regression models are 
never so big that the estimate of the regression line becomes unstable and no 
independently significant correlation should have missed due to collinearity. 
Repetition of the study with path analysis using a smaller set of variables could give 
rise to higher correlation coefficients. However this was an exploratory study, and so 
the inclusion of a large number of variables was felt to be justified. 
 
Conclusion 
These data do confirm that there is a correlation between physician assessed measures 
of neurological dysfunction and the impact of MS on QoL while the correlation of 
MRI measures with MSIS-29 give new insights into the pathological processes which 
give rise to impaired QoL. However the correlations are modest, indicating that there 
are factors that have a substantial impact on a person’s experience of MS, which are 
not captured even using a large number of MRI and clinical measures. 
 
 
 
 
 
 158 
8. Conclusion 
The aim of this study was to evaluate two MRI techniques, MTR and T1LV, in 
secondary progressive MS; specifically: 
1. The responsiveness of MTR measures and T1LV to change over 24 months, a 
timescale that would be typical for treatment trials in MS. 
2. The correlation of MTR measures and T1LV with measures of clinical status, 
including a quality of life measure. This gives some insight into the 
pathological substrate underlying neurological dysfunction and, along with 
data regarding sensitivity, gives an indication of the most suitable measures 
for monitoring clinically important brain pathology. 
3. The effects of lamotrigine, a putative neuroprotective agent, on MTR 
measures and T1LV.  
 
Responsiveness over 24 months 
 
The responsiveness to change of T1LV was very similar to that of T2LV (see table 
13). T1 hypointense lesions were defined as regions corresponding to a T2 
hyperintense lesion that were hypointense compared to the surrounding brain tissue, 
so by definition the absolute change in this measure was smaller (see table 13). 
However the variability in T1LV was slightly smaller and so what was lost in 
sensitivity may have been gained in reliability. The technique used was largely 
manual (see section 2.3.) which may have impaired its reproducibility, and inter-rater 
variability was quite high (see table 2). Other investigators are now employing 
automated protocols for identifying and contouring T1 hypointense lesions (Fisher et 
al 2007), which may improve the reproducibility of this measure. Head-to-head 
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comparison is needed to establish whether this automated technique has a better 
responsiveness than the semi-automated technique that was employed in this study. 
 
The responsiveness of the MTR measures was limited; in the placebo group only three 
out of nine measures (NAGM mean, lesion PL and lesion mean) changed significantly 
over the 24 months. Two of these measures (lesion PL and mean) increased over the 
follow up period, which would not be consistent with a measure that reflects 
progressive demyelination or axonal loss. Very strict measures were used to minimize 
the effects of partial volume voxels, which may have reduced the sensitivity of these 
measures somewhat but to ensure, as far as possible, that the NABT MTR measures 
were independent of the effects of atrophy and lesion load, the exclusion of these 
voxels was necessary.  
 
NAGM MTR mean was the only measure in the placebo group that showed a reliable 
decrease over the 24 months. This may reflect the relative severity of grey matter 
pathology in secondary progressive MS (Kutzelnigg et al 2005) or simply a better 
signal to noise ratio in grey matter measures. Grey matter comprises a greater 
proportion of brain volume than either white matter or lesions (Furby et al 2010) and 
so a proportionally smaller change in grey matter measures may be more easily 
detected. The coefficient of variance for both volume and MTR measures were 
smaller than those for white matter and for lesion volume measures (Furby et al 2010, 
table 2, table.) meaning that grey matter may have been more reliably segmented than 
white matter or lesions. The greater signal to noise ratio of grey matter measures may, 
therefore, provide part of the explanation for why NAGM mean changed significantly 
over 24 months, while lesion and white matter MTR did not. 
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Correlation with clinical status 
In both the cross-sectional and longitudinal analysis there were positive correlations 
of MTR measures in all three tissue types with the MSFC and with the PASAT-3 and 
9HPT considered individually. Only NAGM measures, PL in the cross-sectional 
analysis and mean in the longitudinal analysis, correlated with the timed walk and the 
strength of the correlation was modest. It is possible to make two inferences from 
these results: 
 
1. While brain pathology may be important in determining cognitive and upper limb 
dysfunction in progressive MS, it may have less impact on mobility than cord 
pathology. This would be consistent with the well recognized clinical-radiological 
paradox in MS, where lesion burden does not necessarily correlate with disability 
measured using the EDSS. This phenomenon is most pronounced in progressive 
forms of the condition (Li et al 2006), particularly primary progressive MS 
(Thompson et al 1990) where there is a high burden of spinal cord pathology 
(Bjartmar et al 2000).  
 
2. Using the techniques employed in this study, grey matter measures, are better than 
white matter or lesion measures for detecting clinically important pathology in 
secondary progressive MS. In previous studies grey matter atrophy and MTR 
measures have been consistently found to correlate with and predict neurological 
dysfunction (Dehmeshki et al 2003, Davies et al 2004, Sanfilipo et al 2005, Tedeschi 
et al 2005, Agosta et al 2006, Ramio-torrenta et al 2006, Vrenken et al 2007, Fisher et 
al 2008, Fisniku et al 2008a, Fisniku et al 2008b, Furby et al 2008, Furby et al 2010) 
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often as the best, or only correlate (Dehmeshki et al 2003, Davies et al 2004, Agosta 
et al 2006, Fisher et al 2008, Fisniku et al 2008a, Fisniku et al 2008b, Furby et al 
2008, Furby et al 2010). This may reflect superior responsiveness of the grey matter 
measures; that grey matter MRI measures are markers for global brain pathology. On 
the other hand there is thought to be a dissociation between the burden of grey matter 
pathology and the severity of pathology in focal white matter lesions (Kutzelnigg et al 
2005); an alternative explanation would be that grey matter pathology really does 
contribute substantially to neurological dysfunction in secondary progressive MS and 
that this is independent of any effect of focal white matter pathology. 
 
T1LV correlated with arm and cognitive function cross-sectionally and longitudinally. 
In the cross-sectional analysis T1LV was the only independently significant correlate, 
‘canceling out’ the correlation of T2LV with the same clinical measures. This 
indicates that T1LV may be a more specific measure for clinically relevant brain 
pathology than T2LV and might be used in preference in studies of neuroprotective 
agents in secondary progressive MS. 
 
Across the board the association of brain MRI measures with EDSS was poor. There 
was a correlation of NAGM PL at baseline and of increasing lesion PL and MTR 
mean with an increased probability of experiencing a sustained increase in EDSS, but 
in both cases the association was modest. There was no association of any of the 
lesion volume measures with EDSS either at baseline or longitudinally; although this 
finding may partly be due to the fact that the change in EDSS over the course of the 
trial was very limited.  
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EDSS is known to be dependent on mobility, especially in the range that was selected 
for this study (4.0 to 6.5) (Kurtzke et al 1983) and the limited correlation between 
mobility and brain MRI measures may partly explain why the association between 
EDSS and MRI measures was so limited. It is possible that if subjects with a wider 
range of EDSS score had been selected, such that upper limb, visual, cognitive, 
function and bladder or bowel function contributed more to the overall score, 
significant correlations would have emerged.  
 
The longitudinal correlation of MRI measures with clinical measures was limited. 
This may, in part, reflect the relatively low responsiveness of the measures to change 
over the two-year study period. Previous studies suggest that both white matter lesion 
volume (Fisniku et al 2008) and grey matter MTR measures (Agosta et al 2006, 
Fisniku et al 2009) should correlate with or predict late disability. It be would 
interesting to follow up the study group after a longer interval to see if changes in 
MTR or lesion volume seen over the two years of the trial period correlate with 
changes in the level of disability or neurological deficit over the longer term.  
 
Multi-modal correlations of MRI measures with MSFC 
The same statistical process used to identify the best MRI and clinical predictors of 
MSIS-29 (see section 7.2) was applied to identify the best MRI predictors of MSFC 
and component measures. MRI variables were grouped into: ‘brain volume/atrophy 
measures’ (NBV/PBVC, WMF, GMF, CCV); ‘lesion volume measures’ (lntT1LV, 
lnT2LV, T1 to T2 lesion volume ratio, active lesion number); ‘MTR’ (Mean, peak 
height and peak location for NAGM, NAWM and lesions); and spinal cord cross 
sectional area. A fifth group of variables was ‘baseline demographic data’ (Sex, age 
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and disease duration at baseline). Multiple linear regression analysis was used to 
identify first the independently significant correlates from each group and then which 
of these were independntly significant when included in a multi-modal model. To 
ensure that no variables were erroneously omitted from the final model because of 
multiple colinearity at an earlier stage of the analysis, all discarded variables were 
tested against the final model. The results for cross-sectional correlations at baseline 
for the whole cohort are shown in table 21 rows 1 to 4 and the results for longitudinal 
correlations over 24 months for the placebo group (∆[MRI measure]* ∆[clinical 
measure]) is shown in table 21 rows 5 to 8; only the results of the second stage of the 
analysis are shown. 
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Table 21: Multimodal ‘Best predictor’ analysis for MSFC and ∆MSFC.  
1. MSFC  PASAT-3 1/9HPT 1/TW 
2.Variables 
included in 
model 
NAGM mean, NBV, GMF, WMF, 
lnT1LV 
Female sex, 
NAGM mean, NBV, lnT1LV  
NAGM mean, NBV, lnT1LV Female sex, age, NAWM peak 
location, NAGM peak location, T1 
to T2 ratio, NBV 
3. Independently 
significant 
variables 
NAGM mean rp=0.22, 
p=0.016 
NAGM mean rp=0.54, 
p<0.0001 
NBV rp=0.45, 
p<0.0001 
Female sex rp=-0.25, 
p=0.009 
GMF rp=0.20, 
p=0.024 
Female sex rp=-0.17, 
p=0.036 
Lesion peak 
location 
rp=0.22, 
p=0.019 
NAWM peak 
location 
rp=0.20, 
p=0.036 
NBV rp=0.184, 
p=0.042 
    GMF rp=0.18, 
p=0.050 
4. R
2
 =0.24, p<0.0001 R
2
 =0.34, p<0.0001 R
2
 =0.23, p<0.0001 R
2
 =0.25, p=0.002 
5. ∆MSFC  ∆PASAT-3 ∆1/9HPT ∆1/TW 
6.Variables 
included in final 
model 
PBVC, ∆WMF, ∆NAGM mean, 
∆SCCA 
Age, ∆NAWM peak height, ∆GMF ∆GMF, ∆NAWM peak height PBVC 
7. Independently 
significant 
variables 
PBVC rp=0.40, 
p=0.016 
∆NAWM peak 
height 
rp=0.28, 
p=0.046 
∆GMF rp=-0.31, 
p=0.025 
PBVC rp=-0.39, 
p=0.003 
∆WMF rp=-0.27, 
p=0.036 
      
∆NAGM mean rp=-0.27, 
p=0.036 
      
8. R
2
 =0.24, p<0.0001 R
2
 =0.07, p=0.046 R
2
 =0.09, p=0.025 R
2
 =0.09, p=0.048 
MSFC - multiple sclerosis functional composite, PASAT-3 - paced auditory serial addition test, 9HPT - 9 hole peg test, TW -  timed 25 foot walk, NAGM -  normal appearing 
grey matter, NBV -  normalized brain volume, GMF -  grey matter fraction, WMF -  white matter fraction, T1LV -  T1 hypointense lesion volume,  NAWM – normal 
appearing white matter, SCCA – spinal cord cross-sectional area, PBVC percentage brain volume change, ∆ change in a variable (value at 24 months – value at baseline). 
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Cross-sectional analysis at baseline showed that the majority of the multimodal 
models included both a brain volume and an MTR measure. One potential criticism of 
MTR, particularly when used to evaluate grey matter in isolation, is that since it is 
affected by neuroaxonal density (van Waesberghe et al 1999, Heihle et al 1995, 
Filippi et al 1999, Fisher et al 2007) and correlates with brain atrophy (Phillips et al 
1998, Traboulsee et al 2003, Khaleeli et al 2007, Hayton et al 2009), it may 
essentially just be another measure of atrophy and not confer any information about 
brain pathology that is not captured using other, more reproducible atrophy measures. 
The finding that atrophy and MTR measures are independently significant correlates 
of the MSFC would suggest that this is not the case and that MTR is measuring some 
clinically relevant pathological process, such as cortical demyelination (Schemierer et 
al 2010) or changes in axonal function (Fisher et al 2007, Young et al 2008, Moll et al 
2009). 
 
In the longitudinal analysis the picture is not as clear. The ‘best-predictor’ model for 
MSFC comprised two atrophy measures and one MTR measure (PBVC, change in 
white matter fraction and change in NAGM mean). However the only independently 
significant correlates of change in TW or 9HPT were atrophy measures, perhaps 
reflecting the superior longitudinal responsiveness of atrophy measures (Furby et al 
2010). For change in PASAT-3 the only independently significant longitudinal 
correlate was change in NAWM peak location. Performance in the PASAT-3 is 
strongly associated with central processing speed (Forn et al 2008), which in turn is 
associated with white matter tract integrity (Yu et al 2012) so the finding that a 
putative measure of NAWM myelinated axon content is the best MRI predictor of this 
particular cognitive test is not totally implausible. However the level of significance is 
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not high and the amount of variability accounted for by this model is very low, so it 
would unwise to put too much weight on this finding. 
 
Association of clinical MRI measures with quality of life 
The association of MRI and objective clinical measures with quality of life measures 
was interesting. There was no association of quality of life measures with EDSS, a 
measure that is thought to be heavily influenced by mobility yet the TW was almost 
uniformly the only clinical measure that independently correlated with the MSIS-29 
scores both cross-sectionally and longitudinally. It seems that impaired and 
deteriorating mobility is associated with impaired and deteriorating quality of life but 
that in this quite typical secondary progressive subject group EDSS was not be 
sensitive enough to detect this change. 
 
Of the MRI measures T1 to T2 lesion volume ratio was the only independent 
significant correlate of quality of life in the cross-sectional analysis while change in 
NAGM MTR measures correlated with change in MSIS-29 over the 24 months of the 
follow up period. These results add further support to the hypothesis that T1 
hypointense lesions and NAGM MTR are useful measures of clinically relevant 
pathology and suggest that the pathological processes denoted by these measures do 
have an impact on a person’s experience of MS.  
 
The amount of variability in the MSIS-29 score explained by even the best combined 
models was modest, 32%, suggesting that there are other important influences, such as 
fatigue, depression and social circumstances, which influence quality of life in MS, 
but are simply not captured using the MRI and clinical tools employed in this study.  
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Effects of lamotrigine treatment 
The effects of lamotrigine treatment were disappointing. There was no significant 
difference between the two arms of the trial in terms of lesion measures, with a 
similar increase in both T1LV and T2LV in both groups. Three out of nine of the 
MTR measures showed a significant difference between the two arms of the trial. 
However two of these NAGM and lesion PH showed a larger reduction in MTR in the 
verum arm, which is the opposite of what would be expected if lamotrigine was 
neuroprotective. 
 
The atrophy data from the trial also gave no support to lamotrigine as a 
neuroprotective medication. The reduction in whole brain volume was greater in the 
verum arm than in the placebo arm (Kapoor et al 2010). This reduction was fastest 
over the first 12 months, plateaued over the second and, in a subgroup who underwent 
post-treatment scanning, started to reverse when the treatment was withdrawn. 
Because treatment with lamotrigine was not associated with any greater clinical 
deterioration in the verum arm it was felt that the more rapid loss of brain volume 
could be related among other mechanisms to reduction in white matter oedema 
through possible anti-inflammatory interaction of lamotrigine with sodium channels 
on microglia or reduction in axonal diameter through inhibition of sodium loading. 
 
There is some recent work which indicates that MTR could potentially change 
according to the expression of cell surface proteins (Young et al 2008, Moll et al 
2009) which could in turn be influenced by lamotrigine. However appropriate studies 
in EAE would be needed to establish whether these putative mechanisms are 
biologically plausible. In contrast to the atrophy measures there was no post-treatment 
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MTR imaging performed, so it is more difficult to argue that the changes in MTR are 
more likely to represent reversible changes in axonal structure or function rather than 
axonal loss.  
 
 
Strengths and limitations of the study and suggested further work 
The data presented here are taken from a large, well characterized group of people 
with secondary progressive MS. MRI data were collected at the same intervals for 
each subject, using the same protocol on a single MRI scanner. The MRI sequences 
used were well validated and the MTR measures had good reproducibility. MRI 
images were anonymized prior to analysis and the same investigator carried the 
analysis for each subject at each timepoint. For each subject the clinical data were 
collected by the same investigator at every timepoint, the ‘assessing physician’ who 
was blinded to recent clinical events. 
 
A large number of MRI measures were obtained, giving information about both focal 
and global brain pathology and spinal cord atrophy and the measures chosen were 
appropriate for investigating a condition in which progressive neurodegeneration may 
be responsible for the much of the associated disability. Both objective and subjective 
clinical measures were obtained, giving information about disability, neurological 
dysfunction and quality of life. Subject retention was good, with 108 out of 118 
subjects who were scanned at baseline returning at 24 months. 
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Every reasonable effort was made to ensure that the data acquired were of good 
quality and that the results presented were reliable. However the interpretation of 
these results could have been clarified further with some additional data.  
 
T1 weighted images with Gd enhancement and at more frequent intervals would allow 
better identification of those new, acutely inflamed T1 hypointense lesions and so 
give a better idea of whether the neurological dysfunction associated with T1LV was 
due primarily to axonal degeneration and dysfunction in chronic lesions or due to 
inflammatory demyelination, conduction block and axonal transection in acute 
lesions. It would also help clarify the pathological substrate underlying the apparent 
increase in lesion MTR in those subjects who experienced a sustained increase in 
EDSS. One suspects that those subjects who had a sustained increase in EDSS had 
more inflammatory lesions at baseline, with a lower MTR and that the increase in 
MTR was resolution of oedema and/or partial remyelination, but without a reliable 
measure of acute neuroinflammation this remains pure speculation. Finally it would 
be interesting to know if lamotrigine had any effect on Gd enhancing lesion number. 
Recently published data from EAE suggests that sodium channel blockers may have 
some anti-inflammatory potential (Black et al 2007) and it would be interesting to test 
this in MS. 
 
Post treatment MTR data would have been valuable in determining whether the 
apparent differences in MTR measures seen between the two trial arms were 
temporary and reversible or permanent. As stated in section 2.2, limited post treatment 
MRI and clinical data was acquired from this subject group, but the principal aim of 
aqcuiring these data was to establish safety and to make sure that the validity of the 
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primary end-point of the trial was not compromised. To maximize uptake, the MRI 
protocol at the post treatment follow up (27 months) was made as short as possible 
and comprised just markers of acute inflammation (active T2 lesion number and 
T2LV) the primary end-point (CCV) and the most sensitive atrophy measure 
(SIENA).    
 
There are clearly factors which have a substantial impact on quality of life, which are 
not captured using the clinical and MRI measures used in this study. Some of these, 
such as the changed social circumstances that come with a chronic disabling medical 
condition, are likely to be insoluble with medication and largely unrelated to MRI 
detected brain pathology. However factors such as depression and fatigue may well be 
related to MRI detectable pathology (Pujol et al 1997, Bakshi et al 2000, Feinstein et 
al 2004, Sepulcre et al 2009, Andreason et al 2010, Pellicano et al 2010) and are 
potential targets for medication. It would have been interesting and fairly 
straightforward to add specific fatigue or depression scales to the clinical assessment 
and to gather data on social circumstances, co-morbidity or synchronous treatment 
with anti-depressants etc. 
 
Finally it would be good to re-visit this cohort after a longer interval. Previous studies 
have shown an association of MTR measures at baseline with progressive 
neurological impairment up to eight years later (Agosta et al 2006) and it may be 
informative to see whether baseline MTR or T1LV measures, or change in these 
measures over one or two years were associated with later brain atrophy or 
neurological deterioration. In addition, one would like to know if treatment with 
lamotrigine over 24 months could lead to an improved outcome after a longer interval, 
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to test the possibility that early neuroprotection could result in long term differences 
in atrophy, MTR measures or clinical status. 
 
Conclusion 
 
The data presented here do give some insight into the pathological process that give 
rise to neurological impairment and disability in secondary progressive MS, and 
should be informative for investigators planning further treatment trials in similar 
subject groups.  
 
The responsiveness of T1LV was similar to T2LV, but the correlation of the former 
with clinical measures was closer, perhaps suggesting the two MRI measures have 
similar sensitivity but the former better specificity for clinically important pathology. 
These findings would support the hypothesis that T1 hypointense lesions comprise 
more severe MS pathology and that the pathological processes underlying T1 
hypointesne lesions – axonal loss and dysfunction (Fisher et al 2007) and acute 
inflammation (Barkhof et al 2003) – contribute to neurological dysfunction and 
impact on QoL in secondary progressive MS. 
 
The longitudinal responsiveness of MTR measures was limited, perhaps in part by the 
stringent exclusion criteria used to minimize the contribution partial volume voxels; 
only NAGM mean showed a reliable reduction over 24 months. The correlation of 
MTR measures with clinical measures was good, however, with ‘best predictor’ 
models of both MSFC (cross-sectionally) and MSIS (longitudinally) comprising at 
least one MTR measure. 
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While all three tissue types correlated with MSFC, PASAT-3 and 1/9HPT, only 
NAGM MTR measures (PL in the cross-sectional analysis and mean in the 
longitudinal analysis) correlated significantly with TW. These results may reflect the 
relative importance of grey matter pathology in determining neurological dysfunction 
or the superior reliability of grey matter MTR when using the analysis techniques 
employed in this study. Either way these data would support the inclusion of brain 
grey matter MRI measures when monitoring secondary progressive MS.   
 
Although the EDSS has been criticized for being heavily weighted towards mobility 
(Cutter et al 1999) the finding that 1/TW does have a significant impact on QoL may 
indicate that this is not a serious weakness. What is more concerning, however, was 
the very limited association of any MRI measure with the EDSS, either cross-
sectionally or longitudinally, possibly highlighting the relative insensitivity of the 
latter in this particular subject group over a short study period. The EDSS should be 
included in future treatment trials in MS, being easily measured, widely understood 
and the best established measure of disability due to MS, but the data presented here 
suggest that it should not be used as the only measure of neurological impairment, 
particularly in short studies in secondary progressive subject groups.  
 
There were significant correlations of both MRI and clinical measures with MSIS 
both cross-sectionally and longitudinally, demonstrating that the pathological 
processes and neurological impairment measured using these techniques do have a 
meaningful impact on people with MS. However even using the best multi-modal 
predictor models, the association between MRI and clinical measures with the impact 
of MS on quality of life was limited. This finding demonstrates that a large number of 
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factors contribute to QoL in MS and the inclusion of a dedicated QoL measure in 
treatment trials is potentially important. 
 
Finally the effects of treatment with lamotrigine were not as hoped at the start of the 
trial with no difference in lesion measures and no relative ‘preservation of MTR 
levels’ in the treatment group. Brain volume data from the trial did suggest that some 
of the apparent atrophy in the verum arm may be reversible (psuedoatrophy) (Kapoor 
et al 2010) and it is possible that the same is true for changes in MTR. These findings 
emphasize the potential value of post-treatment MRI and clinical data and suggest that 
further trails of putative neuroprotective treatments should include a longer follow up 
period. 
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Appendix 1: Multiple Sclerosis Impact Scale (MSIS-29) 
Please circle or tick the answer you feel in most appropriate. 
In the past two weeks, how much 
has your MS limited your ability 
to... 
Not at 
all 
A 
little 
Moderately Quite a 
bit 
Extremely 
1. Do physically demanding 
tasks? 
1 2 3 4 5 
2. Grip things tightly (e.g. 
turning on taps)? 
1 2 3 4 5 
3. Carry things? 1 2 3 4 5 
In the past two weeks, how much 
have you been bothered by... 
Not at 
all 
A 
little 
Moderately Quite a 
bit 
Extremely 
4. Problems with your balance? 1 2 3 4 5 
5. Difficulties moving about 
indoors? 
1 2 3 4 5 
6. Being clumsy? 1 2 3 4 5 
7. Stiffness? 1 2 3 4 5 
8. Heavy arms and/or legs? 1 2 3 4 5 
9. Tremor of your arms or legs? 1 2 3 4 5 
10. Spasms in your limbs? 1 2 3 4 5 
11. Your body not doing what you 
want it to do? 
1 2 3 4 5 
12. Having to depend on others to 
do things for you? 
1 2 3 4 5 
13. Limitations in your social and 
leisure activities at home? 
1 2 3 4 5 
14. Being stuck at home more 
than you would like to be? 
1 2 3 4 5 
15. Difficulties using your hands 
in everyday tasks? 
1 2 3 4 5 
16. Having to cut down the 
amount of time you spent on 
work or other daily activities? 
1 2 3 4 5 
17. Problems using transport (e.g. 
car, bus, train, taxi, etc.)? 
1 2 3 4 5 
18. Taking longer to do things? 1 2 3 4 5 
19. Difficulty doing things 
spontaneously (e.g. going out 
on the spur of the moment)? 
1 2 3 4 5 
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In the past two weeks, how much 
have you been bothered by... 
Not at 
all 
A 
little 
Moderately Quite a 
bit 
Extremely 
20. Needing to go to the toilet 
urgently? 
1 2 3 4 5 
21. Feeling unwell? 1 2 3 4 5 
22. Problems sleeping? 1 2 3 4 5 
23. Feeling mentally fatigued? 1 2 3 4 5 
24. Worries related to your MS? 1 2 3 4 5 
25. Feeling anxious or tense? 1 2 3 4 5 
26. Feeling irritable, impatient, or 
short tempered? 
1 2 3 4 5 
27. Problems concentrating? 1 2 3 4 5 
28 Lack of confidence? 1 2 3 4 5 
29. Feeling depressed? 1 2 3 4 5 
 
Questions 1 to 20 inclusive are summed to give the MSIS-29 physical component 
(MSIS-phys); questions 21 to 29 inclusive are summed to give the MSIS-29 
psychological component (MSIS-Psych) 
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